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linical hypoglycemia rarely occurs in healthy human beings, but it is a fact of life 
for people with type 1 and (advanced) insulin-treated type 2 diabetes mellitus 
(DM). Hypoglycemia is feared by many patients not (only) because of the associated 
physical symptoms, but mainly because of the risk of cognitive function deterioration 
that may lead to loss of personal control and adequate conscious behavior, and 
eventually to coma. Iatrogenic hypoglycemia has been described ever since the 
introduction of insulin (1), and especially those patients attempting to optimize glycemic 
control may suffer multiple episodes per week (2). The increased hypoglycemic risk can 
be explained by two factors: (i) the pharmacokinetic imperfections of therapeutic insulin 
substitution compared to endogenous insulin secretion and (ii) impairments in glucose 
counterregulation, i.e. the collection of physiological mechanisms that normally prevent 
or correct hypoglycemia. 
 
I: THERAPEUTIC INSULIN 
 
In the nondiabetic individual, endogenous insulin release is instantaneous and tailor-
made to the amount of carbohydrates that enter the circulation or to any other increase 
of the blood glucose level. Moreover, after its release by the pancreatic β-cell, insulin 
first reaches the liver via the portal vein to stimulate hepatic glycogen synthesis and to 
inhibit hepatic gluconeogenesis. Within the liver, insulin is degraded by approximately 
50% (3,4), so that only half of the insulin that is released enters the systemic circulation 
and reaches muscle and fat tissue where it stimulates glucose uptake and inhibits 
lipolysis. In contrast, insulin injected subcutaneously enters the circulation much slower 
and follows the reverse route. As a consequence, the plasma insulin concentration 
remains elevated long after injection, yet does not reach the peak values that can be 
reached by endogenous insulin (5). Moreover, because of erroneous estimation of the 
amount required to obtain normoglycemia and variations in absorption, a dose of insulin 
sufficient to hold plasma glucose at nondiabetic levels at one time may be too much at 
other times. All these factors may lead to inappropriate hyperinsulinemia despite 
corrected hyperglycemia, hence creating a risk for hypoglycemia (6). Interestingly, 
although clearly fundamental to its occurrence, absolute or relative excess of 
therapeutic insulin does not seem to play an important role in the majority of severe 
iatrogenic hypoglycemic events (7). In order to explain the frequency and the 
C 
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pathogenesis of severe hypoglycemia in patients with diabetes, it is therefore necessary 
to look beyond the traditional risk factors such as missed meals or other conditions that 
only take hyperinsulinemia into consideration (8).  
 
II: GLUCOSE COUNTERREGULATION AND HYPOGLYCEMIC AWARENESS 
 
Healthy subjects In the nondiabetic individual, declining blood glucose levels trigger 
a characteristic and hierarchically organized sequence of responses (9,10) that 
effectively prevents true hypoglycemia almost without exception. When blood glucose 
levels fall within the physiological range, the first response in this sequence is 
suppression of insulin secretion. Suppression of insulin secretion causes slowing of the 
blood glucose fall by inhibition of peripheral glucose uptake and disinhibition of hepatic 
glucose production. When glucose levels fall just below the physiological range (~3.8 
mmol/L), glucagon is released by pancreatic α-cells, possibly facilitated by the falling 
intra-islet insulin concentration that alleviates the suppressive effect of intra-islet insulin 
on the α-cell (11). Glucagon promotes hepatic glucose production by stimulation of 
glycogenolysis and gluconeogenesis. Simultaneously, adrenaline is released, which 
contributes to stimulation of glycogenolysis, mobilizes gluconeogenic precursors and 
inhibits peripheral glucose uptake. Adrenaline is normally not critical to recovery from 
hypoglycemia, but becomes critical when glucagon is deficient. Cortisol and growth 
hormone, only released in response to and aimed at prevention of prolonged 
hypoglycemia, are even less essential for glucose counterregulation. Finally, a complex 
of hypoglycemia warning symptoms such as hunger, sweating and palpitations 
provokes eating behaviour and can be seen as a last resort before cognitive function 
declines as a consequence of neuroglycopenia. Although the glucose levels at which 
these responses to hypoglycemia occur are reproducible in healthy subjects, they are 
by no means static and may shift to higher glucose levels during chronic hyperglycemia 
(12) or to lower glucose levels following repeated hypoglycemia. Except for the 
glucagon response, the trigger for release of counterregulatory hormones and for the 
appearance of hypoglycemic warning symptoms is a decrease in the blood glucose 
supply to the cerebral hypoglycemia sensor, probably located within the hypothalamus 
(13-15). 
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Patients with type 1 diabetes mellitus Type 1 diabetes mellitus is characterized by a 
progressive loss of insulin-producing β-cells in the pancreas due to an auto-immune 
based inflammatory process (insulitis) (16). Parenthetically, this loss of insulin-
producing capacity not only leads to uncontrolled elevation of blood glucose that 
requires exogenous insulin administration, but also disrupts the first-line defense 
against falling blood glucose levels. Because insulin levels are no longer under 
endogenous control, but rather the result of passive absorption of administrative insulin, 
falling blood glucose can coincide with absolute or relative excess of circulating insulin, 
thus creating a risk for hypoglycemia. Secondly, within a few years after diagnosis, 
glucagon fails to rise in response to hypoglycemia. This is a signaling defect, as 
glucagon responses to other stimuli remain – largely – intact. The loss of the glucagon 
response may be due to (early) selective neuropathy of α-cell sympathetic nerves (17) 
or because chronically elevated insulin levels maintain a suppressive effect on 
pancreatic α-cells that are no longer under paracrine control by the β-cell. The central 
role of the failing β-cell in the impaired glucagon response is supported by observations 
that prevention of the decrease in intraislet insulin by a β-cell secretagogue selectively 
reduces the glucagon response to hypoglycemia (18,19). In the absence of glucagon 
responses to hypoglycemia, adrenaline becomes critical for glucose counterregulation. 
However, adrenaline responses to hypoglycemia become typically attenuated and the 
glycemic threshold for adrenaline responses shifts to lower levels of glycemia in a 
substantial proportion – if not the majority – of type 1 diabetic patients (20,21). The 
combination of absent glucagon and attenuated adrenaline responses to hypoglycemia 
constitute the clinical syndrome of defective glucose counterregulation. Patients with 
both hormonal defects have been reported to be at a 25-fold higher risk of developing 
severe iatrogenic hypoglycemia than patients having intact adrenaline responses to 
hypoglycemia (22,23). In addition, a defective adrenaline response interferes with the 
timely and adequate perception of symptoms of impending hypoglycemia, a clinical 
syndrome known as hypoglycemia unawareness. Hypoglycemia unawareness is 
defined by the loss of autonomic warning symptoms before the onset of 
neuroglycopenia (i.e. neuroglycopenic symptoms, cognitive dysfunction, and epileptic 
insults or coma). Hypoglycemia unawareness not only increases the risk for iatrogenic 
hypoglycemia in general, but specifically increases the risk for severe, disabling 
hypoglycemia that requires external assistance. Although it is assumed that 
hypoglycemia unawareness is directly related to or the result of reduced adrenergic 
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responses to hypoglycemia, the observation that hypoglycemia unawareness can exist 
despite normal adrenergic responses suggests that reduced β-adrenergic sensitivity 
contributes to the phenomenon (24,25). 
In summary, patients with type 1 diabetes miss the first two physiological defense 
mechanisms against hypoglycemia by nature of their disease, and are at risk of 
developing (severe) impairments at the other levels of protection against hypoglycemia 
that render them vulnerable to multiple and severe decrements in blood glucose.  
 
Patients with type 2 diabetes mellitus In general, the risk for iatrogenic hypoglycemia 
is considerable lower in patients with type 2 diabetes mellitus than in type 1 diabetic 
patients (26,27). Data from the UKPDS show that patients on intensive insulin treatment 
have an approximately 10-fold lower risk, whereas the risk for iatrogenic hypoglycemia 
in patients on oral agents is even lower (26). Various factors contribute to this lower 
risk, including functional reserve of pancreatic β-cells (28), insulin resistance, and – 
possibly – increased sensitivity to plasma catecholamines (29). Finally, patients with 
type 2 diabetes are traditionally less well controlled than type 1 diabetic patients, 
although the data from the UKPDS no longer justify this attitude. Since the glycemic 
goals in type 2 diabetes are not different from those in type 1 diabetes and intensive 
(insulin) treatment is increasingly advocated, the integrity of glucose counterregulation 
in type 2 diabetes becomes an important issue. Unfortunately, counterregulatory 
function in type 2 diabetes has received little attention, and the data thus far obtained 
appear conflicting.  
  
PATHOGENESIS OF HYPOGLYCEMIA UNAWARENESS AND 
COUNTERREGULATORY FAILURE 
 
Autonomic neuropathy The exact pathogenesis of counterregulatory defects, 
including the clinical syndromes of defective hormonal counterregulation and 
hypoglycemia unawareness, is still not clear. Because sympathoadrenal activation 
involves the autonomic nervous system, counterregulatory defects were originally 
thought to be a variant of diabetic autonomic neuropathy (30,31). Although 
counterregulatory defects occur in patients with severe forms of diabetic autonomic 
neuropathy (32), most patients with counterregulatory failure have no evidence of 
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classical autonomic neuropathy whatsoever. In large cross-sectional studies, the 
contribution of classical diabetic autonomic neuropathy to counterregulatory failure or 
hypoglycemic incidence is minimal (33,34). In a recent cross-sectional study involving 
75 patients with long-term diabetes, we did not find any association between 
(magnitudes of) autonomic neuropathy and hypoglycemia unawareness, despite high 
prevalences of both autonomic neuropathy (69%) and of hypoglycemia unawareness 
(78%) in this group (35). Moreover, while classical diabetic complications – including 
autonomic neuropathy – are related to chronic hyperglycemia and poor metabolic 
control, this is typically not the case with counterregulatory failure. On the contrary, 
counterregulatory impairments are strongly related to frequent and chronic 
hypoglycemia and to tight metabolic control – a surrogate marker of hypoglycemic 
incidence. 
 
Antecedent hypoglycemia The association between counterregulatory failure 
and hypoglycemia has led to the ‘hypoglycemia-begets-hypoglycemia’ hypothesis, 
which posits that recent antecedent hypoglycemia suppresses the autonomic 
responses to a subsequent fall in blood glucose. Perhaps, the earliest support for this 
hypothesis stems from observations of reduced sympathoadrenal responses in 
nondiabetic individuals after ‘insulin shock therapy’ (used in the 1960s as an alternative 
to electroshock therapy) (36). Many studies have now confirmed that recent antecedent 
hypoglycemia reduces neuroendocrine and symptomatic responses to subsequent 
hypoglycemia (37-40), shifts the glycemic thresholds for these responses to lower 
glucose levels (41), and impairs detection of hypoglycemia in a clinical setting (42). 
Since counterregulatory defects themselves predispose for hypoglycemic events, a 
downward vicious cycle of progressively impaired glucose counterregulation and 
repeated hypoglycemic events will eventually lead to defective glucose 
counterregulation and hypoglycemia unawareness (43).  
How antecedent hypoglycemia reduces metabolic and symptomatic responses to a 
subsequent episode is subject of much debate. Several potential mechanisms have 
been suggested. One hypothesis suggests inappropriate sensing of systemic 
hypoglycemia due to preservation of glucose uptake by the brain, so that initiation of 
counterregulatory responses is delayed until lower levels of (cerebral) hypoglycemia are 
reached (44-46). This hypothesis is based on the finding that cerebral glucose uptake 
was preserved during hypoglycemia in well-controlled type 1 diabetic patients with 
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hypoglycemia unawareness, whereas it fell in normal controls and in poorly controlled 
diabetic patients (47). Mechanistically, it is thought that the preservation of brain 
glucose uptake is an adaptation to chronic (recurrent) hypoglycemia (48), due to 
upregulated production and translocation of the cerebral glucose transporter GLUT-1 
(49) and increased (regional) cerebral blood flow (50,51). Recent evidence that 24 
hours of interprandial hypoglycemia does not reduce global blood-to-brain glucose 
transport despite counterregulatory impairments indicates that cerebral adaptation does 
not explain the suppression of glucose counterregulation after short-term hypoglycemia 
(52). At a more fundamental level, it is difficult to accept the brain preservation 
hypothesis as sole explanation, because it predicts that patients with recurrent 
hypoglycemia are protected during subsequent episodes, whereas clinical evidence 
clearly indicates the opposite.  
An alternative hypothesis suggests a pivotal role for the cortisol response to 
antecedent hypoglycemia as mediator of hypoglycemia-induced counterregulatory 
failure. This suggestion is based on observations that prior elevation of plasma cortisol 
can induce many aspects of counterregulatory failure (53) and that patients with 
adrenocortical failure – who lack the capacity to release cortisol – have been found 
insensitive to the suppressive effects of antecedent hypoglycemia (54). However, the 
suppressive effect of prior elevation of cortisol is not of the same magnitude as that of 
prior hypoglycemia, and typically does not include a reduction in symptomatic 
awareness of subsequent hypoglycemia. Therefore, additional factors – e.g. other 
components of the hypoglycemia response profile – are likely to be involved in the 
pathogenesis of hypoglycemia-induced counterregulatory failure. 
  
MANAGEMENT OF HYPOGLYCEMIA UNAWARENESS AND 
COUNTERREGULATORY DEFECTS  
 
Hypoglycemic risk reduction Despite steady progress to unravel its pathogenesis, 
management of counterregulatory impairments and hypoglycemia unawareness has 
been proven extremely difficult. Although it is possible to reverse hypoglycemia 
unawareness and defective counterregulation by scrupulous avoidance of 
hypoglycemic events (55-57), routine use of this method is not advisable because of the 
associated worsening in glycemic control. In fact, many physicians agree that 
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hypoglycemias need to be accepted to a certain degree to allow optimization of 
glycemic control. Patients (and their relatives) should be reassured that apart from its 
immediate inconvenience, permanent damage from hypoglycemia is uncommon (58-
61) and long-term effects of repeated hypoglycemia on intellectual function have not 
been found by studies specifically designed to investigate this issue (62-65). 
Hypoglycemia-avoidance tactics should be reserved for patients with a history of 
severe, complicated hypoglycemia, because of the high risk for recurrence and 
because severe hypoglycemias are associated with potentially fatal (traffic) accidents 
and with considerable negative psychosocial impact on the lifes of patients and their 
relatives (66).  
Nevertheless, treatments that can reduce the risk of iatrogenic hypoglycemia within 
the boundaries of glycemic control would be welcomed by many patients. So far, 
attempts to attain this goal have largely failed. Although individual patients may benefit 
from blood glucose awareness training (BGAT) to detect hypoglycemia more accurately 
(67), or from switching to insulin analogs (68-71) or continuous subcutaneous insulin 
infusion (72-75), the overall effect in larger groups of patients to reduce hypoglycemic 
events has been disappointingly small.  
 
Pharmacological management of hypoglycemia unawareness So far, most 
techniques that have been employed to minimize the risk for iatrogenic hypoglycemia 
without compromising glycemic control have been aimed at reducing the imperfections 
of therapeutic insulin by trying to provide insulin in a more physiological fashion. A 
fundamental change in insulin regimen can, however, be a time-consuming process 
that demands a great deal of motivation and effort from both patient and physician. 
Novel methods that are easier to implement are urgently needed. From this point of 
view, it is remarkable that so few studies have used a pharmacological intervention to 
ameliorate counterregulatory defects or hypoglycemia unawareness. Agents that have 
been tried so far include the glucagon-releasing amino acid alanine, the β2-adrenergic 
agonist terbutaline, and adenosine receptor antagonists. Alanine and terbutaline have 
been reported to prevent nocturnal hypoglycemia somewhat better than a bedtime 
snack, yet their effects on glucose counterregulatory function have not been quantified 
(76).  
From a pharmacological point of view, blocking of central adenosine by adenosine 
receptor antagonists may be more effective to ameliorate hypoglycemia unawareness. 
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Adenosine is involved in the maintenance of cerebral blood flow and levels of 
adenosine increase substantially in response to hypoglycemia (77). Blocking of 
adenosine may reduce cerebral glucose delivery, which in turn renders the brain more 
sensitive to a decrease in blood glucose concentration. Blocking of the adenosine 
receptor within the brain increases cerebral substrate requirements (oxygen and 
glucose), thus uncoupling the relation between cerebral energy metabolism and 
cerebral perfusion (78). In other words, central glucose requirements are higher, yet 
glucose delivery is lower. As a consequence, alertness increases and release of 
counterregulatory hormones is enhanced (to increase blood glucose levels). The 
uncoupling of glucose requirements and glucose delivery becomes even more relevant 
during hypoglycemia, when glucose supply is jeopardized by a coexisting fall in blood 
glucose. The relative glucose deficient state of the brain and the inability of brain blood 
flow to increase glucose supply not only enhance counterregulatory hormone 
responses to hypoglycemia, but also enable prompter (cerebral) perception of 
impending hypoglycemia. As a consequence, the progression of hypoglycemia is 
slower and hypoglycemic symptoms may develop at relatively higher levels of glycemia, 
so that appropriate action (e.g. ingest carbohydrates) can be undertaken at an earlier 
stage. The concept of improved hypoglycemic awareness by adenosine receptor 
antagonism has already been successfully tested in humans, using either the 
methylxanthine derivatives caffeine (79,80) or theophylline (81). Although promising, 
these agents have not yet been investigated in diabetic patients with clinically relevant 
hypoglycemia unawareness. In addition, the effect of long-term use of adenosine 
receptor antagonists on glucose counterregulation has not been properly investigated. 
This is an important issue, because emergence of tolerance has been described to 
occur during prolonged use (82), and this may obviously limit the usefulness of 
adenosine receptor antagonists in improving counterregulatory failure clinically.  
 
CONCLUSION 
 
In insulin-treated diabetic patients, iatrogenic hypoglycemia is typically the result of the 
interplay of insulin excess on the one hand and counterregulatory failure, as reflected 
by defective hormonal counterregulation and hypoglycemia unawareness, on the other. 
Iatrogenic hypoglycemia represents an important burden for patients with type 1 and 
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advanced type 2 diabetes mellitus and is the limiting factor in the glycemic management 
of diabetes. Provided that insulin treatment and blood glucose self monitoring are 
optimized, improvement of glycemic control can at some point only be achieved at the 
expense of increased hypoglycemic incidence, whereas hypoglycemia risk reducing 
strategies almost always compromise metabolic control to a certain degree. Unless we 
learn to overcome the imperfections of therapeutic insulin by providing insulin in a much 
more physiological way (e.g. by glucose-regulated insulin replacement), it will be 
impossible to eliminate hypoglycemia from the lives of diabetic patients. Until then, we 
will need to understand the pathophysiology of counterregulatory impairments and 
hypoglycemia unawareness more thoroughly, and to develop strategies that support 
glucose counterregulation and – consequently – reduce hypoglycemic incidence. 
 
AIMS OF THE PRESENT STUDIES 
 
As will be clear from this overview, metabolic counterregulatory impairments and clinical 
hypoglycemia unawareness have been extensively studied, but there are still 
inconsistencies and gaps in our understanding of the mechanism(s) involved and in the 
way these disorders should be managed. A central disorder in both defective metabolic 
counterregulatory function and in hypoglycemia unawareness is the impaired 
adrenaline response. The current view holds that this impairment is caused by an 
adaptational resetting of the glycemic threshold for adrenaline release to a lower 
glucose level (83). It is unclear whether reduced adrenomedullary secretory function per 
se contributes to this defect. Studies investigating this issue have largely relied on 
adrenergic responses to exercise tests (32,84), an insensitive method to assess 
adrenomedullary capacity. Recently, it has been suggested that measurements of 
plasma metanephrine levels provides a sensitive method to estimate adrenomedullary 
secretory capacity (85-87). We applied this method to assess the role of 
adrenomedullary secretory capacity in the impaired adrenaline response to 
hypoglycemia in patients with diabetes and hypoglycemia unawareness (chapter 2). 
To further elucidate the role of adrenaline, we then investigated whether adrenaline 
could be a mediator of (components of) the hypoglycemia unawareness syndrome and 
related counterregulatory impairments. Previous studies have suggested that the 
suppressive effects that antecedent hypoglycemia exerts on counterregulatory 
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responses to subsequent hypoglycemia are partly mediated by the cortisol response to 
antecedent hypoglycemia (53). We hypothesized that chronically elevated adrenaline 
levels due to recurrent exposure to hypoglycemia (or any other event that increases 
circulating adrenaline) may also act suppressively on responses to subsequent 
hypoglycemia (chapter 3).  
In most studies that investigated hypoglycemia, it is traditional to mainly focus on 
the potentially devastating effects of hypoglycemia on the brain. However, low blood 
glucose may not only be deleterious for brain function, but may affect all processes that 
depend on glucose. In addition, hypoglycemia may have effects as a systemic stressor 
that go beyond those caused by glucopenia alone. Because of its dependence on 
glucose (88) and its sensitivity to stress (89), we hypothesized that hypoglycemia might 
compromise the proinflammatory cytokine network. We first investigated the effect of 
hypoglycemia in nondiabetic healthy volunteers and based on the findings from that 
study we repeated the experiments in type 1 diabetic patients who had a history of 
repeated exposure to hypoglycemic events (chapter 4).  
In chapter 5, the current literature on glucose counterregulation in type 2 diabetes is 
summarized and reviewed. Specific issues that are addressed include: what factors 
contribute to the lower risk for hypoglycemia in type 2 diabetes, and do the traditional 
risk factors for counterregulatory defects apply to type 2 diabetes. 
Adequate treatment options for clinical hypoglycemia unawareness are relatively 
limited. Although hypoglycemia unawareness can be reversed by strict avoidance of 
hypoglycemic events, the associated compromise in metabolic control is by definition 
undesirable. Moreover, minimizing the fall in glycemic control and reoptimizing it after 
return of hypoglycemic awareness (8) requires a great deal of effort from the patient. 
There is thus a need for treatments that are both more effective and easier to 
implement for larger groups of patients. In the second part of this thesis, we 
investigated whether a pharmacological approach could be a valid alternative for or 
adjunctive to other methods in the management of hypoglycemia unawareness. We 
hypothesized that the adenosine receptor antagonist theophylline would enhance 
counterregulatory responses to and symptomatic perception of insulin-induced 
hypoglycemia. We decided to choose theophylline over the methylxanthine related 
derivative caffeine because of its higher potency to block the adenosine receptor (90) 
and because of its availability in various formulations. In chapter 6, the effect of a 
single dose of theophylline was studied in both nondiabetic healthy volunteers and in 
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type 1 diabetic patients with clinical hypoglycemia unawareness, using a randomized 
placebo-controlled cross-over design. Based on the favorable findings in this study, a 
follow-up study was performed to determine the effect of prolonged use of 
theophylline (chapter 8). Finally, because it has been suggested that caffeine (91) 
and aminophylline (92) might reduce glucose tolerance, we investigated whether use 
of adenosine receptor antagonists could have unfavorable effects on insulin 
sensitivity (chapter 7). 
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ABSTRACT 
 
A defective adrenaline response to hypoglycemia is a common disorder in patients with type 1 
diabetes. There is a controversy as to whether this defect reflects a hypoglycemia-specific 
functional impairment or an absolute deficiency in adrenomedullary capacity to secrete 
adrenaline. Because adrenaline leaking from adrenal stores is immediately converted to 
metanephrine by catechol-O-methyl transferase (COMT), and because metanephrine is 
continuously released from the adrenal medulla, plasma metanephrine levels reflect 
adrenomedullary capacity. We measured plasma metanephrine levels in 10 type 1 diabetic 
patients with an established impairment in adrenergic responses to hypoglycemia and in 10 
age-, sex- and BMI-matched nondiabetic controls, during a hyperinsulinemic (360 
pmol·m-2·min-1) normoglycemic-hypoglycemic glucose clamp. Plasma levels of adrenaline, 
noradrenaline and normetanephrine were comparable between patients and controls at 
baseline and normoglycemia. In contrast, plasma metanephrine levels were ~30% lower in 
diabetic patients than in controls (0.18 ± 0.09 versus 0.24 ± 0.02 nmol/L, P = 0.012). In 
response to hypoglycemia, the increments in plasma adrenaline and plasma metanephrine 
levels were significantly lower in diabetic patients than in controls (P < 0.001). However, the 
production of metanephrine from adrenaline directly released into the circulation was 
identical (6.7%).  We conclude that type 1 diabetic patients with impaired adrenaline 
responses to hypoglycemia have lower plasma metanephrine levels than matched controls, 
compatible with decreased adrenomedullary stores of adrenaline and indicating reduced 
adrenomedullary capacity to secrete adrenaline. 
 
_____________________________________________________________________ 
 
ypoglycemia is a very common phenomenon in virtually all patients with type 1 
diabetes, but it is distinctly uncommon in nondiabetic persons. The risk for 
iatrogenic hypoglycemia sharply increases when an already absent glucagon 
response is accompanied by failure to sufficiently synthesize adrenaline in response 
to hypoglycemia (1). In addition, because of adrenaline’s role in the appearance of 
hypoglycemic (warning) symptoms, impaired adrenaline responses may adversely 
affect perception of hypoglycemia, ultimately leading to hypoglycemia unawareness. 
In the absence of overt autonomic neuropathy, it has been proposed that the 
impaired adrenaline response to hypoglycemia is largely caused by resetting of the 
threshold value for adrenaline release to a lower glucose level (2). This hypothesis is 
based on observations that the glycemic threshold for adrenaline release shifts to 
lower glucose levels after antecedent hypoglycemia (3) or after improvement of 
metabolic control (4-9), and to higher glucose levels when hypoglycemias are 
avoided (10-12) or metabolic control is relaxed (13). 
Recent observations have challenged this view and suggest a contribution of 
reduced adrenomedullary secretory capacity to the impaired adrenaline response. 
H 
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For instance, antecedent hypoglycemia has been found to suppress adrenergic 
responses to subsequent exercise (14), and reduced adrenergic responses to 
exercise have been reported in well-controlled uncomplicated diabetic patients 
(15,16). Others, however, found no effect of antecedent hypoglycemia on adrenergic 
responses to exercise (17) or reported that the capacity to synthesize adrenaline 
during exercise remained unaltered in diabetic patients despite recurrent 
hypoglycemia (18). Differences in the intensity and duration of, and compliance with 
the exercise protocols as used in the various studies may explain these conflicting 
data. In addition, exercise tests are not the most profound stimulus for the adrenal 
medulla, so that normal adrenaline responses can occur despite reduced 
adrenomedullary secretory capacity. 
The introduction of a sensitive method for measurements of free plasma 
metanephrines has provided a reliable means to estimate adrenomedullary capacity 
(19-21). Within the adrenal medulla, adrenaline that leaks from storage vesicles into 
the cytoplasm is converted to metanephrine by catechol-O-methyl transferase 
(COMT). In contrast to adrenaline, metanephrine is continuously released into the 
bloodstream, almost independent of adrenergic stimulation (22). Since over 90% of 
circulating metanephrine has an adrenomedullary source, plasma metanephrine 
levels reflect adrenomedullary stores of adrenaline and as such reflect the 
adrenomedullary capacity to synthesize adrenaline. In the present study, we 
measured plasma metanephrine levels to determine whether adrenomedullary 
secretory capacity is reduced in type 1 diabetic patients with impaired adrenaline 
responses to hypoglycemia. We used a hyperinsulinemic normoglycemic-
hypoglycemic glucose clamp to correct for an effect of hyperglycemia (23), and to 
investigate the effect of hypoglycemia on metanephrine release in relation to 
adrenaline release. 
 
PATIENTS AND METHODS 
 
From a previous study, we selected 10 patients who had an adrenaline response to 
hypoglycemia that was below the lower limit of the normal response, and 10 matched 
nondiabetic controls (24). All patients used regular insulin or insulin analogs in basal-
bolus regimen or in a subcutaneous pump. No patients had signs of autonomic 
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neuropathy as measured by standard cardiovascular reflex tests (25) and no one 
used medication other than insulin or oral contraceptives. The study was approved by 
the local hospital ethics committee and all participants gave written informed consent. 
 
Hyperinsulinemic clamp Patients were instructed to reduce the evening insulin 
dose or nocturnal insulin infusions prior to the studies to avoid nocturnal 
hypoglycemia. Both patients and controls were admitted to the research unit at 8.00 
am after an overnight fast and having abstained from caffeine-containing beverages 
for at least 48 hours. The brachial artery of the non-dominant arm was cannulated 
under local anesthesia for blood sampling and blood pressure recording. The 
antecubital vein of the contralateral arm was cannulated for infusion of insulin 
(Actrapid, Novo Nordisk, Bagsvaerd, Denmark) and glucose. Baseline variables were 
obtained after a stabilization period of 30-45 min. Thereafter, a hyperinsulinemic (360 
pmol·m-2·min-1) normoglycemic-hypoglycemic glucose clamp procedure was 
performed, as described previously (24). Briefly, using a variable infusion of glucose 
20%, the arterial plasma glucose concentration was sequentially clamped at 5.0, 3.5, 
and 2.5 mmol/L at hourly intervals, guided by plasma glucose levels measured in 
duplicate every 5 minutes by the glucose oxidation method (Beckman Glucose 
Analyzer II, Beckman, Fullerton, CA). Arterial blood was sampled for measurements 
of plasma catecholamines and metanephrines at baseline, during the final 30 
minutes of clamped normoglycemia and during the final 30 minutes of the second 
hypoglycemic phase (2.5 mmol/L). 
 
Analytical methods Plasma levels of adrenaline and noradrenaline were 
analyzed by high performance liquid chromatography (HPLC) with fluorometric 
detection, as described previously (26). Plasma levels of metanephrine and 
normetanephrine were performed by HPLC and electrochemical detection, using a 
modification of an earlier described procedure (19). Plasma insulin was measured by 
radioimmunoassay (24).  
 
Calculations and statistics Metanephrine/adrenaline (M/A) ratios were 
calculated as marker of COMT activity for each individual participant. Serial data 
were compared by two-way analysis of variance (ANOVA) and means were 
compared using Student’s t-test. For data that had no normal distribution, we used 
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Table 1. – Baseline characteristics 
 
 Type 1 DM patients Healthy controls 
Number (M/F) 10 (5/5) 10 (5/5) 
Age, years 32.7 ± 10.9  32.2 ± 8.7 
BMI, kg/m2 23.4 ± 2.6  22.9 ± 2.1 
Duration of diabetes, years 15.0 ± 6.4 - 
HbA1c, %   7.3 ± 0.5**    5.1 ± 0.2 
Fasting plasma glucose, mmol/L 12.2 ± 3.2**    5.2 ± 0.5 
Insulin, pmol/L  337 ± 215*     65 ± 18 
Data are means ± SD. *P < 0.05 and **P < 0.005 versus controls. To convert plasma glucose values to mg/dL, 
multiply by 18; to convert plasma insulin values to µU/mL divide by 6.0. 
 
the Wilcoxon signed rank test and Mann-Whitney U test to compare paired and 
unpaired data, respectively. For calculations and statistical analyses, the SPSS 
personal computer software package version 9.0 (SPSS, Chicago, IL) was used and 
P < 0.05 was considered statistically significant. Results are presented as means ± 
SEM, unless otherwise specified. 
 
RESULTS 
 
Characteristics of the participants are given in Table 1. As expected, type 1 diabetic 
patients had higher HbA1C, fasting plasma glucose and plasma insulin levels than 
controls (all P < 0.05). At baseline, there were no differences in arterial plasma 
adrenaline, noradrenaline or normetanephrine levels between patients and controls, 
but plasma metanephrine levels were 30% lower in diabetic patients than in controls 
(P = 0.012) (Table 2). As a consequence, diabetic patients had a lower M/A ratio than 
controls (0.93 ± 0.11 versus 1.72 ± 0.30, P = 0.034).  
 
Normoglycemia Plasma glucose levels obtained during the normoglycemic phase 
of the clamp were similar in patients and controls (5.0 ± 0.0 versus 4.9 ± 0.1 mmol/L, 
P = 0.16). Plasma insulin levels increased by similar amounts in both groups, so that 
insulin levels remained somewhat higher in patients than in controls (836 ± 92 versus 
559 ± 24 pmol/L, P = 0.013). During normoglycemia, plasma adrenaline levels did not 
change significantly in both control and diabetic subjects. Plasma metanephrine 
levels decreased in controls (P = 0.008) and tended to decrease in patients 
(P = 0.10), but remained about 25% lower in patients than in controls (P = 0.019). As 
a consequence, the M/A ratio decreased in both patients and controls (both P < 0.05) 
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during normoglycemia, but remained lower in the patients (0.58 ± 0.07 versus 1.08 ± 
0.12, P = 0.005). Plasma noradrenaline levels increased in both patients (P = 0.007) 
and controls (P = 0.005), whereas plasma normetanephrine levels but did not change 
in either group. 
 
Hypoglycemia Plasma glucose levels obtained during the hypoglycemic phase 
of the clamp were 2.4 ± 0.0 mmol/L in the patients and 2.5 ± 0.0 mmol/L in the 
controls (P = 0.24). Hypoglycemia increased plasma adrenaline and metanephrine 
levels in both patients and controls (all P < 0.01) (Table 2). Plasma adrenaline levels 
increased by 52-fold in the control and by 12-fold in the diabetic subjects (P < 0.001). 
Plasma metanephrine levels increased by 2.9-fold in the control subjects and by 2.0-
fold in the diabetic patients (P < 0.001). The increase above baseline in absolute 
plasma concentration of metanephrine as percentage of the absolute increase in 
plasma concentration of adrenaline was 6.7 ± 0.9% in control subjects and 6.7 ± 
1.5% in diabetic patients (P = 0.97) (Figure 1). In response to hypoglycemia, plasma 
noradrenaline levels increased by 2.7-fold in diabetic patients and by 4.3-fold in 
controls (P = 0.015), whereas plasma normetanephrine levels slightly increased in 
diabetic patients and controls, but to similar extent (Figure 1). 
Table 2. – Plasma levels of catecholamines and metanephrines at baseline and during the normoglycemic and 
hypoglycemic phase. 
 
 Type 1 DM patients Healthy controls P-value* 
Adrenaline, nmol/L 
baseline 
normoglycemia (5.0 mmol/L) 
hypoglycemia (2.5 mmol/L) 
 
0.22 ± 0.03 
0.31 ± 0.05 
2.49 ± 0.29† 
 
0.19 ± 0.03 
0.22 ± 0.03 
7.60 ± 0.87† 
 
NS 
NS 
<0.0001 
Metanephrine, nmol/L 
baseline 
normoglycemia (5.0 mmol/L) 
hypoglycemia (2.5 mmol/L) 
 
 0.18 ± 0.01 
 0.16 ± 0.01 
 0.34 ± 0.03† 
 
0.24 ± 0.02 
0.20 ± 0.01# 
0.69 ± 0.05† 
 
0.012 
0.019 
<0.0001 
Noradrenaline, nmol/L 
baseline 
normoglycemia (5.0 mmol/L) 
hypoglycemia (2.5 mmol/L) 
 
0.76 ± 0.11 
1.15 ± 0.12# 
1.80 ± 0.21† 
 
0.68 ± 0.09 
0.90 ± 0.07# 
2.92 ± 0.55† 
 
NS 
NS 
0.005 
Normetanephrine, nmol/L 
baseline 
normoglycemia (5.0 mmol/L) 
hypoglycemia (2.5 mmol/L) 
 
 0.16 ± 0.01 
 0.17 ± 0.01 
 0.25 ± 0.02† 
 
0.20 ± 0.02 
0.16 ± 0.01 
0.26 ± 0.03† 
 
NS 
NS 
NS 
Data are mean ± SEM. * P-values given denote differences between patients and controls. † P < 0.01 for trend 
from baseline (ANOVA). # P < 0.01 versus baseline value. NS, not significant. To convert plasma values for 
adrenaline and noradrenaline to pg/mL, multiply by 183.2 and 169.2, respectively; to convert plasma values of 
metanephrine and normeta-nephrine to pg/mL, divide by 5.08 and 5.46, respectively. 
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DISCUSSION 
 
The results of the present study indicate that type 1 diabetic patients with an impaired 
adrenergic response to hypoglycemia have a reduced adrenomedullary capacity to 
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Figure 1. – Mean (± SEM) increases in plasma adrenaline and metanephrine (top) and of plasma 
noradrenaline and normetanephrine (bottom) in response to hypoglycemia. In both patients and controls, the 
increase in plasma metanephrine was 6.7% that of plasma adrenaline (P = NS). * P < 0.05, 
** P < 0.001 higher plasma concentration versus that in DM-1 patients.  
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secrete adrenaline. This conclusion is based on the finding of lower plasma 
metanephrine levels in patients as compared to the matched controls, irrespective of 
prevailing glucose levels. In contrast, plasma levels of adrenaline, noradrenaline, and 
normetanephrine were comparable between patients and controls. 
In humans, over 90% of plasma metanephrine is produced from adrenaline 
leaking from storage vesicles into the cytoplasm of chromaffin cells. This conversion 
is catalyzed by intracytoplasmatic COMT. Because metanephrine is continuously 
released into the bloodstream, reduced plasma metanephrine levels reflect reduced 
adrenomedullary storage of adrenaline. This reduced adrenaline storage then 
translates into a reduced capacity to synthesize or release adrenaline. Our findings 
are in agreement with previous observations of reduced adrenergic responses to 
exercise tests in well-controlled diabetic patients (15,16), already suggesting that 
patients who may be assumed to have counterregulatory failure to some extent have 
a reduced adrenomedullary capacity to synthesize adrenaline. Based on our 
observation of 25-30% lower metanephrine levels in the diabetic patients, one would 
anticipate the plasma adrenaline response to hypoglycemia quantitatively similarly 
reduced. The fact that the plasma adrenaline response to hypoglycemia was almost 
70% lower in the diabetic patients than in controls (2.5 versus 7.5 nmol/L) indicates 
that another factor such as a resetting of the glycemic threshold value is required to 
explain the full extent of the impaired adrenaline response. 
It could be hypothesized that the lower plasma metanephrine levels in diabetic 
patients were the result of reduced COMT-activity within the adrenal medulla rather 
than reduced adrenaline content. Animal data have suggested that chronic 
hyperglycemia reduces COMT-activity in diabetes mellitus (23). The lower M/A ratio 
(as a surrogate marker for COMT-activity) indeed suggests reduced COMT-activity in 
diabetic patients. However, the identical increase in plasma metanephrine levels 
relative to the increase in plasma adrenaline levels during hypoglycemia provides an 
important argument against reduced COMT-activity in the patients. The increase in 
plasma metanephrine levels above baseline results from the metabolism of elevated 
adrenaline levels either after reuptake by the adrenals or by extraadrenal conversion, 
both of which are catalyzed by COMT (22,27). Prior studies involving 3H-labeled 
adrenaline and insulin tolerance tests have shown that the proportion of circulating 
metanephrine produced from infused adrenaline or from adrenaline directly released 
into the circulation is approximately 7.5% that of the increase in plasma adrenaline 
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(22). This proportion appears to be largely independent of the magnitude of the 
increase in plasma adrenaline. In both diabetic and control subjects, the absolute 
increase in plasma metanephrine above baseline during hypoglycemia was close to 
7% that of the increase in plasma adrenaline, indicating that the capacity of COMT to 
metabolize catecholamines was similar between patients and controls. In addition, 
the similar increments of plasma normetanephrine to hypoglycemia supports this 
notion of intact COMT in the patients.  
It seems unlikely that our findings are explained by diabetic autonomic 
neuropathy. First of all, all patients had normal responses on cardiovascular reflex 
tests (25). Secondly, plasma noradrenaline levels and the noradrenaline responses 
to insulin (during clamping) in the patients were not different from those in controls. 
Finally, basal plasma adrenaline levels were not reduced in the diabetic patients, and 
even tended to be higher than in controls. Many studies have reported low plasma 
adrenaline levels in patients with diabetic autonomic neuropathy (28-30). Since 
adrenomedullary cells secrete their content directly into the circulation upon 
stimulation, reduced plasma adrenaline levels generally reflect reduced neuronal 
outflow to the adrenal medulla (21). Consequently, the normal adrenaline levels in 
the diabetic patients clearly indicate that autonomic function was normal. 
A limitation of our study is the small sample size. In addition, it needs to be 
established prospectively whether low plasma metanephrine can be used as a 
marker of or as a risk factor for counterregulatory failure in diabetic patients. This is 
clinically relevant, because counterregulatory failure confers a high risk for iatrogenic 
hypoglycemia. Another limitation is that it cannot be determined from our data 
whether the reduced plasma metanephrine levels in diabetic patients reflect a 
temporal depletion of adrenal stores or a structural loss of adrenal mass. Because 
hypoglycemia has been reported to suppress the adrenergic response to subsequent 
exercise (14), temporal exhaustion of adrenal stores seems a plausible phenomenon 
in patients with type 1 diabetes. It could even be hypothesized that repeated 
hypoglycemia-induced exhaustion of adrenal stores may eventually become a 
structural defect. A structural loss of adrenal mass could explain why adrenaline 
responses to exercise tests remain lower in diabetic patients despite scrupulous 
avoidance of hypoglycemia (15), and why hypoglycemia prevention programs do not 
completely restore the impaired adrenaline response to hypoglycemia (10).  
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In conclusion, our study shows that diabetic patients with established 
(hypoglycemia-induced) counterregulatory failure have low plasma metanephrine 
levels compared to nondiabetic controls, reflecting reduced adrenaline stores and 
indicating reduced adrenomedullary secretory capacity. This reduced 
adrenomedullary capacity may explain in part the failure to secrete sufficient amounts 
of adrenaline under hypoglycemic conditions. The exact cause of this reduced 
adrenomedullary capacity cannot be derived from the present study, but it is unlikely 
to be a manifestation of or mediated by autonomic neuropathy. 
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ABSTRACT 
 
Hypoglycemia unawareness is thought to be the consequence of recurrent hypoglycemia, yet 
the underlying mechanism is still incompletely understood. The aim of the present study was 
to determine the role of antecedent elevated adrenaline in the pathogenesis of hypoglycemia 
unawareness. Sixteen healthy volunteers (8 of either sex) participated in two experiments, 
performed in random order and at least 3 weeks apart. During the morning, three consecutive 
doses of 0.04, 0.06, and 0.08 µg·kg-1·min-1 of adrenaline or matching placebo (normal saline) 
were infused for the total duration of one hour. Three hours later, a hyperinsulinemic (360 
pmol·m-2·min-1) two-step hypoglycemic (5.0-3.5-2.5 mmol/L) clamp study was performed. 
During hypoglycemia, hypoglycemic symptoms, counterregulatory hormones, cardiovascular 
responses, and cognitive function were monitored. Hypoglycemia induced similar responses 
of autonomic and neuroglycopenic symptoms, counterregulatory hormones, and lengthening 
in reaction time on the choice reaction time task, irrespective of antecedent infusions. 
However, prior adrenaline was associated with higher exogenous glucose requirements at 
hypoglycemic nadir (10.1 ± 1.3 versus 7.3 ± 1.3 µmol·kg-1·min-1, P = 0.017), an attenuated 
hypoglycemia-induced fall in blood pressure (MAP, -13 ± 2 versus -8 ± 2 mmHg, P = 0.006) 
and preserved cognitive function as assessed by the symbol digit test during hypoglycemia, 
when compared to prior placebo. We conclude that elevated adrenaline attentuates the 
responsiveness to, but not the release of counterregulatory hormones during subsequent 
hypoglycemia. As such, adrenaline’s role in the development of hypoglycemia unawareness is 
limited. 
  
___________________________________________________________ 
 
ypoglycemia unawareness, defined as the onset of neuroglycopenia before 
the development of appropriate autonomic warning symptoms (1), is a 
common complication of type 1 diabetes. Patients with hypoglycemia unawareness 
require lower levels of glycemia to initiate warning symptoms and counterregulatory 
hormone release, and have reduced magnitudes of both symptom and hormone 
responses to any given level of hypoglycemia. Pivotal to the occurrence of 
impairments in hypoglycemic awareness and counterregulatory hormone responses 
are the frequency, duration and severity of hypoglycemic episodes (2), and the 
degree of glycemic control (2), which – by inference – is also an index of 
hypoglycemic incidence. Conversely, by maintaining a high risk for undetected 
(severe) hypoglycemia, hypoglycemia unawareness remains a barrier for 
optimization of glycemic control (3). 
Despite the undisputed role of hypoglycemia per se in the development of 
hypoglycemia unawareness (4-6), the underlying mechanism remains incompletely 
understood. Increased blood-to-brain glucose transport has been suggested as 
underlying mechanism (7), but may not explain the blunted counterregulatory 
H 
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responses after short duration of hypoglycemia (8). Another proposed mechanism 
suggests the cortisol component of the metabolic response to hypoglycemia as 
mediator (9). Antecedent increases in plasma cortisol have been found to reduce 
responses of adrenaline, noradrenaline and growth hormone to subsequent 
hypoglycemia (9-12), but they do not invariably seem to affect symptom responses. 
Therefore, additional factors are likely to be involved. 
Adrenaline is a key component of the hypoglycemia response profile and closely 
related to the appearance of hypoglycemic warning symptoms (13). Conversely, the 
loss of hypoglycemic warning symptoms, which characterizes clinical hypoglycemia 
unawareness, can result from either a reduced adrenaline response to hypoglycemia 
or from a reduced sensitivity to catecholamines (14-17). Because adrenaline still 
increases at least severalfold in response to hypoglycemia even in patients with 
severe counterregulatory failure, patients with repeated hypoglyemic events may 
have chronically elevated adrenaline levels. Animal studies have indicated that prior 
elevation of adrenaline (18) and repeated stress (which primarily stimulates 
adrenaline) (19) downregulate sympathetic responses to novel stress, whereas prior 
exposure to β-adrenergic agonists (20,21) and strenous exercise (22) reduce β-
adrenergic sensitivity. Based on these data, we hypothesized that the adrenaline 
response to antecedent hypoglycemia may contribute to the hypoglycemia 
unawareness syndrome by exerting a downregulating effect on adrenaline responses 
to and adrenergic sensitivity during subsequent hypoglycemia. Therefore, the aim of 
the present study was to determine the effect of prior elevation of plasma adrenaline 
on hormone and symptom responses to subsequent hypoglycemia. 
 
SUBJECTS AND METHODS 
 
Subjects We studied 16 healthy non-smoking normotensive volunteers (8 males 
and 8 females), aged 22.5 ± 0.5 years and with a body mass index of 21.6 ± 0.4 
kg/m2. Subjects were studied on two occasions performed at least 3 weeks apart. 
Female subjects were studied at exact 4-week intervals to ensure that experiments 
were performed during corresponding periods of the menstrual cycle. The order of 
the experiments was randomized and performed in a single blind fashion. Studies 
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were approved by the medical ethics committee of the University Medical Center 
Nijmegen and written informed consent was obtained before participation.  
 
Experimental design Each participant was admitted to the University Medical 
Center Nijmegen at 8:00 AM, having abstained from alcohol for 24 hours and from 
caffeine-containing substances for 48 hours. Under local anesthesia (Xylocaine 2%), 
the brachial artery of the non-dominant arm was cannulated (Angiocath 20-gauge, 
Beckton Dickinson, Sandy, UT) for blood sampling and for hemodynamic monitoring 
(Monitor 378341A, Hewlitt Packard GmbH, Germany). The antecubital vein of the 
dominant contralateral arm was cannulated for administration of adrenaline 
(International Medication Systems Ltd, Slough, UK) or placebo (NaCl 0.9%), and for 
glucose 20% and insulin (Actrapid, Novo Nordisk, Denmark) infusions.  
After a 30-minute equilibration period following insertion of the cannulae, blood 
was sampled for baseline measurements. Thereafter, adrenaline (or an equivalent 
volume of placebo solution) was administered intravenously at an initial rate of 0.04 
µg·kg-1·min-1 for 20 minutes, followed by 0.06 and 0.08 µg·kg-1·min-1 for another 20 
minutes each (total amount, 3.6 µg/kg body weight over 60 minutes). Target plasma 
adrenaline levels were 6-9 nmol/L to match those obtained in response to 
hypoglycemia (23,24). At the end of the final infusion step, blood was sampled and 
the infusion discontinued.  
After a 3-hour rest period, a stepped hyperinsulinemic (360 pmol·m-2·min-1) 
hypoglycemic glucose clamp procedure was performed, as described before (24). 
Using a variable infusion of glucose 20%, the arterial plasma glucose concentration 
was sequentially clamped at 5.0, 3.5, and 2.5 mmol/L at hourly intervals, guided by 
plasma glucose levels measured in duplicate every 5 minutes by the glucose 
oxidation method (Beckman Glucose Analyzer II, Beckman, Fullerton, CA). Arterial 
blood samples for all analytes other than glucose were drawn before and after 
adrenaline or placebo infusion, before the start of the clamp and at each glycemic 
plateau during the clamp, and kept on melting ice until centrifugation. After 
centrifugation at 4 °C, plasma was stored at –20 °C until analysis. 
At 15-minute intervals during the clamp, a semiquantitative symptom 
questionnaire was administered. Subjects registered 6 neuroglycopenic symptoms 
(blurred vision, difficulty speaking, feeling faint, difficulty thinking, confused, and 
sleepiness), 6 autonomic symptoms (tingling, sweating, feeling hungry, palpitations, 
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anxiety, trembling), 4 general symptoms (dry mouth, weakness, nausea, and 
headache) and 2 dummy symptoms (yellow vision and pain in the legs) on a scale 
from 0 (absent) to 6 (severe). The appearance of a sweating response was detected 
objectively using a sensor applied to the forearm (Evaporimeter EP1, Servomed AB, 
Stockholm, Sweden) (25).  
Two cognitive tests were applied at 20-minute intervals during the clamp, the 
Choice Reaction Time task (CRT), to test vigilance and attention, and the Symbol 
Digit Test (SDT) from the dutch version of the Wechsler Adult Intelligence Scale (26), 
to test psychomotor and cognitive speed. On the CRT, a computer pad is used that 
contains four buttons with corresponding lights, of which only the light corresponding 
to the start button is illuminated. Subjects are asked to press the start button until the 
illumination switches to one of the other three lights, after which they have to press 
the corresponding button of that light. The reaction time – defined as the sum of the 
actual reaction time (i.e. the time to depress the start button) and movement time (i.e. 
the time to press the subsequent button) – is recorded. On the SDT, subjects are 
provided with a sheet of paper containing a total of 100 blank squares in four rows 
paired with one out of 10 randomly selected symbols. Using the digit-symbol key 
displayed at the top of the sheet, the subjects are asked to manually insert 
appropriate digits (0-9) in the squares below the symbols. The score is calculated as 
the number of correct substitutions within 60 seconds. Subjects were provided with 
sufficient practice on each test prior to the experiments. 
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Analytical methods Plasma insulin and plasma glucagon were measured by 
radioimmunoassays (24). Plasma adrenaline and noradrenaline were analysed by 
high performance liquid chromatography (HPLC) using a modification of an earlier 
described laboratory procedure (27). Plasma cortisol was assayed using the TDx 
batch analyzer of Abbott laboratories (Abbott Diagnostics, Hoofddorp, The 
Netherlands), as described before (24).  
 
Calculations and statistical analyses The glycemic threshold for detection of sweat 
production was defined for each individual as the plasma glucose level at which dew-
point electrode readings showed at least doubling of baseline values. Serial data 
were compared between groups by repeated measures analysis of variance 
(ANOVA) and differences in means were tested using paired Student’s t-test. 
Correlations were examined by Pearson’s correlation analysis. For calculations and 
statistical analyses, the SPSS personal computer software package (SPSS, Chicago, 
IL) was used. A P < 0.05 was considered statistically significant. Results in tables 
and figures are expressed as means ± SEM, unless otherwise indicated. 
 
RESULTS 
 
Effects of adrenaline After adrenaline infusion, arterial plasma adrenaline levels 
increased from 0.10 ± 0.02 to 8.11 ± 0.42 nmol/L (P < 0.001), values comparable to 
Table 1. – Cardiovascular responses to adrenaline and placebo infusion 
 
 Before infusion End of infusion P-value* 
Heart rate (b/min) 
placebo 
adrenaline 
 
   64 ± 2 
   66 ± 2 
 
   62 ± 2† 
   82 ± 2# 
 
<0.001 
Systolic BP (mmHg) 
placebo 
adrenaline 
 
 139 ± 3 
 136 ± 3 
 
 141 ± 3 
 147 ± 4# 
 
<0.001 
Diastolic BP (mmHg) 
placebo 
adrenaline 
 
   77 ± 2 
   75 ± 2 
 
   78 ± 2 
   67 ± 2# 
 
<0.001 
MAP (mmHg) 
placebo 
adrenaline 
 
   99 ± 2 
   97 ± 2 
 
 101 ± 2 
   93 ± 3† 
 
<0.001 
Data are means ± SEM. *Effect of placebo versus effect of adrenaline (ANOVA). †P < 0.05, #P < 0.001 
versus values before infusion 
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the usual adrenaline response to hypoglycemia (24). Adrenaline transiently increased 
plasma glucose (P < 0.001) (Figure 1), heart rate, and systolic blood pressure (sBP), 
and decreased diastolic blood pressure (dBP) and MAP (all P < 0.01) (Table 1). After 
cessation of adrenaline, glucose levels normalized at levels slightly, but significantly, 
lower than after placebo. Placebo infusion had no cardiovascular or metabolic 
effects, except for a slight fall in heart rate (P = 0.032). 
 
Plasma insulin and glucose Plasma insulin levels increased from 65 ± 8 pmol/L 
at baseline to stable levels of 521 ± 24 pmol/L during the clamp in the placebo control 
study. Corresponding values after prior adrenaline infusion were 59 ± 6 pmol/L at 
baseline and 524 ± 16 pmol/L during the clamp. Mean (± SD) glucose levels at target 
glycemic plateaus were similar in both study-arms, and measured 4.9 ± 0.1 (CV, 
4.1%), 3.4 ± 0.1 (CV, 4.3%), and 2.6 ± 0.1 (CV, 5.0%) mmol/L (Figure 1). 
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Figure 2. – Responses of autonomic symptoms (top) and neuroglycopenic symptoms (bottom) to 
hypoglycemia. P-values given are by ANOVA. 
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Responses to hypoglycemia In response to hypoglycemia, all of the following 
parameters increased: plasma levels of glucagon, adrenaline, noradrenaline, and 
cortisol (all P < 0.001) (Table 2), autonomic and neuroglycopenic symptom scores 
(both P < 0.001) (Figure 2), and heart rates (from 64 ± 2 to 68 ± 2 b/min, P < 0.001). 
Hypoglycemia caused decrements in sBP, dBP, and MAP (all P < 0.001) (Figure 3), 
and in performance on cognitive function tests, as reflected by an increase in 
reaction time on the CRT (from 466 ± 13 to 535 ± 15 ms, P < 0.001) and a fall in 
number of correct substitutions on the SDT (P = 0.001) (Figure 4), respectively. 
 
Effect of prior adrenaline on responses to hypoglycemia The glucose infusion 
rate (GIR) to maintain hypoglycemic nadir was significantly higher after prior 
adrenaline than after prior placebo (10.1 ± 1.3 versus 7.3 ± 1.3 µmol·kg-1·min-1, 
P = 0.017). Prior administration of adrenaline did not affect the release of glucagon, 
adrenaline, noradrenaline or cortisol in response to hypoglycemia (Table 2). 
Responses of autonomic and neuroglycopenic symptom scores to hypoglycemia 
were similar between prior placebo and prior adrenaline studies (Figure 2), and 
sweating responses were elicited at comparable glycemic thresholds (2.8 ± 0.1 
mmol/L [prior placebo] versus 2.7 ± 0.1 mmol/L [prior adrenaline], P = 0.31). Prior 
adrenaline administration reduced the falls in sBP (-7 ± 3 versus -1 ± 3 mmHg, 
ANOVA P = 0.010), dBP (final values, -15 ± 2 versus -10 ± 1 mmHg, ANOVA 
Table 2. – Hormonal responses to hypoglycemia 
 
 Hyperinsulinemic clamp P-value* 
 
Prior to clamp 
Euglycemia Hypoglycemic nadir  
Glucagon (pmol/L) 
prior placebo 
prior adrenaline 
 
16.1 ± 1.0 
20.1 ± 2.3 
 
14.9 ± 0.8 
12.9 ± 0.9 
 
48.8± 6.0† 
41.7 ± 4.3† 
 
0.17 
Adrenaline (nmol/L) 
prior placebo 
prior adrenaline 
 
0.25 ± 0.04 
0.40 ± 0.08 
 
0.24 ± 0.04 
0.33 ± 0.04 
 
6.76 ± 1.07† 
6.27 ± 0.85† 
 
0.58 
Noradrenaline (nmol/L) 
prior placebo 
prior adrenaline 
 
1.09 ± 0.09 
0.97 ± 0.07 
 
1.29 ± 0.12 
1.15 ± 0.07 
 
2.47 ± 0.25† 
2.24 ± 0.26† 
 
0.38 
Cortisol (µmol/L ) 
prior placebo 
prior adrenaline 
 
0.42 ± 0.05 
0.42 ± 0.08 
 
0.37 ± 0.05 
0.47 ± 0.09 
 
1.07 ± 0.09† 
1.09 ± 0.10† 
 
0.28 
Data are means ± SEM. *Effect of prior placebo versus effect of prior adrenaline (ANOVA). †P < 0.001 for 
change from ‘prior to clamp’-values (ANOVA). 
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P = 0.005), and MAP (-13 ± 2 versus -8 ± 2 mmHg, ANOVA P = 0.006) in reponse to 
hypoglycemia (Figure 3). There was a significant correlation between the 
hypoglycemia-induced fall in dBP and GIR at hypoglycemic nadir (R = 0.39, 
P = 0.027). Prior adrenaline had no effect on the heart rate response to 
hypoglycemia. After prior adrenaline infusion, hypoglycemia caused a similar 
increase in reaction time on the CRT (from 475 ± 15 to 550 ± 29 ms, P = 0.007), but 
did no longer interfere with the number of correct substitutions on the SDT (ANOVA, 
P = 0.34) (Figure 4). 
 
 DISCUSSION 
 
The present study was conducted to test whether adrenaline released during prior 
hypoglycemia exerts a suppressive effect on counterregulatory responses to 
subsequent hypoglycemia. To test this hypothesis, we mimicked the adrenaline 
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response to hypoglycemia by exogenous infusion and then measured the 
adrenomedullary responses to subsequent hypoglycemia. The findings are twofold. 
On the one hand, we found that prior elevation of plasma adrenaline to levels that 
matched those attained by hypoglycemia, did not affect counterregulatory hormone 
responses to or symptomatic awareness of subsequent afternoon hypoglycemia. 
These results do not support a role for adrenaline in the pathogenesis of 
hypoglycemia unawareness. On the other hand, prior adrenaline infusion was 
associated with higher exogenous glucose requirements (reflected by GIR) to 
maintain hypoglycemic nadir, attenuated blood pressure responses to subsequent 
hypoglycemia, and preserved cognitive function as assessed by SDT during 
subsequent hypoglycemia. These results therefore suggest an effect of prior 
adrenaline on the responsiveness to rather than the release of counterregulatory 
hormones during hypoglycemia. 
At hypoglycemic nadir, GIR is inversely related to the glucose-stimulating 
capacity of metabolic counterregulation as a whole; i.e. the higher the GIR, the lower 
the ability of metabolic counterregulation to raise plasma glucose. In the present 
study, counterregulatory hormone responses to hypoglycemia were not different 
according to pretreatment infusions, so that the higher GIR after adrenaline 
pretreatment can only be explained by reduced responsiveness to counterregulatory 
hormones to stimulate glucose. To what extent this reduced responsiveness is 
caused by reduced endogenous glucose production or by reduced suppression of 
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insulin-induced glucose uptake cannot be determined from our data. In studies 
investigating the effect of antecedent hypoglycemia or cortisol on responses to 
subsequent hypoglycemia, it has been reported that increased exogenous glucose 
reqiurements during subsequent hypoglycemia are primarily the result of reduced 
glucose production (9). It could then be hypothesized that the reduction in glucose 
production was the result of depletion of glycogen stores by prior adrenaline. This is 
however unlikely, because systemic adrenaline has a very modest effect on (hepatic) 
glycogenolysis (28) and because any fall in glycogen content would be corrected 
promptly by the sufficient supply of glucose (and insulin) during the initial phase of 
the clamp. 
Based on adrenaline’s role in acute glucose counterregulation and because 
adrenaline exerts its glucose-stimulating effects on liver and muscle primarily through 
the β-adrenergic receptor (29), it seems plausible that the reduced responsiveness 
after prior adrenaline specifically involves the β-adrenergic receptor (30). In line with 
this reasoning is the finding that blood pressure responses to hypoglycemia were 
attenuated after prior adrenaline, and are previous findings of reduced β-adrenergic 
sensitivity after short- (20) or long-term (21) exposure to β-adrenergic agonists. The 
fact that we were unable to detect an effect of prior adrenaline on autonomic 
symptom responses may be due to insensitivity of the checklists, or because other 
factors besides β-adrenergic stimulation are involved in the development of 
hypoglycemic symptoms (e.g. cerebral glucopenia) (7). Reduced adrenergic 
sensitivity has been suggested to play a role in hypoglycemia unawareness (1), in 
order to explain observations of unawareness despite normal plasma catecholamine 
responses to hypoglycemia (31). Recently, β-adrenergic sensitivity was found to be 
reduced in type 1 diabetic patients with hypoglycemia unawareness when compared 
to patients with normal hypoglycemic awareness and controls (14). After avoidance 
of hypoglycemias, this reduced β-adrenergic sensitivity improved in parallel with the 
increase in autonomic warning symptoms (17), while β-adrenergic sensitivity 
appeared to decrease after an antecedent hypoglycemic episode (32,33). The 
present data suggest that an inhibiting effect of hypoglycemia on β-adrenergic 
sensitivity (15,16) is mediated by adrenaline. The extent to which this phenomenon 
can be extrapolated to diabetic patients with hypoglycemia unawareness requires 
further study.  
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Surprisingly, prior adrenaline administration was associated with absence of 
hypoglycemia-induced deterioration of performance on the SDT cognitive function 
test. Since prior exposure to stressful stimuli may reduce anxiety caused by certain 
cognitive tests (34), a lower level of anxiety after adrenaline pretreatment may have 
led to a better performance. Alternatively, adrenaline-induced desensitization of α1-
adrenergic receptors in the brain, stimulation of which has been associated to 
impaired cognitive function in rats (35), might also have inhibited the hypoglycemia-
induced fall in cognitive function after adrenaline. However, neither habituation to 
stress nor desensitization of α1-adrenergic receptors provides an explanation for the 
lack of prior adrenaline to affect performance on the CRT cognitive function test. It 
cannot be excluded that the results obtained on the SDT during hypoglycemia in the 
prior adrenaline study were to some extent flawed by the lower peak performance 
obtained during normoglycemia. Moreover, potential limitations apply to the use of 
cognitive function tests during studies of acute hypoglycemia. Both CRT and SDT are 
appropriate tests for this purpose as they are susceptible to hypoglycemia, require 
little time, provide measures with clinical relevance, and do not lead to sustained 
arousal (36). However, the SDT – but not the CRT – requires fine motor co-ordination 
of the (dominant) writing hand. It cannot be excluded that hypoglycemia-induced 
autonomic symptoms – e.g. tremor, sweating, agitation – to some extent interfered 
with the performance on the SDT, independent of cortical malfunction (37). This 
would, again, suggest some sort of reduction in end-organ sensitivity caused by prior 
adrenaline. 
Our study design differed in some aspects from those of other studies 
investigating the pathogenesis of hypoglycemia-induced counterregulatory failure. 
Firstly, in most studies on this subject, an intervention on day 1 is followed by 
measurement of responses to hyperinsulinemic hypoglycemia on day 2 (9-12). It 
could be argued that the interval between the intervention and the subsequent clamp 
study was too short in the present study, since we measured counterregulatory 
responses to subsequent hypoglycemia on the same day. Conceptually and in 
clinical practice however, an interval of 24 hours is not required for interaction 
between hypoglycemic episodes. For instance, a single episode of asymptomatic 
nocturnal hypoglycemia was found to impair both hormonal and symptom responses 
to hypoglycemia the following morning (38). Recently, Davis et al. demonstrated that 
moderate antecedent morning hypoglycemia blunted all neuroendocrine responses 
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to hyperinsulinemic hypoglycemia 2 hours later, and to similar extent as the blunting 
effect of two previous-day hypoglycemic episodes (39). As such, it is unlikely that the 
intervaltime affected our results. Secondly, in many studies the intervention to be 
investigated is performed twice to ensure a stronger stimulus, whereas in our study 
we scheduled one intervention. Nevertheless, it has previously been shown that one 
recent hypoglycemic episode is sufficient to induce counterregulatory impairments 
(38). Lastly, it could be claimed that one hour of elevated adrenaline was too short a 
stimulus. However, the suppressive effect of prior hypoglycemia on responses to 
subsequent episodes seems to be relatively independent of the initial episode’s 
duration, as even episodes of <30 minutes duration have been reported to cause 
counterregulatory impairments (40). In addition, plasma adrenaline levels after 
adrenaline infusion were at least twice as high as those attained by studies using 
antecedent (moderate) hypoglycemia as stimulus, so that on balance the adrenaline 
stimuli were at least similar. Despite these considerations, it cannot be totally 
excluded that prolonged, repeated or higher doses of adrenaline would have 
produced more pronounced effects.  
In summary, we found that prior elevation of plasma adrenaline did not affect 
hormonal responses to or symptomatic awareness of subsequent hypoglycemia, but 
was associated with higher exogenous glucose requirements and attenuated blood 
pressure responses during hypoglycemia. The higher exogenous glucose 
requirements and the attenuated cardiovascular responses after prior adrenaline 
administration are compatible with reduced responsiveness to counterregulatory 
hormone action, most likely explained by reduced β-adrenergic sensitivity. Since 
hypoglycemia may suppress β-adrenergic sensitivity (32), our data raise the 
intriguing possibility that this suppression of β-adrenergic sensitivity is mediated by 
the adrenaline response to hypoglycemia, which then would contribute to 
compromised counterregulatory function. Despite this potential contribution, however, 
adrenaline is probably not the missing link to explain the suppressive effect of 
antecedent hypoglycemia on a subsequent episode.   
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ABSTRACT 
 
The aim of the present study was to investigate the effect of hypoglycemia on the production 
capacity of the proinflammatory cytokines tumor necrosis factor (TNF)-α and interleukin 
(IL)-1β in subjects with and without diabetes. Hyperinsulinemic (360 pmol·m-2·min-1) stepped 
hypoglycemic (5.0–3.5–2.5 mmol/L) glucose clamps were performed in 8 diabetic patients 
and in 6 nondiabetic subjects, and hyperinsulinemic normoglycemia (5.0 mmol·L-1) control 
experiments were performed in 4 nondiabetic subjects. Circulating levels of cytokines and 
endotoxin-induced production of TNFα, IL-1β, IL-6, and IL-10 were assessed. The effects of 
insulin and adrenaline were measured in separate in-vitro experiments. In nondiabetic 
subjects, hypoglycemia downregulated the production capacity of TNFα in a concentration-
dependent fashion (P = 0.007), but not of IL-1β, IL-6, or IL-10. Compared to controls, the 
production capacity of TNFα in diabetic patients was already suppressed at normoglycemia 
(P = 0.02) and only fell in response to hypoglycemic nadir (P = 0.04). The downregulation of 
TNFα could not be explained by increased insulin or adrenaline levels. We conclude that 
hypoglycemia specifically downregulates TNFα production capacity. Diabetic patients 
already have a suppressed TNFα production capacity at non-hypoglycemic levels. 
 
___________________________________________________________ 
 
roinflammatory cytokines, such as tumor necrosis factor-α (TNFα), interleukin-
1β (IL-1β), and IL-6 are important mediators of the inflammatory response. 
Cytokines are elicited when the host is exposed to infectious organisms (1), but may 
also appear in response to physical exercise (2), trauma (3), surgery (4,5), and 
resuscitation/hemorrhagic shock (6) as part of a stress response. Often, stressful 
events are followed by downregulated production of proinflammatory cytokines, 
which may be associated with release of adrenaline and cortisol (7), with 
antiinflammatory effects of IL-10 (8,9), (10)or with other factors (11,12). The 
downregulation of TNFα and IL-1β production capacity may be seen as a means to 
protect the host against excessive release of potentially deleterious cytokines. On the 
other hand, a decrease in cytokine production may increase vulnerability to 
secondary stressors, such as infections (13). This higher susceptibility to (secondary) 
infections has been demonstrated in mice (14) and has been designated as ‘post-
traumatic immune paralysis’ (15).  
Hypoglycemia is perceived as considerably stressful by the human body. Apart 
from glucagon release necessary to restore normoglycemia, plasma adrenaline 
levels increase dramatically as do plasma levels of noradrenaline, cortisol, and 
growth hormone (16). Most (insulin-treated) diabetic patients suffer from 
hypoglycemic episodes more than once a week, especially since tight metabolic 
P 
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control has become standard in the management of diabetes (17,18). As far as we 
know, the effect of hypoglycemia on cytokine kinetics has not been studied before. 
As a systemic stressor, hypoglycemia may be expected to downregulate ex-vivo 
cytokine production. Alternatively, downregulation may also occur as an effect of 
hypoglycemia per se, because cytokine production capacity (19) has been shown to 
depend directly on the ambient glucose level (20). The purpose of the present study 
was to determine the effect of in-vivo hypoglycemia, using a two-step 
hyperinsulinemic hypoglycemic clamp, on ex-vivo endotoxin-induced cytokine 
production in healthy volunteers – having no prior hypoglycemic experience – and in 
well-controlled Type 1 diabetic patients known to have frequent hypoglycemic 
episodes. In addition, the role of the clamp procedure per se was investigated by a 
separate normoglycemic time control experiment, and the roles of insulin and 
adrenaline were investigated by separate in-vitro studies.  
 
MATERIALS AND METHODS 
 
Subjects Written informed consent was obtained from 10 healthy individuals (6 
men and 4 women), mean (±SD) age, 26.2 ± 5.3 years, and 8 Type 1 diabetic 
patients (4 men and 4 women), age 34.5 ± 2.9 years, duration of diabetes, 15.0 ± 2.1 
yrs, and HbA1c, 7.2 ± 0.1%. Diabetic patients reported to have hypoglycemic 
episodes at least once weekly and they were instructed to avoid hypoglycemia for 3 
days prior to the experiments. The study was approved by the hospital ethics 
committee of the University Medical Center Nijmegen. 
 
Hypoglycemic clamp All participants were admitted to the research unit at 8.00 
am after an overnight fast. The brachial artery of the non-dominant arm was 
cannulated under local anesthesia for blood sampling and an intravenous catheter 
was inserted in an antecubital vein of the contralateral arm for infusion of insulin 
(Actrapid, Novo Nordisk, Bagsvaerd, Denmark) and glucose. Baseline variables were 
obtained after a stabilization period of 30-45 min. Thereafter, a hyperinsulinemic (360 
pmol·m-2·min-1) hypoglycemic glucose clamp procedure was initiated in all diabetic 
and in 6 healthy subjects, as described previously (21). Using a variable infusion of 
glucose 20% (supplemented with 10 mmol KCl per 500 ml), the arterial plasma 
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glucose concentration was sequentially clamped at ~5.0, 3.5, and 2.5 mmol/L at 
hourly intervals, guided by plasma glucose levels measured in duplicate every 5 
minutes by the glucose oxidation method (Beckman Glucose Analyzer II, Beckman, 
Fullerton, CA). At baseline and at each glycemic plateau, arterial blood was sampled 
for whole blood stimulation and for measurement of insulin, plasma catecholamines, 
and cortisol. To determine the effects of in-vivo hyperinsulinemia and of the clamp 
procedure itselves, four healthy subjects participated in a separate hyperinsulinemic 
normoglycemia time-control study, which was identical to the hypoglycemia study 
except that plasma glucose was kept constant at ~5.0 mmol/L for the duration of the 
study.  
 
Whole blood stimulation  Blood for cytokine measurements was aseptically 
drawn in sets of three heparin anticoagulated tubes. One tube (a) was centrifuged 
immediately to obtain plasma for measurement of cytokine concentrations. Whole 
blood was stimulated with lipopolysaccharide (LPS) 10 ng/mL (E. coli O55:B5 Sigma 
Chemical, St Louis, MO) for 24h at 37oC (tube b) and the third tube (c) was incubated 
for 24h at 37oC without LPS, serving as a negative control. After incubation, both 
tubes were centrifuged and plasma was stored at –80oC until assays were 
performed. The net LPS-stimulated cytokine production was calculated as the 
difference between the levels in the stimulated and the non-stimulated (control) 
tubes. 
 
In-vitro studies In separate in-vitro experiments, the differential effects of insulin 
and adrenaline alone on cytokine production and cytokine production capacity were 
studied. Therefore, venous blood was collected from 5 healthy individuals to isolate 
PBMCs, as previously described (22). The cells were washed in saline and 
suspended in culture medium (RPMI 1640 DM, ICN Biomedicals Inc, Costa Mesa) to 
which human serum 5%, gentamicin 1%, L-glutamine 1%, and pyruvate 1% was 
added. One mL of cell suspension was incubated for 24h in 24-wells plates (Becton 
Dickinson, Parsippany, NJ) with various insulin concentrations (60, 300, 600, 1200, 
3000, and 6000 pmol/L) or adrenaline concentrations (0.05, 0.55, 5.5, 55 nmol/L) in 
the presence of either 1 ng/mL LPS or no LPS to calculate net LPS-stimulated 
cytokine production as described above. 
 
CHAPTER 4 
 66 
Analytical methods Plasma adrenaline and noradrenaline were analyzed by 
HPLC with a modification of an earlier described laboratory procedure (23). Plasma 
insulin was measured by radioimmunoassay (21) and plasma cortisol was measured 
using the TDx batch analyzer of Abbott laboratories (interassay CVs, 4.6% and 6.6% 
at cortisol concentrations of 8 and 38 µg/dL, respectively). HbA1C was measured 
using HPLC (Bio-Rad Laboratories, Veenendaal, The Netherlands) with reference 
values of 4.8–6.2%. TNFα and IL-1β were determined by RIA using polyclonal rabbit 
anti-cytokine antibodies, as described previously (2). IL-6 and IL-10 were both 
determined by commercial available ELISA kits (Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands).  
 
Statistics Statistical analysis was done by means of a Friedman two-way ANOVA 
for comparison of sequential data. A Wilcoxon signed rank test was used for 
comparison of paired data, a Mann-Whitney U-test for unpaired data. For calculations 
and statistical analyses, the SPSS personal computer software package version 9.0 
(SPSS, Chigaco, IL) was used and P < 0.05 was considered statistically significant. 
Results in tables and figures are expressed as means ± SEM, unless otherwise 
specified. 
 
RESULTS 
 
Prior to the clamp, plasma glucose levels were significantly higher in diabetic 
subjects than in healthy controls (11.2 ± 0.1 versus 5.0 ± 0.1 mmol/L, P < 0.001). 
Mean (± SD) glucose levels obtained at each glycemic plateau during hypoglycemia 
Table 1. –  Hormone responses to hypoglycemia 
 
 Glucose level (mmol/L)  
 5.0 3.5 2.5 
Healthy controls    
adrenaline, nmol/L   0.22 ± 0.07  2.68 ± 0.48**   7.23 ± 0.89** 
noradrenaline, nmol/L   0.85 ± 0.06  1.27 ± 0.06**   2.31 ± 0.27** 
cortisol, µmol/L   0.43 ± 0.10  0.69 ± 0.08*   1.21 ± 0.16* 
Type 1 diabetic patients    
adrenaline, nmol/L   0.37 ± 0.07  0.76 ± 0.19*††   2.79 ± 0.61**†† 
noradrenaline, nmolL   1.11 ± 0.14  1.36 ± 0.16*   2.05 ± 0.28** 
cortisol, µmol/L   0.38 ± 0.09  0.41 ± 0.12   0.70 ± 0.12**† 
Data are means ± SEM. *P < 0.05, **P < 0.01 versus normoglycemic values. †P < 0.05, ††P < 0.01 versus 
corresponding values in control subjects  
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studies in both diabetic patients and healthy subjects were 5.0 ± 0.1, 3.4 ± 0.1, and 
2.5 ± 0.1 mmol/L, respectively. During the normoglycemia control study, plasma 
glucose remained 5.0 ± 0.1 mmol/L throughout the experiment. Corresponding 
insulin levels were 930 ± 132 and 1014 ± 84 pmol/L in diabetic patients and healthy 
subjects during hypoglycemia studies, and 678 ± 72 pmol/L during the 
normoglycemia control study. In both patients and controls, hypoglycemia stimulated 
plasma adrenaline, noradrenaline, and cortisol (all P < 0.01), but responses of 
plasma adrenaline and cortisol were significantly blunted in diabetic patients 
compared to controls (Table 1).  
0
2
4
6
BL ~5.0 ~3.5 ~2.5
TN
Fα
  (
ng
/m
L)
Glucose  (mmol/L)
0
2
4
6
8
10
0 90 150 210
Time (min)
IL
-1
β 
(n
g/
m
L)
Figure 1. – Effect of normoglycemia (open triangles) and hypoglycemia (open circles) in healthy controls and 
of hypoglycemia in type 1 diabetic patients (solid squares) on net LPS stimulated ex-vivo production of TNFα 
(top) and IL-1β (bottom). Hypoglycemia suppresses TNFα production glucose-dependently in controls 
(P = 0.007, ANOVA), but not in diabetic patients (P versus controls = 0.005, ANOVA). Normoglycemia has 
no effect on TNFα. Hypoglycemia does not affect IL-1β in either patients or controls. *P = 0.02 (Mann-
Whitney U test) diabetic patients versus controls in hypoglycemia studies. 
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In-vivo studies Baseline circulating levels of TNFα were 0.11 ± 0.01 and 
0.13 ± 0.01 ng/mL in healthy controls and diabetic patients, respectively (P = 0.11), 
and remained unaffected by hypoglycemia (data not shown). In healthy controls, 
TNFα production at baseline was 4.9 ± 0.8 ng/mL after ex-vivo stimulation with 
lipopolysaccharide (LPS) and 0.5 ± 0.1 ng/mL without LPS-stimulation, respectively. 
The net ex-vivo TNFα production, calculated as the difference between these two 
values, averaged 4.4 ± 0.8 ng/mL (range, 2.7-7.4). In response to hypoglycemia, net 
ex-vivo TNFα production decreased gradually to a nadir of 0.8 ± 0.2 ng/mL (range 
0.1-1.0) (ANOVA, P = 0.007), which could not be explained by high insulin levels, 
since it did not change during normoglycemia control studies (Figure 1). Compared to 
nondiabetic subjects, net ex-vivo TNFα production in diabetic patients tended to be 
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Figure 2. – Effect of hypoglycemia on net LPS stimulated ex-vivo production of IL-6 and IL-10 in healthy 
controls. P-values given are by ANOVA. 
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lower at baseline (P = 0.06) and was significantly lower during the normoglycemic 
phase (P = 0.02). The hypoglycemia-induced downregulation of net ex-vivo TNFα 
production was significantly diminished in diabetic patients compared to controls 
(ANOVA, P = 0.005). In fact, net ex-vivo TNFα production remained unaltered in 
diabetic patients until the final phase of the clamp and only fell in response to 
hypoglycemic nadir (from 2.7 ± 0.6 to 1.3 ± 0.3 ng/mL, P = 0.04). 
Circulating levels of IL-1β were comparable between diabetic patients and controls 
(0.06 ± 0.01 versus 0.05 ± 0.01 ng/mL, P = 0.7), as was net ex-vivo production of 
IL-1β (3.8 ± 2.2 versus 5.3 ± 2.0 ng/mL, P = 0.7). Hypoglycemia did not affect 
circulating levels or net ex-vivo production of IL-1β in either patients or controls 
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Figure 3. – In-vitro effect of insulin (top) and adrenaline (bottom) on net LPS stimulated ex-vivo TNFα 
production. P-values given are by ANOVA. 
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(Figure 1). In healthy controls, circulating levels of the proinflammatory cytokine IL-6 
and the antiinflammatory cytokine IL-10 were 0.19 ± 0.08 ng/mL and 0.006 ± 0.005 
pg/mL, respectively, which did not change in response to hypoglycemia. Similarly, 
neither net ex-vivo production of IL-6 nor net ex-vivo production of IL-10 were 
affected by hypoglycemia (Figure 2). IL-6 and IL-10 were not measured in diabetic 
patients.  
 
In-vitro studies In-vitro studies were performed using peripheral blood mononuclear 
cells (PBMCs) from healthy control subjects. PBMCs did not release TNFα in the 
absence of LPS stimulation, which remained unaffected by incubation with either 
insulin or adrenaline (data not shown). When stimulated by LPS, the production of 
TNFα tended to increase dose-dependently with increasing insulin concentrations 
(P = 0.08), but did not fall (Figure 3). In-vitro, adrenaline appeared to suppress net 
ex-vivo TNFα production dose-dependently from 0.29 ± 0.03 ng/L at baseline to 0.17 
± 0.04 ng/L at the highest adrenaline concentration (Figure 3), but this failed to reach 
statistical significance (P = 0.13).  
 
DISCUSSION 
 
The main findings of our study were that insulin-induced hypoglycemia specifically 
downregulated LPS-stimulated TNFα synthesis in a glucose 
concentration-dependent manner in healthy individuals. In type 1 diabetic patients, 
the effect was less accentuated and only significant at hypoglycemic nadir. Under 
normoglycemic conditions, the production capacity of TNFα was significantly lower in 
Type 1 diabetic patients than in healthy controls, whereas levels of circulating TNFα 
tended to be higher. The downregulated TNFα response appeared unrelated to IL-10 
and adrenaline, and was not caused by the high insulin levels during the 
experiments. In-vitro, supraphysiological insulin levels (>1200 pmol/L) even tended to 
stimulate TNFα production capacity, which is in accordance with a study reporting 
enhancement of proinflammatory cytokine production (including TNFα) during 
simultaneous LPS and insulin administration (24). Our observation that ex-vivo 
synthesis of other cytokines were not affected seemed to exclude hypoglycemia-
induced early cell death as a cause of downregulation. 
HYPOGLYCEMIA AND TNFα 
 71 
Downregulation of the cytokine production capacity has been demonstrated in 
response to a variety of stress conditions, such as surgery (4), exercise (2), and 
psychological stress (25). This ex-vivo phenomenon can be demonstrated within a 
few hours after contact with the inflammatory stimulus and often coincides with 
upregulation of antiinflammatory cytokines. Although it has been suggested that 
downregulation of the cytokine network is aimed at preventing excessive production 
of potentially detrimental proinflammatory cytokines, it occurs even in the absence of 
significant cytokine production. Our results of downregulated TNFα production 
capacity without altering plasma cytokine levels during hypoglycemia were consistent 
with an effect of moderate stress, such as seen with hip replacement surgery (5) or 
psychological stress (25). In contrast to other stimuli and despite substantial 
increases in plasma catecholamines and cortisol, neither LPS-stimulated release of 
IL-1β was inhibited (10), nor was the antiinflammatory cytokine IL-10 upregulated 
(12). There are several possible explanations. First of all, the specific hormonal 
response profile might be distinct from that caused by stress conditions other than 
hypoglycemia. Secondly, it might be due to the short duration of (hypoglycemic) 
stress as antiinflammatory responses may require 2-3 hours to reach maximum 
values (5,26). Alternatively, the discrepant effects of hypoglycemia on the cytokine 
network might be associated with glucose-specific effects. In-vitro studies have 
suggested that production (20) and production capacity (19) of TNFα, but not IL-1β, 
are upregulated when glucose levels increase. A fall in plasma glucose might thus 
lead to a fall in TNFα production capacity. The inability of adrenaline alone to 
suppress LPS-induced TNFα production in our assay further supports a direct effect 
of low plasma glucose on TNFα production capacity, although it does not exclude a 
contribution of adrenaline (7).  
The effect of hypoglycemia on TNFα production capacity differed considerably 
between diabetic and control subjects. Two factors may have played a role. Firstly, 
the reduced counterregulatory hormone responses to hypoglycemia indicate that the 
hypoglycemic stimulus was not of the same magnitude for the diabetic patients as it 
was for the nondiabetic volunteers, as a consequence of differences in prior 
‘hypoglycemic experience’ (27). It is plausible that a further reduction in glucose level 
might have suppressed TNFα production capacity more in the diabetic patients as 
well. A second explanation for the limited effect of hypoglycemia in the diabetic 
patients is that the TNFα production capacity was already suppressed in these 
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patients before induction of hypoglycemia. To our knowledge, this has not been 
reported before, although there are indications that long-term diabetes is associated 
with suppressed production capacity of other proinflammatory cytokines (28,29). The 
suppressed TNFα production capacity may be a complication of diabetes per se, or – 
due to the fact that the hypoglycemic rate was high in our patientgroup – a 
consequence of recurrent hypoglycemia-induced downregulation of TNFα.  
In summary, we showed that insulin-induced hypoglycemia downregulated TNFα 
production capacity in nondiabetic subjects, but did not affect IL-1β, IL-6 or IL-10. 
The effect of hypoglycemia on TNFα production capacity was suppressed in long-
term type 1 diabetic patients, possibly becasue the production capacity was already 
suppressed under non-hypoglycemic conditions. The clinical relevance of these 
observations are not yet clear, but it could be hypothesized that downregulated TNFα 
production capacity increases vulnerability to stressors, such as infections (13). 
Clinical studies of sufficient size are required to further delineate this issue.  
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ABSTRACT 
 
Glucose counterregulatory failure and hypoglycaemia unawareness frequently complicate 
treatment of type 1 diabetes mellitus, especially when aiming for intensive metabolic control. 
Since tight metabolic control reduces microvascular long-term complications in type 2 diabetes 
mellitus, the integrity of glucose countrerregulation in type 2 diabetic patients is important. 
Using a medline search, we identified 12 studies in which counterregulatory responses to insulin-
induced hypoglycaemia were compared between type 2 diabetic patients and appropriate 
controls. A review of these studies showed that some patients with type 2 diabetes mellitus 
develop mild counterregulatory dysfunction and reduced awareness of insulin-induced 
hypoglycemia. Some studies suggested an association between counterregulatory impairment 
and intensity of metabolic control. We speculate that the relatively low frequency of (severe) 
hypoglycemic events in type 2 diabetes may explain why glucose counterregulation remains 
unaffected in most patients. We hypothesize that residual β-cell reserve and insulin resistance 
provide protection against severe hypoglycemia and limit impaired counterregulation. 
 
_____________________________________________________________ 
 
lucose is the primary source of energy for cerebral function. Since the brain is 
unable to synthesize or store the substrate, hypoglycemia jeopardizes normal 
brain function. To protect the brain, a hierarchical series of counterregulatory responses 
is initiated when glucose levels exceed critical glycemic thresholds (1), beginning with 
suppression of insulin release when glucose levels fall below 4.6 mmol/L. This system 
of counterregulation is so efficient that clinically significant hypoglycemia rarely occurs 
in healthy individuals. However, patients with type 1 diabetes mellitus (DM) – who lack 
insulin suppression as a first-line defense – are prone to develop impaired hormonal 
counterregulation (2-4) and awareness (5) of falling blood glucose levels. The 
magnitude of this impairment depends in part on the effect of previous hypoglycemic 
episodes (6-10). Since repetitive iatrogenic hypoglycemia is usually an inevitable 
consequence of intensive insulin treatment (11), defective counterregulation may 
become a limiting factor in maintaining strict metabolic control in type 1 DM. 
Compared with type 1 DM, hypoglycemic events are less common in patients with 
type 2 diabetes, and severe episodes, requiring external assistance, are rare (Table 1) 
(12-15). However, tight metabolic control increases the risk of hypoglycemia both in 
‘newly’ diagnosed type 2 DM patients (13,14) and in those with longer disease duration 
(7.8 ± 4 years) (15). It should also be noted that hypoglycemia in the elderly commonly 
evokes ‘non-classical’ symptoms, such as light-headedness and unsteadiness, which 
may be incorrectly attributed to other causes (16). Asymptomatic hypoglycemic 
G 
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episodes occur more frequently in type 2 DM than originally thought (17), and in the 
elderly particularly hypoglycemia as a cause of mortality in the community is probably 
not always recognized (18). Finally, hypoglycemia associated with oral agents, 
particularly glibenclamide and chlorpropamide (19-21), may be very persistent and 
occasionally lethal (22). Relatively little is known about the integrity of counterregulation 
in patients with type 2 DM and its role in the vulnerability to hypoglycemia (23-37). 
Since tight metabolic control is being increasingly advocated in type 2 DM (38), it is 
important to understand whether impaired glucose counterregulation might limit its 
implementation. The purpose of this review is to provide a critical analysis of studies on 
glucose counterregulation in type 2 DM. 
 
METHODS 
 
We conducted a MEDLINE search from 1966 until present and reviewed bibliographies 
of relevant articles. All papers concerning glucose counterregulatory hormone 
responses to hypoglycemia in type 2 DM were regarded eligible for evaluation in this 
review. We were able to retrieve 16 research articles (23-37,39), the characteristics of 
which are shown in Table 2. From the study by Polonsky et al. (27), who reported on 
counterregulation in four groups of diabetic patients, only data involving diabetic 
patients with residual β-cell function are shown; in addition, the presentation of 
individual data permitted us to reclassify patients according to treatment regimen, either 
insulin or oral agents. From another study (34), investigating counterregulatory 
responses to hypoglycemia in type 2 diabetic patients before and after intensified 
metabolic control, only data after improved control are shown. In 12 studies (24-
32,34,35,37), metabolic responses to hypoglycemia were compared between type 2 
DM and healthy controls, which form the focus of this review. 
 
OUTCOMES OF STUDIES ON COUNTERREGULATION IN TYPE 2 DIABETES 
MELLITUS 
 
Methodology of the studies  In general, investigating patients with type 2 
DM is hindered by their heterogeneity. The development of type 2 diabetes is insidious 
and continues with a long period of decreasing insulin sensitivity in combination with 
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(relative) β-cell failure. It is thought that the ‘true’ onset of disease precedes the date of 
diagnosis by 9-12 years (40). The severity of type 2 DM is partly associated with its 
duration, but also depends on residual β-cell function, the extent of insulin resistance, 
and the presence of long-term diabetic complications. Indeed, type 2 diabetic patients 
who were included in studies on counterregulation differed considerably with respect to 
age, treatment modality, metabolic control, body composition, and the presence of 
autonomic neuropathy. 
Well-matched control groups are also required to justify firm conclusions on 
counterregulatory functioning in type 2 DM. Since counterregulation tends to deteriorate 
with increasing age (41), matching should preferably include age. Most studies on 
counterregulation in type 2 DM did use control subjects who were age-matched, but in 
two studies controls were approximately 20 years younger than diabetic patients 
(24,27). This may have biased the results towards a false estimate of counterregulation 
in type 2 diabetes. 
A major methodological difference between the studies concerns the techniques 
employed to induce hypoglycemia and the subsequent glycemic nadirs (Table 3). 
Continuous insulin infusions (24-27,29) or single bolus injections (28,30) were used in 
earlier investigations. As a consequence, glycemic nadirs sometimes differed between 
control and diabetic subjects. Since lower levels of glycemia elicit higher 
counterregulatory responses, differences in hypoglycemic nadir may lead to 
misinterpretation of counterregulatory function (42). Hyperinsulinemic hypoglycemic 
 
Table 1. – Severe hypoglycaemic reactions complicating glucose-lowering therapy (episodes per 100 patient-
years) 
 
  Prospective Data Retrospective Data 
Type 1 diabetes mellitus DCCT (11) 
− Intensive treatment 
− Conventional treatment 
ASD (56) 
MacLeod et al. (12), 1993 
 
                 62 
                 19 
                 24 
 
 
 
 
 
               170 
Type 2 diabetes mellitus UKPDS (13,14)* 
− Insulin 
− Glibenclamide 
− Metformin 
 
 5.8 
 2.9 
 1.7 
 
 
 
 
 VA CSDM (15) 
MacLeod et al. (12), 1993† 
                    3                  26 
                 73 
DCCT, Diabetes Control and Complications Trial; ASD, Working group on structured diabetes therapy of the 
german diabetes association; UKPDS, United Kingdom prospective diabetes study; VA CSDM, Veterans Affairs 
cooperative study on glycaemic control and complications in Type 2 diabetes; *Estimated from data by refs. 13 
and 14. †Data concern 56 patients all on insulin therapy. 
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clamps were performed in the remaining five studies (31,32,34,35,37). 
Hyperinsulinemic clamps allow glucose level matching and a better quantification of 
counterregulatory responses. They are regarded as the best tool to estimate 
counterregulation, although the high level of insulin (43) and the long (non-
Table 2. – Characteristics of studies on counterregulatory hormone functioning in Type 2 DM 
 
Source, year Study subject Type 2 diabetic patients Controls 
   
Mean GHb, % 
(ref. values) 
 
N 
total/on insulin 
Disease 
duration , 
years 
 
 
N 
Nonaka et al. 
(23), 1977 
Counterregulation in juvenile vs adult-
onset DM 
- 35/ND - - 
Campbell et al. 
(24), 1979 
Counterregulation in Type 2 DM vs 
controls 
- 20/9 8 ± 2 14¶ 
Levitt et al. 
(25), 1979 
Counterregulation in Type 2 DM vs 
controls 
- 10/0 2-10 17 
Boden et al. 
(26), 1983 
Counterregulation in Type 2 DM vs 
controls 
- 10/0 3-13 6 
Polonsky et al. 
(27), 1984 
Counterregulation in Type 2 DM vs 
controls 
Orally-treated patients 
Insulin-treated patients 
 
10.4 
8.4 
  
(8.3)* 
(8.3) 
 
4/0 
8/8 
 
<0.1-8 
0.4-28 
6¶ 
Bolli et al. 
(28), 1984 
Counterregulation in Type 2 DM vs 
controls 
Orally-treated patients 
Insulin-treated patients 
 
9.2 
8.9 
  
(7.5)* 
(7.5)* 
 
5/0 
8/8 
 
5.0 ± 1.7 
4.1 ± 1.5 
11 
Heller et al. 
(29), 1987 
Counterregulation in Type 2 DM vs 
controls 
7.1  (5.9)* 10/0 1.5-10 10 
Laager et al. 
(30), 1993 
Counterregulation in Type 2 DM vs 
controls 
5.6  (4.4)† 6/0 - 5 
Meneilly et al. 
(31), 1994 
Counterregulation in elderly Type 2 
DM vs controls 
6.9 (6.4)† 10/0 1-10 10 
Shamoon et al. 
(32), 1994 
Counterregulation in Type 2 DM vs 
controls 
9.4  (6.2)* 9/2 6.4 ± 2 6 
Meneilly et al. 
(33), 1995 
Effect of human vs animal insulin on 
counterregulation in Type 2 DM 
7.2  (6.4)† 12/0 6 ± 1 - 
Korzon-
Burakowska et 
al. (34), 1998 
Effect of glycaemic control on 
counterregulation in Type 2 DM vs 
controls 
8.1 (ND)‡ 7/7 7-16 7 
Levy et al. 
(35), 1998 
Counterregulation in Type 2 DM vs 
controls 
9.7  (6.7)* 11/0 8 ± 5 8 
Landstedt-
Hallin et al. 
(36), 1999 
Effect of glibenclamide during 
insulin-induced hypoglycaemia in 
Type 2 DM 
7.6  (5.2)* 13/13 1.5 - 
Spyer et al. 
(37), 2000 
Counterregulation in Type 2 DM vs 
controls 
7.4  (5.7)* 7/0 <7 7 
Peacey et al. 
(39), 2000 
Effect of treatment choice on 
counterregulation in type 2 DM 
Orally-treated patients 
Insulin-treated patients 
 
 
8.3 
9.2 
 
 
(ND) 
(ND) 
  
 
7 ± 1 
7 ± 1 
 
Data are number, mean ± SD, or range. GHb, glycosylated hemoglobin. ND, no data available * p<0.05 diabetic 
patients vs reference value. † p-value not available. ‡ After improved glycemic control. ¶ Control subjects not age-
matched to diabetic patients.  
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physiological) duration of hypoglycemia (44) may have an affect on counterregulation 
and hypoglycemic awareness.  
 
Impairments in glucose counterregulation Seven out of 12 studies, including that 
of Polonsky et al. on insulin-treated patients (27), reported impaired metabolic 
responses to hypoglycemia in type 2 DM, both in young (27) and elderly (31) patients 
and irrespective of body mass index (32). Four used bolus injections or continuous 
insulin infusions (24,27,28,30) and two employed hyperinsulinemic hypoglycemic 
clamps (31,32). Blunted glucagon responses were universal, whereas many reported 
impaired growth hormone (24,28,30,31) and cortisol (24,28,30) responses (Table 3). 
Only one study reported the combination of blunted glucagon and adrenaline responses 
(30), whereas others found responses of adrenaline (31,32) and cortisol (31,35) to be 
increased. In six studies and in the oral treatment group studied by Polonsky et al. (27), 
responses were reported to be similar between patients and controls. 
Because of the association between antecedent hypoglycemia and 
counterregulatory impairment, we examined the link between tight glycemic control and 
glucose counterregulation, as few reported the rate of hypoglycemia prior to the 
experiments. Information concerning metabolic control was available in nine out of 12 
studies. Improvement of metabolic control (with insulin therapy) resulted in blunting of 
all responses to hypoglycemia in type 2 diabetic patients (34). Another study reported 
an inverse relation between metabolic control and degree of counterregulation in 
patients not treated with insulin (35). Six studies investigated patients with a 
glycosylated haemoglobin close to normal (Table 2), three of which reported one or 
more defects in glucose counterregulation (27,30,31) and two found generally normal 
counterregulation in well-controlled patients (29,37). In contrast, various degrees of 
impairment were reported in some poorly controlled patients (28,32).  
Unlike the situation in type 1 diabetes, the degree of counterregulatory impairment 
in type 2 DM does not appear to be a function of disease duration per se as 
counterregulatory disturbances may occur within the first year of diagnosis (27,31). 
Furthermore, hormone responses remain unimpaired in some patients with a duration 
of diabetes of over 10 years (26,34,35). However, this does not fully exclude a role of 
diabetes duration. Important factors related to diabetes duration which may affect 
glucose counterregulation include loss of insulin secretory capacity or the occurrence of 
autonomic neuropathy. One study reported blunted glucagon responses in 10 patients 
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of whom four exhibited C-peptide levels below assay sensitivity, suggesting that 
diminishing β-cell reserve adversely affects glucose counterregulation, although some 
may have had type 1 diabetes (24). Bolli et al. did not find a correlation between β-cell 
reserve – measured by glucagon-stimulated C-peptide responses – and the glucagon 
response to hypoglycemia in either diabetic patients or nondiabetic controls (28). 
However, the patients were studied early after diagnosis and all had considerable β-cell 
reserve. More research is required to investigate the effect of β-cell function on 
counterregulation. The effect of autonomic neuropathy on glucose counterregulation in 
Table 3. – Results of studies on counterregulatory hormone responses to hypoglycemia in Type 2 DM in 
comparison to controls 
 
Source Method of insulin 
administration 
Patients’ 
treatment 
regimen 
Hypoglycemic 
nadir (mM) 
Glucagon Adrenaline Growth 
Hormone 
Cortisol 
Campbell et 
al. (24) 
Continuous 
infusion until 
glycemic nadir 
Insulin and 
oral agents 
2.1 ↓ - ↓ ↓ 
Polonsky et 
al. (27) 
Continuous 
infusion until 
glycemic nadir 
Insulin 
only 
2.4 ↓ = = = 
Korzon-
Burakowska 
et al. (34)* 
Hyperinsulinemic 
clamp 
Insulin 
only 
2.4 = = = = 
Bolli et al. 
(28) 
Subcutaneous 
bolus injection 
Insulin 
only 
3.1 ↓ = ↓ ↓ 
Shamoon et 
al. (32) 
Hyperinsulinemic 
clamp 
Insulin and 
oral agents 
3.4 ↓ ↑ = = 
Levitt et al. 
(25) 
Intravenous bolus 
injection 
Oral agents 
only 
1.7 = - - - 
Boden et al. 
(26) 
Continuous 
infusion until 
glycemic nadir 
Oral agents 
only 
2.1 = = = = 
Levy et al. 
(35) 
Hyperinsulinemic 
clamp 
Oral agents 
and diet  
2.2 = =/↑ ↓ ↑ 
Polonsky et 
al. (27) 
Continuous 
infusion until 
glycemic nadir 
Oral agents 
and diet  
2.4 = = = = 
Heller et al. 
(29) 
Continuous 
infusion until 
glycemic nadir 
Oral agents 
only 
2.4 = = = = 
Spyer et al. 
(37) 
Hyperinsulinemic 
clamp 
Oral agents 
and diet 
2.4 = = ↓ ↑ 
Meneilly et 
al. (31) 
Hyperinsulinemic 
clamp 
Oral agents 
only 
2.8 ↓ ↑ ↓ ↑ 
Bolli et al. 
(28) 
Subcutaneous 
bolus injection 
Oral agents 
and diet  
3.7 ↓ = ↓ ↓ 
Laager et al. 
(30) 
Intravenous bolus 
injection 
Oral agents 
only 
4.5 ↓ ↓ ↓ ↓ 
↓ Hormone responses decreased in patients vs controls; ↑ Hormone responses increased in patients vs controls; 
= Hormone responses are comparable between patients and controls. *Only data after improved glycaemic control 
included. 
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type 2 DM is difficult to ascertain, as most studies were performed in diabetic patients 
free of long-term complications, including autonomic neuropathy. However, one 
reported that glucagon responses to hypoglycemia were impaired in five patients with 
some form of autonomic neuropathy but no postural hypotension, whereas those 
without autonomic neuropathy had normal responses (25). This suggests that, as in 
type 1 DM (45), impaired counterregulation is not an inevitable complication of type 2 
DM. 
 
Awareness of hypoglycemia Accurate and timely perception of falling blood 
glucose is crucial for appropriate protective action. One retrospective study has 
indicated that approximately 7% of insulin-treated type 2 diabetic patients report partial 
awareness of autonomic hypoglycemic symptoms (46). Unfortunately, this issue has 
not been extensively examined in type 2 DM. Polonsky et al. reported that the threshold 
for awareness of hypoglycemia was comparable to controls in both orally and insulin 
treated patients, irrespective of disease duration and hormonal counterregulation (27). 
Some recent studies have indicated that hypoglycemic symptoms may be perceived at 
higher glucose levels in young (46 ± 11 years) type 2 diabetic patients compared to 
controls (37) or even at normoglycemia in poorly controlled patients (34), although this 
finding is not consistent (39). In one study a group of elderly orally treated patients 
demonstrated impaired perception of hypoglycemia and cognitive function in 
comparison with age-matched controls (31). Since ageing is associated with reductions 
in glucose counterregulation and symptom awareness (41), elderly patients may be at 
increased risk of serious hypoglycemia, especially when psychomotor performance is 
altered (31).  
 
Glucose counterregulation and different medication  Various studies investigated 
the effect of insulin or oral antidiabetic drugs on counterregulatory function. Both 
treatments may have different effects on glucose counterregulation. High insulin levels, 
even within the physiological range, can suppress hormonal counterregulation in 
healthy subjects (43). Sulphonylureas, on the other hand, may suppress glucagon 
responses to insulin-induced hypoglycemia in both healthy controls (47-49) and type 2 
diabetic patients (36), and increase the requirement for exogenous glucose (36). In a 
research letter, Peacey et al. specifically addressed the effect of type of treatment on 
counterregulatory responses to insulin-induced hypoglycemia in a group of newly-
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diagnosed diabetic patients randomized to sulphonylurea or insulin (39). They reported 
a lower sweating response in insulin-treated patients, but found similar hormone 
responses in patients allocated to either sulphonylurea or insulin. Two other studies that 
investigated type 2 DM patients irrespective of treatment regimen reported similar 
impairments in one or more hormone responses between patients treated with insulin 
and those who were not (24,32). However, in contrast to the study by Peacey et al., 
patients were not randomized to type of treatment, so that differences in β-cell function, 
magnitude of insulin sensitivity, and duration of diabetes may have influenced the data.  
 
Patients on oral therapy 
In nine studies, the exclusion of insulin-treated patients permitted separate observations 
on counterregulatory functioning in 73 patients using either diet or tablets, most of 
whom received sulphonylureas (24,26-31,35,37). Diabetic participants generally 
abstained from oral agents for 24-72 hours prior to the experiments, although some 
were studied only after an overnight fast (24,31). Counterregulatory impairments – 
mainly glucagon – were recorded in three of these studies (28,30,31), comprising 16 
patients on oral agents and five treated with diet alone (29% of patients) (Table 2). In a 
fourth study, impaired glucagon responses to hypoglycemia were recorded in two 
patients on sulphonylureas, but not in two patients on diet alone (27), and Shamoon et 
al. (32) reported blunted glucagon responses in nine patients, six of whom used 
sulphonylureas and one diet. However, the hypoglycemic stimulus was mild (above 3.4 
mmol/L) in all studies but one (31). The latter is the only one reporting impaired 
responses at a glucose level below 3.0 mmol/L in 10 well-controlled patients on 
sulphonylureas, although in this study oral agents were only stopped overnight (31). 
This may have had an effect, as some agents have long plasma half-life times. In 
summary, responses to insulin-induced hypoglycemia are unimpaired in most type 2 
diabetic patients on oral therapy. However, sulphonylureas may interfere with glucagon 
responses to hypoglycemia, especially when combined with insulin (36). 
 
Patients on insulin 
Three studies have evaluated metabolic and/or symptom responses to hypoglycemia 
exclusively in insulin-treated type 2 diabetic patients (27,28,34). Glucagon responses 
alone were diminished in eight well-controlled patients, half of whom were young adults 
within the first year of diagnosis (27). In another study, patients with moderately 
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controlled diabetes expressed impaired glucose recovery and significantly reduced 
responses of glucagon, cortisol, and growth hormone to a single insulin infusion (28).  
Although adrenaline responses were not different from control values, they were 
considered insufficient as impaired glucose recovery should have evoked greater 
increases. In a different study, hyperinsulinemic hypoglycemic clamps were performed 
in seven poorly controlled orally treated patients before and after improving glycemic 
control with insulin treatment. Parallel to improvements in metabolic control, thresholds 
for counterregulatory hormone responses were shifted from supranormal glucose levels 
to levels similar to control (34). Preliminary data indicate that insulin-treated type 2 DM 
patients have lower glucagon and adrenaline responses to hypoglycemia (50) and 
experience autonomic symptoms at lower glucose levels than do patients treated with 
sulphonylureas (51). However, these effects may be due to better metabolic control (7.4 
vs. 8.3%) and advanced loss of β-cell function rather than to insulin itself. 
 
INTERPRETATION OF THE DATA 
 
In the following sections, we will discuss the available data in terms of glycemic 
thresholds and we will consider those factors that might modulate glucose 
counterregulation in type 2 diabetes.  
 
Glycemic thresholds Patients with type 1 DM on good metabolic control (7,52) 
require lower plasma glucose levels to elicit both symptoms and counterregulatory 
hormone responses compared to nondiabetic subjects and patients who are less well 
controlled (53,54), a phenomenon related to an adaptation to frequent hypoglycemia 
(10,52). However, significant hormonal responses might still be achieved if glucose 
levels are lowered sufficiently. Indeed, glucose levels below 1.0 mmol/L may exert both 
glucagon and adrenaline responses in type 1 DM of longer duration (8,55), revealing 
counterregulatory hormone reserve that is underestimated when the hypoglycemic 
stimulus is not profound enough. Comparing counterregulatory responses between 
patients and controls thus requires that glycemic nadirs are similar. Unfortunately, in 
some studies glycemic nadirs were significantly different between subgroups of patients 
and controls (24,28). In the study by Bolli et al. (28), nadirs were slightly higher in 
noninsulin treated patients compared to controls and insulin treated patients. Although 
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both groups of patients had blunted glucagon, cortisol and growth hormone responses, 
the higher glycemic nadir may explain why the lowest responses were recorded in 
patients not treated with insulin. The study by Levitt et al. (25) further illustrates the 
importance of similar glycemic nadirs. They found that insuline tolerance tests caused 
significantly higher glucagon responses in nondiabetic volunteers compared with 
diabetic patients, but also induced the blood glucose level to fall to lower glycemic 
nadirs (1.7 vs 2.8 mmol/L, respectively).  In contrast, no differences were recorded 
when the same experiment was repeated using identical glycemic nadirs of 2.0 mmol/L 
in both groups. 
Alternatively, a profound hypoglycemic stimulus may mask discrete 
counterregulatory impairments that are revealed using lesser degrees of hypoglycemia. 
Indeed, when evaluating counterregulatory responses in type 2 diabetes with respect to 
hypoglycemic stimuli,  studies reporting normal counterregulatory function apparently 
used lower glycemic nadirs (1.7-2.4 mmol/L) (25-27,29,34,35,37) than studies reporting 
one or more impairments in hormonal counterregulation (2.8-4.5 mmol/L) (28,30-32). 
This observation might indicate that glycemic thresholds for counterregulatory 
responses shift to lower glucose levels in type 2 diabetes compared with controls, 
whereas the magnitude of hormonal responses remains unaffected during severe 
hypoglycemia. This is supported by studies in type 2 diabetes showing that glycemic 
thresholds for release of catecholamines correlate with the level of HbA1c (35), and that 
lower glycemic levels are required to elicit counterregulatory hormone responses after 
initiation of intensive treatment (34). 
 
The impact of metabolic control and previous hypoglycemias The presented data 
indicate that impaired glucose counterregulatory hormone responses and awareness of 
hypoglycemia do occur in type 2 DM. These disturbances, particularly glucagon, appear 
more common in those treated with insulin. Since studies on type 1 diabetic patients and 
healthy controls have shown that impaired counterregulation is related to antecedent 
hypoglycemia (10), we suggest that these differences are related to the higher incidence 
of hypoglycemia in insulin-treated patients. In the UKPDS (13,14), hypoglycemic risk 
was twice as high in patients on insulin when compared to those treated with 
glibenclamide, whereas metformin treatment rarely caused hypoglycemia. Similarly, 
differences in degree of counterregulatory failure between type 1 and type 2 DM may be 
explained largely by differences in the risk of experiencing hypoglycemia (Table 1).  
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Since the frequency of hypoglycemia is strongly related to the intensity of metabolic 
control, patients may also be more prone to counterregulatory impairments after 
tightening their glycemic control. Levy et al. found that patients with near-normal HbA1c 
levels had the lowest counterregulatory responses to hypoglycemia (35), whereas 
decrements of all counterregulatory hormone responses to hypoglycemia parallel 
improvements in glycemic control (34). In most studies on counterregulation in type 2 
diabetes mellitus, metabolic control was at best moderate (26-29,32), which may also 
explain why counterregulation is often apparently normal. Indeed, both in type 1 (53) 
and type 2 (34) diabetes, hormone responses to and awareness of hypoglycemia are 
largely undisturbed when metabolic control is poor. Three studies involving well 
controlled type 2 diabetic patients that reported counterregulatory impairments 
(27,30,31) support this suggestion. Unfortunately, no studies have yet been published 
that have investigated the effect of (repeated) hypoglycemia on counterregulatory 
function in type 2 DM. 
 
β-cell reserve and insulin resistance Data from both retrospective (12,15) and 
prospective (11,13,14,56) studies show that hypoglycemias requiring external 
assistence are 3-10 times more common in type 1 compared to type 2 diabetic patients, 
which cannot be explained by differences in glycemic control. Two factors may explain 
why type 2 diabetic patients are less prone to severe hypoglycemia and subsequent 
counterregulatory impairments. First, most patients with type 2 DM retain some 
functional β-cell reserve and will suppress insulin release in response to a falling blood 
glucose. This may contribute to prevention of hypoglycemia, partly due to a direct effect 
on glucose disposal and also as a result of disinhibition of α-cells (57) promoting 
glucagon release. In type 1 diabetes, the intraislet communication between insulin and 
glucagon release may be lost due to β-cell destruction, leading to an impaired glucagon 
response. With time however, some of those with Type 2 diabetes may lose functional 
β-cell reserve. In those patients, hypoglycemic risk rates may increase substantially. To 
what extent progressive loss of β-cells increases the risk of hypoglycemia or impairs 
counterregulation is unknown. However, preliminary data indicate that counterregulation 
is compromised in insulin-treated well-controlled type 2 diabetic patients in whom 
advanced loss of β-cell function can be anticipated (50). 
CHAPTER 5 
 88 
 
Second, in situations of insulin resistance, as in type 2 DM, insulin effects on 
adipose tissue are reduced relative to the lipolytic effects of adrenaline (32,58). Indeed, 
patients with type 2 DM exhibit enhanced glycemic responses to short-term increases 
of plasma adrenaline at all plasma glucose concentrations (59), and various 
investigators have reported elevated levels of free fatty acids in response to insulin-
induced hypoglycemia in type 2 (28,29,32,58), but not in type 1 DM (60). The relase of 
adrenaline during hypoglycemia in the presence of increased sensitivity to adrenaline 
may help to prevent drug-induced hypoglycemia in patients with type 2 compared with 
those with type 1 diabetes.  
Thus, both preserved β-cell responsiveness and insulin resistance may help to 
explain the relatively low incidence of hypoglycemia in type 2 diabetic patients. As a 
consequence, hormonal counterregulation remains largely intact, which in turn 
diminishes the frequency and severity of hypoglycemic episodes. Although protective to 
a certain extent, these conditions cannot fully prevent counterregulatory impairments in 
type 2 diabetes. Moreover, insulin resistance may be less prominent in certain 
subgroups of type 2 DM and β-cell function may eventually be lost with longer disease 
duration. These patients may be more prone to severe hypoglycemia and 
counterregulatory failure (50). 
 
CONCLUSION 
 
Interpretation of the work on glucose counterregulation in type 2 DM has been 
complicated by: (i) the relatively low number of patients studied; (ii) the heterogeneity of 
the study population; (iii) differences in methodology; and (iv) difficulty in assessing 
disease progression. Nevertheless, patients with type 2 DM who use glucose-lowering 
agents appear at risk of developing impaired counterregulation, but to a lesser extent 
than type 1 diabetic patients. In contrast to the latter, glucagon responses to 
hypoglycemia are relatively preserved in type 2 DM and the combined failure of 
glucagon and adrenaline responses is rare. Impaired counterregulation is associated 
with the intensity of metabolic control and, by inference, the frequency of hypoglycemic 
events rather than being a complication of diabetes per se.  
Functional β-cell reserve and insulin resistance may contribute significantly to the 
prevention of severe hypoglycemia in type 2 DM, which helps to preserve glucose 
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counterregulation. It is presently unclear whether type 2 diabetic patients without overt 
insulin resistance and those with substantial loss of insulin secretory capacity are at 
increased risk for hypoglycemia and subsequent counterregulatory failure. These 
issues should be explored more extensively. Although in most type 2 diabetic patients, 
tight metabolic control may not severely compromise counterregulatory function, the 
possibility of recurrent hypoglycemia should be acknowledged. Moreover, as elderly 
patients and patients with macrovascular disease are often more vulnerable to 
permanent injury from hypoglycemia, intensive treatment should be restricted to those 
for whom the benefit clearly outweighs the potential harm. 
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ABSTRACT 
 
Iatrogenic hypoglycemias and the subsequent occurrence of hypoglycemia unawareness are 
well-known complications of intensive insulin therapy in type 1 diabetic patients that limit 
glycemic management. From a pharmacological point of view, the adenosine-receptor 
antagonist theophylline might be beneficial in the management of hypoglycemia unawareness. 
Theophylline stimulates the release of catecholamines and reduces cerebral blood flow, 
thereby facilitating stronger metabolic responses to and a prompter perception of decreasing 
glucose levels. To test the effect of theophylline on responses to hypoglycemia, we performed 
paired hyperinsulinemic-hypoglycemic clamp studies in 15 diabetic patients with 
hypoglycemia unawareness and 15 matched healthy control subjects. In random order, we 
concurrently infused either theophylline or placebo. Measurements included counterregulatory 
hormones, symptoms, hemodynamic parameters, and sweat detection using a dew-point 
electrode. Additionally, middle cerebral artery velocities (VMCA) using transcranial Doppler 
were monitored as an estimate of cerebral blood flow. When compared with placebo, 
theophylline significantly enhanced responses of plasma adrenaline, noradrenaline, and 
cortisol levels in both diabetic patients and control subjects. Because of the theophylline, 
sweat production started at 0.3 mmol/l higher glucose levels in both groups (P < 0.01), and 
symptom scores in diabetic patients approached those in control subjects. Theophylline 
decreased VMCA in both groups (P < 0.001), but significantly greater in diabetic patients (P < 
0.01), and prevented the hypoglycemia-induced increase of VMCA that occurred during the 
placebo studies. We conclude that theophylline improves counterregulatory responses to and 
perception of hypoglycemia in diabetic patients with impaired awareness of hypoglycemia.  
 
___________________________________________________________ 
 
n type 1 diabetes, iatrogenic hypoglycemias frequently occur because (relative) 
insulin excess is accompanied by an insufficient counterregulatory network that is 
unable to prevent glucose levels from decreasing too much (1). This often results in 
the loss of characteristic hypoglycemic warning symptoms, so that neuroglycopenia 
or overt cognitive impairment becomes the first manifestation of hypoglycemia, a 
phenomenon known as hypoglycemia unawareness (2). Hypoglycemia unawareness 
thus jeopardizes a patient’s ability of self-management and is thought to be the result 
of cerebral adaptation to recurrent hypoglycemic events (3,4), further increasing the 
risk for hypoglycemias that require external help. Whereas defects in hormonal 
counterregulation might be considered as more or less unavoidable consequences of 
intensive insulin treatment, complete loss of warning symptoms is often thought 
unacceptable in the pursuit for better glycemic control. Therefore, hypoglycemic risk-
reducing strategies are required that reverse the syndrome of hypoglycemia 
unawareness, but preferably within the boundaries of optimal glycemic control (5). 
I 
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Currently, meticulous avoidance of hypoglycemias (6) and blood glucose 
awareness training (BGAT) (7) are the only means to successfully combat 
hypoglycemia unawareness and defective counterregulation. Recently, it has been 
suggested that antagonism of central adenosine receptors might be an effective 
alternative (8,9). Theophylline and the related methylxanthine derivative, caffeine, 
block central adenosine receptors, leading to increased alertness and enhanced 
secretion of catecholamines (10). Secondly, by blocking adenosine-induced 
maintenance of vascular tone, they reduce cerebral blood flow (CBF), enabling faster 
perception of decreasing plasma glucose levels and earlier initiation of metabolic and 
symptom responses. The concept of improved hypoglycemia awareness by 
adenosine-receptor antagonism has already been successfully tested in humans 
(9,11,12). However, studies in type 1 diabetic patients with proven hypoglycemia 
unawareness are still lacking. Therefore, we conducted a placebo-controlled cross-
over study to investigate the effect of theophylline on metabolic responses to and 
perception of insulin-induced hypoglycemia in type 1 diabetic patients with 
hypoglycemia unawareness. Theophylline was chosen over caffeine because it is 
widely available in various formulations, allowing a controlled pharmacological 
approach, and because it is a more potent adenosine-receptor antagonist (13).  
 
SUBJECTS AND METHODS 
 
Subjects Written informed consent was obtained from 15 type 1 diabetic patients 
with hypoglycemia unawareness and 15 age-, sex-, and BMI-matched healthy control 
subjects. The patients were recruited from the outpatient clinic of our hospital. 
Hypoglycemia unawareness was assessed on the basis of self-reported failure to 
accurately perceive low blood glucose levels, a consistent history of hypoglycemic 
events (i.e., readings <3 mmol/l by self-measurement methods) for at least 1 year, 
and the identification of principally neuroglycopenic, as opposed to autonomic 
symptoms, of hypoglycemia on a standardized symptom questionnaire. Although 
metabolic control was not regarded as a criterion per se, the majority of patients had 
HbA1c values well below 8.0%. All patients were treated for diabetes for at least 5 
years and were free of long-term diabetes complications. Autonomic neuropathy was 
excluded by normal cardiovascular tests, including heart rate response to Valsalva 
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maneuver, beat-to-beat variation to deep breathing, heart-rate and blood pressure 
responses to standing up, and blood pressure response to sustained handgrip (14). 
Patients were otherwise healthy and did not use additional medication other than 
insulin or oral contraceptives. The study was approved by the medical ethical 
committee of the University Medical Center Nijmegen.  
 
Hyperinsulinemic hypoglycemic glucose clamp All participants completed two 
experiments performed at least 3 weeks apart. Women were tested at 4- or 8-week 
intervals to ensure that the experiments took place in corresponding periods of the 
menstrual cycle. Subjects arrived at the test location at 8.00 A.M after an overnight 
fast. To exclude the contribution of caffeine, the participants abstained from caffeine-
containing substances (coffee, tea, cola, and chocolate) for at least 3 days to render 
them caffeine-naive. All patients were requested to reduce bedtime insulin dosages 
by one-half to avoid nocturnal hypoglycemia. They checked their capillary glucose 
levels at least four times daily the week before the experiments and at 3:00 A.M. the 
night before the experiments.  
The brachial artery of the nondominant arm was cannulated under local 
anesthesia for blood sampling and continuous blood pressure measurements. An 
intravenous catheter was inserted in an antecubital vein of the contralateral arm for 
infusion of insulin, glucose, and theophylline or placebo solutions. Baseline variables 
were obtained after a resting period of 30 min.  
In a randomized double-blind fashion, a loading dose of 2.8 mg/kg theophylline 
(Euphyllin; Byk, Zwanenburg, the Netherlands) or a comparable volume of placebo 
solution (NaCl 0.9%) was subsequently administered intravenously over 20 min, 
followed by a continuous infusion of 0.5 mg·kg-1·h-1 for the remainder of the study 
period (15). A stepped hyperinsulinemic (60 mU·m-2·min-1) - hypoglycemic glucose 
clamp procedure was initiated thereafter (16). Using a variable infusion of glucose 
20%, to which 10 mmol KCl per 500 ml was added, the plasma glucose concentration 
was sequentially clamped at 5.0, 3.5, and 2.5 mmol/L, based on arterial plasma 
glucose levels, measured in duplicate at 5-min intervals. Normoglycemia was 
obtained within 60–70 min in all diabetic patients and continued for 20–30 min, after 
which plasma glucose was allowed to subsequently decrease to 3.5 and 2.5 mmol/L, 
respectively, over 30 min and was maintained at these plateaus for another 30 min. 
At 30-min intervals, arterial blood samples were taken for the measurement of 
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theophylline, insulin, glucagon, adrenaline, noradrenaline, cortisol, and growth 
hormone (GH). At baseline, blood sampling included caffeine and C-peptide 
measurements.  
Participants were asked to complete semiquantitative symptom questionnaires 
every 20 min. Symptoms could be scored from 0 (absent) to 6 (severe) and included 
six neuroglycopenic symptoms (blurred vision, difficulty in speaking, feeling faint, 
difficulty in thinking, confusion, and dizziness), six autonomic symptoms (cholinergic: 
tingling, sweating, and feeling hungry) (adrenergic: palpitations, anxiety, and 
trembling), four general symptoms (dry mouth, weakness, nausea, and headache), 
and two dummy symptoms (yellow vision and pain in the legs). In addition to this 
subjective information concerning hypoglycemic symptoms, sweat evaporation rate 
was measured by a dew-point sweat detection electrode (Evaporimeter EP1; 
Servomed, Stockholm, Sweden) connected to the inner portion of the forearm (17). 
Further, blood pressure and heart rate were continuously monitored (Monitor 
378341A; Hewlett Packard, Germany).  
Middle cerebral artery velocity (VMCA) was monitored using transcranial Doppler 
(Multidop L; DWL Elektronische Systeme, Sipplingen, Germany) as an indicator for 
cerebral blood flow. Based on the assumption that caliber changes in the vessels are 
small, alterations in velocity appear to be closely associated to changes in blood flow 
(18). Previous studies have shown that the transcranial Doppler technique can be 
reliably applied to detect blood flow changes during hypoglycemia (9,11).  
 
Analytical methods Plasma glucose was measured in duplicate by the glucose 
oxidation method (Glucose Analyzer II; Beckman, Fullerton, CA) in arterial blood 
samples and immediately centrifuged for 10 s after withdrawal. Blood samples for 
measurements of catecholamines were collected in prechilled tubes containing 
glutathione (0.2 mol/L) and EGTA (0.25 mol/L) and immediately stored on ice. Blood 
samples for measurements of glucagon, GH, cortisol, insulin, C-peptide, caffeine, and 
theophylline were collected in lithium-containing heparin tubes and stored on ice. 
Plasma insulin was assessed by radioimmunoassay (RIA) using 125I-labeled human 
insulin and anti-human insulin antiserum raised in guinea pig. Bound and free tracer 
were separated by sheep anti-guinea pig antiserum; human insulin (Novo Biolabs, 
Copenhagen, Denmark) was used for standards. The interassay coefficient of 
variation (CV) for the insulin measurement was 10.3% at a level of 20.7 mU/L. 
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Plasma C-peptide was determined with a commercially available double-antibody RIA 
(Diagnostic Products, Los Angeles, CA) with an interassey CV of 6.4% at a level of 
0.21 nmol/L. Plasma adrenaline and noradrenaline were analyzed by high 
performance liquid chromatography (HPLC) with a modification of an earlier 
described laboratory procedure (19). Plasma glucagon was measured by competitive 
RIA using a commercially available kit (Eurodiagnostica, Malmö, Sweden). The 
procedure of glucagon determination was modified as follows. To diminish the risk of 
interference by larger glucagon-like peptides, serum samples were extracted with 
ethanol and then washed twice with diethylether. Residues were dried and dissolved 
in assay buffer. In each assay series, six randomly selected samples were spiked 
with standard for recovery measurements. The average recovery per series was 102 
± 13%, intra-assay CVs were 8% at a level of 80 pmol/L and 11% at 10 pmol/L, and 
interassay CVs were 12.5 and 13.9%, respectively. Plasma cortisol was assayed 
using the TDx batch analyzer (Abbott Laboratories), and interassay CVs were 9.1 
and 6.6% at plasma levels of 0.22 and 1.06 µmol/L, respectively. GH was measured 
by direct RIA using the World Health Organization standard for human GH 80/505 
(interassay CVs 9.2 and 6.0% at plasma concentrations of 4.7 and 53.5 mU/L, 
respectively) (20). HbA1c was measured using HPLC (Bio-Rad Laboratories, 
Veenendaal, the Netherlands) with reference values of 4.8–6.2%. Plasma 
Table 1. – Baseline characteristics 
 
 Type 1 DM patients Healthy controls 
Number (M/F) 15 (8/7) 15 (10/5) 
Age, yrs 33.6 ± 10.3 31.5 ± 8.4 
BMI, kg/m2 23.2 ± 2.3 23.2 ± 2.9 
Duration of diabetes, yrs 15.5 ± 6.9 - 
Insulin dose in DM, U/kg 0.72 ± 0.26 - 
Systolic BP, mmHg  135 ± 10  128 ± 9 
Diastolic BP, mmHg    79 ± 6    75 ± 7.5 
Heart rate, bpm    71 ± 10*    63 ± 7 
HbA1c, % 7.37 ± 0.60† 5.13 ± 0.33 
Glucagon, pmol/L 13.6 ± 3.4 15.6 ± 4.7 
C-peptide, nmol/L     <0.01† 0.49 ± 0.21 
Adrenaline, nmol/L 0.23 ± 0.10 0.17 ± 0.08 
Noradrenaline, nmol/L 0.76 ± 0.35 0.59 ± 0.28 
Cortisol, µmol/L 0.61 ± 0.31 0.57 ± 0.33 
Growth Hormone, IU/L 19.1 ± 20.5 10.2 ± 19.9 
VMCA, cm/s 72.2 ± 3.9 70.8 ± 4.8 
Data are means ± SD. *P < 0.05 versus controls, †P < 0.01 versus controls. VMCA, median cerebral artery 
velocity; BP, blood pressure. 
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theophylline and caffeine were determined by fluorescence polarization 
immunoassay and HPLC (limit of detection 0.2 mg/l), respectively.  
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Figure 1 – A: Glucose levels during both clamp studies in diabetic (closed symbols) and control (open) 
subjects, and theophylline levels during the theophylline study-arm. B: Glucose infusion rates during clamp at 
5.0, 3.5, and 2.5 mmol/L, respectively. During hypoglycemia, rates are significantly lower in the presence of 
theophylline compared with placebo. *P < 0.01, ** P < 0.001 versus placebo. 
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Statistical methods The gradual decrease in glucose levels between the 
plateau phases enabled us to calculate glycemic thresholds. Glycemic threshold for 
the detection of sweat production was defined as the plasma glucose level at which 
dew-point electrode readings showed at least doubling of the individual values 
recorded at baseline. For hemodynamic parameters, the threshold was defined as 
the plasma glucose concentration at which the parameter consistently exceeded the 
95% CI observed for changes in that parameter during the normoglycemic steady-
state period. Statistical analysis was done using repeated measures ANOVA, and 
differences in means were tested using paired Student’s t test. For calculations and 
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Figure 2. – Responses of hypoglycemic symptoms and counterregulatory hormones to hypoglycemia. Except for 
symptom responses in controls, responses are significantly (P < 0.05) higher during theophylline infusion than 
during placebo. 
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statistical analyses, the SPSS personal computer software package was used, and 
P < 0.05 was considered statistically significant.  
 
RESULTS 
 
Baseline characteristics of type 1 diabetic patients and control subjects are shown in 
Table 1. Patients and control subjects were well matched for age, sex, and BMI. 
Except for higher fasting glucose, HbA1c, and heart rates in diabetic patients, 
hemodynamic and metabolic parameters were comparable at baseline between 
diabetic patients and control subjects and between placebo and theophylline for 
either group (data not shown). After insulin infusion, plasma insulin levels increased 
to similar values in both patients (140 ± 14 mU/L) and control subjects (158 ± 8 mU/L) 
on either occasion. Similarly, plasma glucose levels were equivalent in all study arms 
from the moment that normoglycemic steady state was achieved onward (Figure 1). 
CVs for glucose levels at each plateau were all <5%. Caffeine (and theophylline) 
levels were below assay sensitivity before the start of either study. After theophylline 
bolus, plasma theophylline levels increased to 11.7 ± 0.5 mg/L in control subjects and 
to 11.1 ± 0.6 mg/L in diabetic patients and remained elevated during the maintenance 
infusion at 8.1 ± 0.3 and 7.5 ± 0.4 mg/L, respectively (Figure 1).  
 
Metabolic responses to hypoglycemia In healthy control subjects, glucose 
infusion rates (GIRs) required to maintain glucose at normoglycemic levels were 
similar between placebo and theophylline, but at hypoglycemic nadir, GIR was 
significantly lower in the presence of theophylline (2.9 ± 1.1 vs. 9.5 ± 1.5 
µmol·kg-1·min-1, P < 0.01) (Figure 1). In diabetic subjects, theophylline tended to 
reduce GIR during normoglycemia (19.8 ± 2.3 vs. 27.7 ± 2.2 µmol·kg-1·min-1, 
P = 0.05) and significantly reduced rates for the remainder of the study (12.5 ± 2.1 vs. 
19.5 ± 1.6 µmol·kg-1·min-1 [glucose 3.5 mmol/L] and 4.8 ± 1.7 vs. 13.9 ± 1.4 
µmol·kg-1·min-1 [glucose 2.5 mmol/L], both P < 0.01) (Figure 1).  
Baseline levels of counterregulatory hormones were similar between theophylline 
and placebo studies in both groups. At the end of the normoglycemic period, 
theophylline significantly enhanced adrenaline release in both patients (0.35 ± 0.08 
vs. 0.10 ± 0.04 nmol/L, P < 0.01) and control subjects (0.20 ± 0.04 vs. 0.07 ± 0.04 
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nmol/L, P < 0.01), whereas noradrenaline levels increased significantly more only in 
control subjects (0.45 ± 0.07 vs. 0.28 ± 0.04 nmol/L, P < 0.03) compared with placebo 
(Figure 2). Levels of glucagon, cortisol, and GH did not change before hypoglycemia.  
During hypoglycemia, diabetic patients had almost absent glucagon responses (P 
< 0.001 vs. control subjects), severely impaired adrenaline responses (P < 0.001), 
and small but significant impairments in noradrenaline (P < 0.001) and cortisol (P < 
0.001) responses compared with healthy control subjects (Figure 2). In both groups, 
theophylline significantly augmented hypoglycemia-induced responses of adrenaline 
(levels at hypoglycemic nadir 8.2 ± 0.7 vs. 6.5 ± 0.5 and 4.8 ± 0.6 vs. 3.4 ± 0.4 nmol/L 
for control subjects and type 1 diabetic patients, respectively, both P < 0.05), 
noradrenaline (2.9 ± 0.3 vs. 2.2 ± 0.2 and 2.4 ± 0.2 vs. 1.9 ± 0.2 nmol/L for control 
* 
* 
* * 
*P<0.05 versus previous value 
Type 1 diabetic patients (theophylline) 
Type 1 diabetic patients (placebo) 
Control subjects (theophylline) 
Controls subjects (placebo) 
Figure 3. – Responses of VMCA to hypoglycemia. In the placebo studies, VMCA increases significantly in both 
groups when hypoglycemic nadir is reached (~2.5 mmol/L). Immediately after theophylline (bolus) infusion, 
VMCA falls in both patients and controls and remains decreased (left graph). The fall in VMCA is significantly 
higher in diabetic patients than in controls (right graph). VMCA, median cerebral artery velocity. 
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subjects and type 1 diabetic patients, respectively, both P < 0.01), and cortisol (1.2 ± 
0.4 vs. 1.1 ± 0.1 and 1.1 ± 0.1 vs. 0.9 ± 0.1 µmol/L for control subjects and type 1 
diabetic subjects, respectively, both P < 0.02). During theophylline stimulation in 
diabetic patients, hypoglycemia-induced noradrenaline and cortisol levels reached 
values similar to nonstimulated levels in control subjects, whereas adrenaline levels 
remained somewhat lower (P < 0.05). Theophylline did not affect GH and glucagon 
responses to hypoglycemia in either group. 
 
Hypoglycemic symptoms Diabetic patients had reduced symptom responses 
to hypoglycemia compared with nondiabetic control subjects, both in terms of 
magnitude (P = 0.02) and glycemic thresholds (P < 0.001) (Figure 2, Table 2). In 
diabetic patients, theophylline shifted glycemic thresholds for symptoms to 
significantly higher glucose levels compared with placebo (3.37 ± 0.05 vs. 3.00 ± 0.05 
mmol/L, P < 0.001), and symptom responses tended to be higher (P = 0.09). In 
control subjects, theophylline had no additional effect on magnitude of symptoms or 
glycemic threshold.  
Table 2. –  Glycemic thresholds for hemodynamic and symptom responses to hypoglycemia 
 
 Type 1 DM patients Healthy controls 
 Glycemic 
threshold 
(glucose, mM) 
Magnitude of 
response 
Glycemic 
threshold 
(glucose, mM) 
Magnitude of 
response 
Systolic BP, mmHg     
placebo 2.40 ± 0.05* +2.5 ± 2.0* 2.57 ± 0.04      -3.4 ± 2.6 
theophylline 2.90 ± 0.07†  -5.9 ± 2.9‡        none      -1.7 ± 2.2 
Diastolic BP, mmHg     
placebo 3.35 ± 0.05  -5.6 ± 0.9 3.24 ± 0.06      -8.5 ± 1.1 
theophylline 3.86 ± 0.12†  -7.0 ± 1.1 3.43 ± 0.05*      -7.4 ± 1.8 
Pulse pressure, mmHg     
placebo 2.69 ± 0.05* +4.9 ± 1.3 3.22 ± 0.05     +6.5 ± 1.9 
theophylline 3.47 ± 0.05† +2.6 ± 1.5 3.59 ± 0.06†     +7.7 ± 1.9 
Heart rate, bpm     
placebo 3.38 ±0.05 +6.5 ± 3.3 3.22 ± 0.05   +10.7 ± 1.9 
theophylline 3.86 ± 0.12†  +14.9 ± 2.5‡ 3.43 ± 0.06†   +17.7 ± 2.9‡ 
Sweating response, g/m §     
placebo 2.38 ± 0.07*    59 ± 11* 2.78 ± 0.10      102 ± 10 
theophylline 2.66 ± 0.08†    71 ± 17 3.05 ± 0.11†        93 ± 9 
Hypoglycemic symptoms     
placebo 3.00 ± 0.05* 13.1 ± 2.8* 3.47 ± 0.05     21.3 ± 2.6 
theophylline 3.37 ± 0.05† 15.9 ± 3.4 3.46 ± 0.06     20.8 ± 2.4 
Data are means ± SE. *P < 0.05 between placebo tests in diabetic patients versus control subjects; †P < 0.01 
for differences between placebo and theophylline tests; ‡P < 0.05 for differences between placebo and 
theophylline tests; § values in patients are derived from 6 patients who had responses during both tests.
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To assess the appearance of hypoglycemic symptoms more accurately, a dew-
point electrode was applied to detect sweating responses. With placebo, sweat 
responses were registered in all healthy subjects and in 6 of the 15 diabetic patients. 
These responses occurred at significantly (P < 0.001) lower glucose levels in diabetic 
patients as compared with control subjects (Table 2). Theophylline shifted sweating 
responses to higher levels of glycemia in both the nondiabetic volunteers (P < 0.01) 
and the aforementioned six diabetic patients (P < 0.01). Furthermore, theophylline 
elicited a response at a mean (± SEM) glucose level of 2.35 ± 0.12 mmol/L in an 
additional four out of nine patients who had no responses with placebo (P < 0.03 by 
χ2).  
 
Middle cerebral artery velocity (VMCA) Baseline VMCA measurements were 
comparable between the study arms in both groups. Recordings in diabetic patients 
appeared higher than in control subjects, but this difference did not attain statistical 
significance (P = 0.3). During the final 30 min in the placebo study, when 
hypoglycemic nadir was reached, VMCA increased to 4.5 ± 1.5 and 7.6 ± 2.5 cm/s in 
control subjects (P < 0.05) and diabetic patients, respectively (P < 0.03). In contrast, 
theophylline caused immediate decreases in VMCA in control subjects (-7.6 ± 1.4 cm/s, 
P < 0.001) and diabetic patients (-14.5 ± 2.1 cm/s, P < 0.001), which remained 
unchanged for the duration of the studies (Figure 3). The decrease in VMCA was 
significantly more pronounced in diabetic patients than control subjects (P = 0.03).  
 
Hemodynamic responses In healthy control subjects, systolic and diastolic 
blood pressure decreased significantly in response to hypoglycemia, whereas heart 
rate and pulse pressure increased (Table 2). Maximal responses in diabetic patients 
were comparable with those in control subjects, except that systolic blood pressure 
increased instead of decreased (P < 0.05 vs. control subjects). Before hypoglycemia, 
theophylline slightly increased heart rates (3.4 ± 0.8 bpm, P < 0.01) in control 
subjects but did not affect blood pressure in either diabetic patients or control 
subjects. Theophylline significantly increased heart rate responses to hypoglycemia 
in both patients (P < 0.05) and control subjects (P < 0.05) and caused the systolic 
blood pressure in patients to decrease (P < 0.05). In the presence of theophyline, 
responses of diastolic blood pressure (P < 0.05), pulse pressure (P < 0.01), and heart 
rate (P < 0.01) in both groups and of systolic blood pressure (P < 0.01) in diabetic 
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patients were elicited at significantly higher glucose levels. Compared with healthy 
control subjects, theophylline largely normalized hemodynamic responses to 
hypoglycemia in diabetic patients (Figure 4).  
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Figure 4. – Change in hemodynamic parameters in response to hypoglycemia, in control subjects (white bars), 
type 1 diabetic patients (DM-1) with placebo (hatched bars), and type 1 diabetic patients with theophylline 
(black bars). Responses in diabetic patients are lower than those in control subjects at both hypoglycemic levels; 
theophylline improves the responses in diabetic patients, up to normalization. *P < 0.05 versus DM-1; other P-
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DISCUSSION 
 
In the present study, theophylline augmented counterregulatory hormone responses 
to and perception of insulin-induced hypoglycemia in type 1 diabetic patients who 
initially had pronounced impairments in glucose counterregulation and in awareness 
of hypoglycemia. Theophylline almost normalized the glycemic threshold for and 
magnitude of symptom responses in the diabetic patients and shifted glycemic 
thresholds for sweating and hemodynamic responses to higher glucose levels in both 
diabetic patients and control subjects. As a consequence of enhanced 
counterregulatory hormone release, GIRs were significantly lower with theophylline, 
reflecting increased endogenous glucose production, diminished glucose uptake, or 
both. This effect on GIR is in line with earlier findings of enhanced recovery from 
hypoglycemia in the presence of theophylline (8).  
Although theophylline has several well-described modes of action, the beneficial 
effect on glucose counterregulation most likely reflects its role as an adenosine-
receptor antagonist (10,13). In the brain, adenosine antagonism induces cerebral 
hypoperfusion accompanied by simultaneous increments in glucose utilization, thus 
uncoupling the relation between (adenosine-maintained) CBF and energy 
metabolism. In other words, glucose requirements are higher, but delivery is lower. 
As a consequence, counterregulatory hormone release is stimulated. Further 
stimulation occurs when cerebral glucose supply is jeopardized by coexisting 
hypoglycemia, especially beyond a critical glycemic threshold when CBF normally 
increases to compensate for the decrease in plasma glucose (21,22). Indeed, the 
finding that theophylline immediately reduced VMCA and prevented hypoglycemia-
induced increases in VMCA (Figure 3) is in accordance with the concept of sensing 
hypoglycemia and subsequent initiation of counterregulatory responses at higher 
levels of glycemia.  
Our observations of enhanced glucose counterregulation during theophylline 
treatment appear to be at variance with those of Hvidberg et al. (8), who reported that 
theophylline did not affect hormonal responses to hypoglycemia. This discrepancy 
may be explained by significantly higher glucose levels at hypoglycemic nadir during 
theophylline in their study, which may have masked any effect on counterregulation. 
Our findings are consistent with those of caffeine reported in diabetic patients without 
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hypoglycemia unawareness, except that caffeine was also found to stimulate GH 
responses (9). This variance with our data may be explained by differences between 
theophylline and caffeine on GH regulation and by differences in study design—in our 
study lower glycemic nadirs were reached and arterial blood was sampled, which 
may be more reliable than arterialized venous blood sampling (23,24).  
While exhibiting pronounced metabolic effects and a clear stimulation of 
symptoms using objective tools, theophylline appeared to have only a modest effect 
on symptom responses scored by checklists, especially in control subjects. This 
apparent discrepancy may be explained, first, by the questionnaire’s sensitivity to 
accurately assess and grade hypoglycemic symptoms, especially in subjects lacking 
prior "hypoglycemic experience," thus explaining why the checklist revealed an effect 
of theophylline in diabetic patients only. Secondly, the hypoglycemic steps may lack 
sufficient power to detect differences in symptom thresholds. In our study, arterial 
plasma glucose values decreased from 3.5 to 2.5 mmol/l in 30 min. A study protocol 
involving more steps to cover the decrease in glucose level or more frequent 
symptom assessments might have revealed differences in symptom scores between 
theophylline and placebo (25).  
Two observations from the transcranial Doppler recordings deserve some 
comment (Figure 3). Firstly, theophylline induced a larger decrease in VMCA in 
diabetic patients than in control subjects, which is consistent with larger adenosine 
availability in diabetic patients. This larger adenosine availability may explain the 
higher CBF reported in type 1 diabetic patients with longstanding disease and 
frequent hypoglycemic events compared with healthy age-matched control subjects 
(21). Second, theophylline almost completely suppressed increases in VMCA at 
hypoglycemic nadir in both diabetic patients and control subjects, indicating that 
hypoglycemia-induced increases are mediated by adenosine. Indeed, adenosine is 
involved in the maintenance of cerebral vascular tone and has been found to 
dramatically increase in rat striatum in response to severe hypoglycemia (26). One 
might speculate that hypoglycemia stimulates adenosine, which by increasing CBF 
and hence cerebral glucose availability, initially compensates for low blood glucose 
but also that the prize of this compensation is reduced awareness of subsequent 
hypoglycemias. As such, adenosine may be involved in the pathogenesis of 
hypoglycemia unawareness as a faster-responding component besides the 
"supposedly slower" upregulation of cerebral glucose transporters (27). Studies 
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showing that avoidance of hypoglycemias for several days partially reverses 
hypoglycemia unawareness and counterregulatory failure (28), but that full recovery 
requires at least 3–4 weeks (6,28,29), support this hypothesis. If further research 
substantiates the role of adenosine in the development of hypoglycemia 
unawareness, adenosine blockade would be a logical target to reverse this condition.  
In summary, we demonstrate that a single dose of theophylline enhances 
counterregulatory hormone responses to hypoglycemia and partially restores 
perception of hypoglycemia in diabetic patients with counterregulatory failure and 
hypoglycemia unawareness. The near normalization of glycemic thresholds allows a 
more timely behavioral response, i.e. eating something or seeking assistance for 
recovery. However, these promising results cannot yet be translated into clinical 
practice because of a number of limitations. Firstly, to obtain stable plasma levels, 
theophylline was administered intravenously, not orally. Whether oral theophylline is 
equally effective remains to be demonstrated. Yet, it should be possible to obtain the 
relatively low plasma levels required to block adenosine receptors (13) by currently 
available oral theophylline preparations (30). Secondly, our study was not designed to 
demonstrate sustained effects of theophylline, in terms of reducing the incidence of 
(severe) asymptomatic hypoglycemic episodes, even though this would be the 
ultimate clinical goal. Long-term use of theophylline (and related methylxanthine 
derivatives) is subject to the emergence of tolerance for many of its effects (31). 
Although there are indications that tolerance remains incomplete under hypoglycemic 
conditions (12), this issue needs to be further explored. Appropriate studies are 
therefore required to establish the clinical potential of theophylline in the management 
of hypoglycemia unawareness.  
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ABSTRACT 
 
Caffeine is a central stimulant that increases the release of catecholamines. As a component of 
popular beverages, caffeine is widely used around the world. Its pharmacological effects are 
predominantly due to adenosine receptor antagonism and include release of catecholamines. 
We hypothesized that caffeine reduces insulin sensitivity, either due to catecholamines and/or 
as a result of blocking adenosine-mediated stimulation of peripheral glucose uptake. 
Hyperinsulinemic normoglycemic glucose clamps were used to assess insulin sensitivity. 
Caffeine or placebo was administered intravenously to 12 healthy volunteers in a randomized 
double-blind crossover design. Measurements included plasma levels of insulin, 
catecholamines, and free fatty acids, and hemodynamic parameters. Insulin sensitivity was 
calculated as whole-body glucose uptake corrected for the insulin concentration. In a second 
study, the adenosine reuptake inhibitor dipyridamole was tested using an identical protocol in 
10 healthy subjects. Caffeine decreased insulin sensitivity by 15% (P versus placebo < 0.05). 
Following caffeine administration, plasma free fatty acids increased (P < 0.05) and remained 
higher than during placebo. Plasma adrenaline increased fivefold (P < 0.0005) and smaller 
increases were recorded in plasma noradrenaline (P < 0.02) and blood pressure (P < 0.001). 
Dipyridamole did not alter insulin sensitivity and only increased plasma noradrenaline (P < 
0.01). We conclude that caffeine can decrease insulin sensitivity in healthy humans, possibly 
as a result of elevated plasma adrenaline levels. Because dipyridamole did not affect glucose 
uptake, peripheral adenosine receptor antagonism appears not to contribute to this effect. 
 
___________________________________________________________ 
 
affeine is one of the most widely consumed ‘drugs’ in the world. The average 
daily intake per capita in the western world is 300 mg (1), and most of it comes 
from dietary sources such as coffee, tea, cola drinks, and chocolate. Caffeine is a 
methylxanthine derivative and a potent adenosine receptor antagonist that exerts its 
effects both centrally and peripherally because it crosses the blood-brain barrier. 
Systemic effects of caffeine include an increase in blood pressure and stimulation of 
the release of catecholamines, particularly adrenaline (2). Local effects of caffeine 
stem from interaction with interstitial adenosine (3).  
Data from animal studies have indicated that methylxanthines are involved in 
insulin-mediated glucose handling and insulin responsiveness in adipose and 
muscular tissue. In obese Zucker rats, the caffeine-related adenosine receptor 
antagonist 1,3 dipropyl-8-(acrylic) phenylxanthine was found to inhibit glucose uptake 
in adipose tissue, whereas the reverse was observed in skeletal muscle (4). Both 
effects were attributed to adenosine receptor antagonism at the tissue site because 
the compound does not cross the blood-brain barrier. Studies showing that adenosine 
or adenosine agonists increase insulin sensitivity in adipose tissue (5) and cardiac 
C 
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muscle (6,7) and decrease insulin sensitivity in skeletal muscle (8) are consistent with 
these observations. Consequently, the ultimate effect of adenosine receptor 
antagonism on whole-body glucose uptake is the sum total of all effects combined 
and depends on the relative amount of muscle and fat tissue and the degree of 
insulin sensitivity. Tissue-specific effects may explain why adenosine receptor 
blockade causes an increase in whole-body glucose uptake, or insulin sensitivity, in 
obese animals and a decrease in lean animals (4).  
Apart from peripheral adenosine receptor blockade, methylxanthines that 
penetrate the blood-brain barrier, such as caffeine, also enhance the release of 
catecholamines. Especially adrenaline exerts insulin-antagonistic activity, including 
inhibition of peripheral glucose uptake (9). Which of these effects prevail in response 
to systemic use of caffeine is unknown. In vivo studies have demonstrated that 
caffeine (10,11) and aminophylline (12) decrease glucose tolerance, so that a 
reduction in insulin sensitivity can be anticipated. However, direct evidence for 
negative effects of caffeine on insulin sensitivity in humans in vivo is still lacking. The 
purpose of this study was to test the hypothesis that systemic caffeine reduces insulin 
sensitivity in humans. We conducted a randomized, placebo-controlled, double-blind 
study using the normoglycemic-hyperinsulinemic clamp technique. To ascertain 
whether the effect of caffeine was mediated by peripheral adenosine antagonism, we 
also evaluated the effect of dipyridamole. Dipyridamole, an adenosine reuptake 
inhibitor, acts opposite to caffeine but is unable to cross the blood-brain barrier. In an 
in vivo study of humans, we have previously shown that dipyridamole-induced effects 
are completely based on adenosine receptor stimulation (13).  
 
PATIENTS AND METHODS 
 
The study group consisted of 21 nonsmoking, lean (mean BMI ± SD, 21.9 ± 2.7 
kg/m2), normotensive, healthy volunteers. Eleven subjects (six women and five men, 
mean age 22.6 ± 2.0 years) participated in the caffeine study, nine subjects 
participated in the dipyridamole study (six women and three men, mean age 21.7 ± 
3.1 years), and one male subject (28 years of age) participated in both studies. All 
participants were studied on two occasions, except for the subject volunteering in 
both studies, who was tested four times. The experiments were separated by at least 
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3 weeks and took place in random order. Female subjects were tested at 4- or 8-
week intervals to ensure that the experiments were performed during corresponding 
periods of the menstrual cycle. The experimental protocols were approved by the 
hospital ethics committee, and written informed consent was obtained before 
participation. 
 
Caffeine study On the morning of each experiment, subjects arrived at the test 
location at 8:00 A.M. after an overnight fast and having abstained from caffeine-
containing substances for 72 h to render them caffeine naive. Under local anesthesia 
(Xylocaine 2%), the left (nondominant) brachial artery was cannulated (Angiocath 20-
gauge; Beckton Dickinson, Sandy, UT) for blood sampling and hemodynamic 
monitoring. The antecubital vein in the contralateral arm was cannulated for 
administration of glucose 20%, insulin (Actrapid; Novo Nordisk, Bagsvaerd, 
Denmark), and test substances (caffeine, dipyridamole, or placebo).  
Arterial cannulation was followed by an equilibration period of 30 min, and then 
baseline variables were obtained at -20 min. Subsequently, a caffeine-loading dose 
(3 mg/kg) or a comparable volume of placebo solution (NaCl 0.9%) was administered 
intravenously over 15 min in a randomized, double-blind manner. This was followed 
by continuous infusion of 0.6 mg·kg-1·h-1 caffeine (or placebo) for the remainder of the 
study period, aiming at a stable caffeine concentration of 5–10 mg/L during caffeine 
experiments (2).  
After the caffeine/placebo loading dose (at 0 min), a hyperinsulinemic 
(60 mU·m-2·min-1) normoglycemic glucose clamp procedure was initiated and 
continued for 120 min (14). To maintain plasma glucose at 5 mmol/l with coefficients 
of variation (CVs) <5%, arterial plasma glucose levels were measured in duplicate at 
5-min intervals. At -20, 0, 90, and 120 min, forearm blood flow (FBF) measurements 
were performed, and arterial blood was sampled for determination of catecholamines, 
cortisol, free fatty acids (FFAs), insulin, and caffeine. FBF was recorded in both 
forearms by venous occlusion plethysmography using mercury-in-silastic strain 
gauges (Hokanson EC4; Hokanson, Washington, DC), as previously described (15).  
 
Dipyridamole study In the dipyridamole study, a loading dose of 0.05 mg/kg 
dipyridamole (or placebo) was intravenously administered over 4 min, followed by 
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continuous infusion of 0.2 mg·kg-1·h-1 (or placebo), to increase peripheral adenosine 
concentrations (16). Thereafter, the studies were concurrent with the caffeine studies.  
 
Analytical methods Plasma glucose was measured in duplicate by the glucose 
oxidation method (Beckman Glucose Analyzer II; Beckman, Fullerton, CA) in arterial 
blood samples and immediately centrifuged. Blood samples for catecholamine 
measurements were collected in prechilled tubes containing glutathione (0.2 mol/L) 
and EGTA (0.25 mol/L) and immediately stored on ice. Blood samples for 
measurements of cortisol, caffeine, insulin, and FFAs were collected in lithium-
containing heparin tubes and stored on ice. Plasma caffeine concentration was 
analyzed with a reversed-phase high-performance liquid chromatography (HPLC) 
method (limit of detection 0.2 mg/L). Plasma catecholamine levels were measured by 
HPLC with fluorometric detection, as previously described (17). Plasma insulin was 
assessed by radioimmunoassay using 125I-labeled human insulin and anti-human 
insulin antiserum raised in guinea pig. Bound and free tracer were separated by 
sheep anti-guinea pig antiserum; human insulin (Novo Biolabs, Danbury, CT) was 
used for standards. The interassay CV for insulin measurements was 10.3% at a 
level of 20.7 mU/L. Plasma cortisol was measured using the TDx batch analyzer of 
Abbott Laboratories (Abbott Diagnostics, Hoofddorp, The Netherlands) (interassay 
CV 5 and 8% at cortisol concentrations of 0.22 and 1.06 µmol/L, respectively). 
Plasma FFA levels were determined with a commercially available ACS-ACOD 
method (Wako NEFA C test; Wako Chemicals, Neuss, Germany).  
 
Statistical methods and calculations  For statistical analyses, the following 
tests were performed. The effect of caffeine and dipyridamole on glucose infusion 
rates (GIRs) and hormonal and cardiovascular responses were tested with analysis 
of variance. As a modification of a previously described method (18), whole-body 
insulin sensitivity was calculated as the GIR divided by the plasma insulin 
concentration during the final 30 min of the study and expressed in µmol·kg-1·min-1 
per mU/L. Area under the insulin sensitivity curve (AUCIS) was calculated and 
compared using Student’s t test. All statistical analyses were performed using the 
SPSS personal computer software package (Version 9.0). Data are presented as 
means ± SEM, unless otherwise specified, and P < 0.05 was considered statistically 
significant.  
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RESULTS 
 
During the clamp, plasma insulin levels increased to 99 ± 5 mU/l during caffeine and 
to 98 ± 5 mU/L during placebo (P = NS). Insulin levels in the dipyridamole study were 
90 ± 4 and 97 ± 3 mU/L during dipyridamole and placebo infusions, respectively (P = 
NS). Caffeine levels were undetectable before the start of either of the four study 
arms.  
 
Effects of hyperinsulinemia alone For this purpose, data of all placebo studies 
(n = 21) were pooled. Mean whole-body insulin sensitivity was 0.47 ± 0.03 
µmol·kg-1·min-1 per mU/L. Hyperinsulinemia alone induced modest increases in 
systolic blood pressure, heart rate, FBF, adrenaline, and noradrenaline and almost 
completely suppressed plasma FFA levels (Table 1). These data reflect systemic 
vasodilation and sympathetic activation, both of which have been previously 
described as a consequence of hyperinsulinemia (19).  
 
Responses to caffeine alone Plasma caffeine concentrations increased to 8.6 ± 
0.7 mg/L directly after the caffeine bolus infusion and remained at 6.5 ± 0.4 mg/L 
during the maintenance infusion. Before initiation of the hyperinsulinemic clamp, 
caffeine significantly stimulated the release of adrenaline (P < 0.0005), noradrenaline 
(P = 0.010), and FFA (P = 0.047) when compared with placebo (Figure 1). Caffeine 
increased systolic and diastolic blood pressure (P <0.001 for both) and modestly 
increased FBF (P = 0.013) but did not affect heart rate (Table 2).  
 
Table 1. – Responses to hyperinsulinemia in 21 subjects 
 
 Baseline 
(t = -30 min) 
During clamp 
(t = 90 min) 
End of study 
(t = 120 min) 
Adrenaline (nmol/L) 0.19 ± 0.03 0.22 ± 0.03 0.28 ± 0.04* 
Noradrenaline (nmol/L) 0.81 ± 0.09 1.00 ± 0.07 1.01 ± 0.06 
Cortisol (µmol/L) 0.58 ± 0.06 0.41 ± 0.03 0.40 ± 0.03* 
Free fatty acids (mmol/L) 0.40 ± 0.04 0.04 ± 0.00 0.03 ± 0.00* 
Systolic BP (mmHg)  126 ± 2  131 ± 2  131 ± 3* 
Diastolic BP (mmHg)    66 ± 1    68 ± 1    68 ± 1 
Heart rate (bpm)    61 ± 2    65 ± 2    66 ± 2* 
FBF (mL·dL-1·min-1) 2.30 ± 0.19 2.49 ± 0.24 2.70 ± 0.27* 
Data are means ± SEM. *P < 0.05 for trend. 
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Responses to caffeine and insulin Glucose and insulin levels and GIR during 
the clamps are depicted in Figure 2. During the first hour, GIR was roughly the same 
in caffeine and placebo arms. Thereafter, the curves diverted significantly, with an 
upward drift in the placebo studies that was absent with caffeine (P < 0.0005). The 
calculated whole-body insulin sensitivity during caffeine administration was 0.39 ± 
0.04 compared with 0.46 ± 0.04 µmol·kg-1·min-1 per mU/L in the placebo arm (P = 
0.043 for difference in AUCIS), equaling a decrease in insulin sensitivity of 15%.  
Plasma FFA levels decreased in both studies as a result of insulin but remained 
higher in the presence of caffeine (P = 0.001). Arterial plasma adrenaline levels 
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Figure 1. – Repsonses of plasma adrenaline, noradrenaline, cortisol, and free fatty acids (FFA) to caffeine 
(closed squares) and placebo (open circles) before and during the clamp study. Arrows denote start of caffeine 
or placebo infusions. P-values are given for differences between caffeine and placebo studies. *P < 0.05 for 
change fom baseline between caffeine and placebo (reflecting effect of caffeine alone). 
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increased significantly more with caffeine than placebo (P = 0.001) (Figure 1). The 
increase in plasma noradrenaline levels and the decrease in plasma cortisol were not 
statistically different between caffeine and placebo. During the clamps, increases in 
systolic blood pressure, heart rate, and FBF did not differ significantly between 
caffeine and placebo, whereas diastolic blood pressure remained stable in either 
group (Table 2).  
 
Responses to dipyridamole Dipyridamole had no effect on insulin sensitivity 
compared with placebo (0.49 ± 0.04 vs. 0.50 ± 0.04 µmol·kg-1·min-1 per mU/L, P = 
NS). Apart from a significant increase in plasma noradrenaline levels during the 
dipyridamole study that did not occur with placebo (0.37 ± 0.05 vs. 0.00 ± 0.13 
nmol/L, P = 0.009), all metabolic and hemodynamic responses were comparable 
during the dipyridamole and placebo studies.  
 
DISCUSSION 
 
The major finding of our study is that caffeine, in a dose that equals moderate 
consumption, decreased insulin sensitivity in healthy volunteers. Caffeine increased 
plasma catecholamines, plasma FFAs, and systolic and diastolic blood pressure. In 
contrast, dipyridamole had no effects on insulin sensitivity and only increased plasma 
noradrenaline levels. The decrease in insulin sensitivity we documented as result of 
caffeine ingestion is close to the magnitude of the increase in insulin sensitivity that 
Table 2. – Responses of blood pressure, heart rate, and forearm blood flow 
 
 Baseline 
(t = -30 min) 
After loading dose 
(t = 0 min) 
During clamp 
(t = 90 min) 
End of study 
(t = 120 min) 
Systolic BP (mmHg)     
placebo  127 ± 2   128 ± 3   131 ± 3  133 ± 4† 
caffeine  122 ± 2   129 ± 2*   134 ± 2  134 ± 2†‡ 
Diastolic BP (mmHg)     
placebo 68 ± 2  68 ± 2  69 ± 2 70 ± 2 
caffeine 64 ± 1  70 ± 1*  69 ± 1 69 ± 1†‡ 
Heart rate (bpm)     
placebo 65 ± 3  65 ± 3  68 ± 3 69 ± 3† 
caffeine 59 ± 2  59 ± 2  64 ± 3 65 ± 3† 
FBF (mL·dL-1·min-1)     
placebo 2.25 ± 0.22  2.17 ± 0.20  2.75 ± 0.31 3.07 ± 0.38† 
caffeine 2.26 ± 0.40  2.60 ± 0.36  3.75 ± 0.85 4.64 ± 1.19† 
Data are means ± SEM. *P < 0.05 vs baseline, †P < 0.05 for trend, ‡P < 0.05 caffeine vs placebo for trend. 
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can be achieved with glucose-lowering agents, such as metformin (20) and 
thiazolidinedione derivatives (21), and is therefore clinically relevant. Our finding may 
have serious health implications, especially when superimposed on already-disturbed 
glucose tolerance or established (type 2) diabetes.  
The following factors probably contributed to the caffeine-induced fall in insulin 
sensitivity. Firstly, there was a fivefold increase in arterial plasma adrenaline levels 
compared with placebo. The effects of adrenaline on glucose metabolism are 
diametrical to insulin and include promotion of hepatic glucose production and 
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Figure 2. – Glucose and insulin levels and glucose infusion rates (GIR) during clamp. The arrow denotes the 
start of caffeine or placebo infusions. Closed squares, caffeine; open circles, placebo. 
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inhibition of glucose uptake in muscle and fat. Using the normoglycemic clamp 
technique, Deibert and DeFronzo (9) showed that adrenaline infusion reduced tissue 
sensitivity to insulin by 50%. Effects of adrenaline were characterized by an inability 
of insulin to stimulate peripheral glucose disposal and to suppress hepatic glucose 
production. Because the adrenaline level attained in that study was fourfold higher 
than that in our study, the 15% fall in insulin sensitivity we observed may be 
comparable with data reported by Deibert and DeFronzo. The observation that 
caffeine does not affect either glucose or insulin levels in the absence of significant 
adrenaline release is consistent with this hypothesis (22). Secondly, caffeine 
stimulated FFA production, either as a consequence of adrenaline-mediated lipolysis 
or by inhibiting adenosine-induced suppression of lipolysis (23). Plasma FFA may 
decrease hepatic and peripheral glucose uptake and correlates negatively with insulin 
sensitivity (24). Also, in essential hypertension (25) and lipid disorders (26), insulin 
resistance has been, in part, attributed to elevated FFAs. Plasma noradrenaline was 
probably of minor relevance because it was only mildly elevated with caffeine, and 
the increase with dipyridamole was not associated with a change in insulin sensitivity. 
The fall in insulin sensitivity can also not be explained by reduced glucose delivery 
because we did not observe any vasoconstrictor effect of caffeine. On the contrary, 
caffeine increased both blood pressure and FBF—effects that can be largely 
attributed to caffeine-induced release of plasma catecholamines (27). The increase in 
FBF with caffeine is somewhat unexpected, as earlier studies reported no effects of 
caffeine on FBF (27,28). Mental stress experienced during the tests might explain this 
observation because caffeine is known to magnify vasodilator responses induced by 
mental stress (28,29).  
Caffeine has two well-described molecular mechanisms of action; it is both an 
adenosine receptor antagonist and a phosphodiesterase inhibitor (30). In the 
periphery, interstitial adenosine may be involved in insulin-mediated glucose 
metabolism, although controversy exists as to whether adenosine exerts opposing 
effects in adipose tissue and skeletal muscle. Some studies have reported adenosine 
to increase insulin-mediated glucose metabolism in adipose tissue (5,31) and to 
decrease metabolism in skeletal muscle (32). Others have recorded decreased 
skeletal muscle glucose uptake with degradation or blocking of adenosine (33,34), 
indicating uniform effects of adenosine on (insulin-mediated) glucose metabolism in 
fat and muscle. In obese Zucker rats, blocking peripheral interstitial adenosine by 
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systemic administration of a methylxanthine not entering the brain increased whole-
body (insulin-mediated) glucose uptake, thus improving glucose tolerance (4). In 
contrast, a decrease in glucose uptake was observed in lean animals. To ascertain 
whether peripheral adenosine receptor antagonism was involved in caffeine effects 
on glucose disposal, the effect of increasing interstitial adenosine by dipyridamole 
was studied. Dipyridamole opposes caffeine only in the periphery, as it does not 
penetrate the blood-brain barrier. Because dipyridamole had no effect on insulin 
sensitivity, a significant contribution of interstitial adenosine on glucose uptake is 
unlikely, although it is possible that opposing effects of adenosine antagonism on 
muscular and adipose tissue glucose uptake outweighed each other. These data are 
in accordance with those of Natali et al. (35), who found no effect of intrabrachial 
adenosine on local glucose uptake despite increased blood flow. Thus, in addition to 
tissue-specificity, adenosine effects may also be species-specific (36). Similarly, the 
lack of effect of dipyridamole on insulin sensitivity almost excludes 
phosphodiesterase inhibition as a mechanism underlying the effect of caffeine 
because dipyridamole also inhibits phosphodiesterase activity. Indeed, plasma levels 
of caffeine achieved in this study are at least 10 times too low for phosphodiesterase 
to become significantly inhibited (30).  
An important question is whether the present observations can be extrapolated to 
chronic use of caffeinated beverages. Chronic use of caffeine (and related 
methylxanthine derivatives) is known to result in attenuation of both humoral and 
pressor effects that are associated with acute ingestion (37), perhaps due to 
upregulation of adenosine receptors (38). The development of tolerance has been 
used to explain that large population-based studies have not identified a relation 
between coffee consumption and cardiovascular disease (39). When emergence of 
tolerance applies to the effect of caffeine on insulin sensitivity, decreases in insulin 
sensitivity may be expected to recover with chronic caffeine use. However, because 
emergence of tolerance is correlated to individual elimination half-lives of caffeine 
(40), tolerance may not develop in subjects with short caffeine half-lives. Also, not all 
caffeine effects appear to be subject to emergence of tolerance (41). Until these 
issues are resolved, considerations about environmental factors contributing to 
insulin resistance might include caffeine.  
In conclusion, we demonstrate that acute administration of a moderate amount of 
caffeine decreases insulin sensitivity in healthy subjects. This effect may be 
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explained by increased plasma adrenaline and FFA levels. Peripheral adenosine 
receptor antagonism is less likely to have played a role. Further investigation is 
required to elucidate whether this effect persists over time with chronic use of 
caffeine. Because tolerance may develop for the effects of caffeine, it is currently 
premature to advise against caffeine use in the management of insulin resistance.  
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ABSTRACT 
 
A single dose of theophylline improves hypoglycemia unawareness in type 1 diabetic 
patients. Prolonged theophylline use is, however, associated with emergence of tolerance. The 
present study investigated whether prolonged use of theophylline retains efficacy on 
counterregulatory defects in type 1 diabetic patients with hypoglycemia unawareness. 
Experiments were carried out in 12 type 1 diabetic subjects with hypoglycemia unawareness. 
All subjects participated in a cross-over study of two randomly scheduled 15-day study 
periods, during which theophylline (250 mg twice daily) or matching placebo was used. On 
the final day of each period, hyperinsulinemic (360 pmol·m-2·min-1) hypoglycemic (5.0–3.5–
2.5 mmol/L) glucose clamps were performed to assess counterregulatory and cardiovascular 
responses. Under normoglycemic conditions, there were no differences between theophylline 
and placebo. Under hypoglycemic conditions, theophylline enhanced responses of growth 
hormone, symptoms, heart rate, and pulse pressure (all P < 0.05), induced sweating at higher 
plasma glucose levels (P = 0.039), and reduced exogenous glucose requirements (P = 0.018). 
Hypoglycemia-induced responses of adrenaline, noradrenaline and cortisol were not enhanced 
by theophylline. These data show that prolonged theophylline has a sustained effect on 
cardiovascular, metabolic and symptom responses to hypoglycemia in type 1 diabetic patients 
with hypoglycemia unawareness. Whether these results translate into clinical benefit remains 
to be determined.  
 
___________________________________________________________ 
 
ne of the main treatment goals in type 1 diabetes is the achievement of near 
normal plasma glucose levels, in order to avoid microvascular complications 
(1). This goal is, however, almost never attained. An important cause for this failure is 
the occurrence of recurrent iatrogenic hypoglycemias and the subsequent loss of 
hypoglycemic awareness (2). In fact, severe hypoglycemia unawareness not 
uncommonly results in poor metabolic control either as a consequence of fluctuating 
glucose levels or because relaxation of metabolic control is used therapeutically to 
reverse this condition. Adenosine receptor blocking agents may provide a potential 
alternative for the treatment of hypoglycemia unawareness. Single doses of either 
caffeine or theophylline enhance counterregulatory responses to (3,4) and recovery 
from (5) insulin-induced hypoglycemia in normal subjects and in patients with type 1 
diabetes. Recently, we demonstrated that theophylline improved counterregulatory 
defects in type 1 diabetic patients with established hypoglycemia unawareness (6), 
indicating that a pharmacological approach might be valid to revert counterregulatory 
failure. 
Unfortunately, the literature on the pharmacology of xanthine derivatives shows that 
the majority of pharmacological effects of theophylline or caffeine disappear during 
O 
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prolonged use (>4 days) as a consequence of tolerance (7). Clearly, this is very 
important as emergence of tolerance may limit the usefullness of these drugs in 
improving counterregulatory defects. At present, there is uncertainty as to whether 
chronic use of xanthine derivatives retains stimulating effects on counterregulatory 
responses to hypoglycemia. One study reported no effect of two weeks of theophylline 
on hormone responses to hypoglycemia (8). In this study, glucose levels were not 
controlled but allowed to fall freely in response to insulin, which resulted in significantly 
higher glucose nadirs after theophylline. These higher glucose nadirs may have 
masked an effect of theophylline. Another study reported increased self-reported 
intensity of hypoglycemia warning symptoms during three months of caffeine use in 
unselected type I diabetic patients (9). However, this study lacked a hypoglycemic 
event to measure counterregulatory function. In addition, neither study was performed 
in patients designated to benefit from improved counterregulation, i.e. those with 
established hypoglycemia unawareness. Therefore, the aim of the present study was to 
examine the effects of two weeks of theophylline on responses to fixed equivalent 
hypoglycemia in patients with type 1 diabetes and hypoglycemia unawareness. We 
used the hyperinsulinemic hypoglycemic glucose clamp to control for differences in 
plasma glucose and insulin levels, allowing exact quantification of counterregulatory 
responses.  
 
RESEARCH DESIGN AND METHODS 
 
Subjects Twelve type 1 diabetic patients (7 males, age [mean±SD] 41 ± 9 years, 
duration of diabetes 16 ± 8 years, HbA1C 7.5 ± 0.9%) with hypoglycemia unawareness 
were enrolled to participate in a doubleblind placebo-controlled randomized cross-over 
study. All met the inclusion criteria of self-reported failure to accurately perceive low 
blood glucose levels, a consistent history of recurrent hypoglycemic events, the 
identification of principally neuroglycopenic as opposed to autonomic symptoms of 
hypoglycemia on a standardized symptom questionnaire, and the absence of classical 
diabetic complications (except background retinopathy). Autonomic neuropathy was 
excluded by normal cardiovascular reflex tests (10). All patients were on basal-bolus 
insulin regimens or on insulin pump therapy and no patient used medication other than 
insulin or insulin analogues. The study was approved by the medical ethics committee 
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of the University Medical Center Nijmegen and all participants provided written 
informed consent before enrollment. 
 
Study design All subjects participated in two 15-day study periods, the order of 
which was randomized. During one period, patients received 250 mg of theophylline in 
slow-release tablets (theolair, 3M Pharma, UK) twice daily, during the other period they 
received matching placebo tablets. A hyperinsulinemic hypoglycemic clamp study was 
performed on the final day of each period. In males, study periods were scheduled so 
that clamp tests were performed at least three weeks apart; in female participants study 
periods were scheduled at exact 4- or 8-week intervals to ensure that clamp tests took 
place in corresponding periods of the menstrual cycle. Patients were requested to 
abstain from caffeinated coffee during the entire study period and to abstain from all 
caffeine containing substances (coffee, tea, cola, and chocolate) for at least three 
days before the clamp tests. Prior to the experimental days, patients were instructed 
to reduce bedtime insulin dosages to avoid nocturnal hypoglycemia and to check 
capillary glucose at 3.00 AM during the night. 
 
Hypoglycemic clamp studies On the morning of each experimental day, subjects 
arrived at the test location at 8.00 AM after an overnight fast. Immediately after 
arrival, subjects ingested the last theophylline or placebo tablet. Subsequently, the 
brachial artery of the non-dominant arm was cannulated under local anesthesia for 
blood sampling and continuous blood pressure monitoring (Monitor 378341A, Hewlett 
Packard GmbH, Germany). An intravenous catheter was inserted into the antecubital 
vein of the contralateral arm for infusion of insulin (Actrapid, Novo Nordisk, Denmark) 
and glucose infusions. Baseline variables were obtained after a resting period of 30 
minutes. Thereafter, a hyperinsulinemic (360 pmol·m-2·min-1) hypoglycemic glucose 
clamp procedure was initiated, as described reviously (6). Using a variable infusion of 
glucose 20% (supplemented with 10 mmol KCl per 500 ml), the arterial plasma 
glucose concentration was sequentially clamped at 5.0, 3.5, and 2.5 mmol/L at hourly 
intervals, based on plasma glucose levels measured in duplicate every 5 minutes by 
the glucose oxidation method (Beckman Glucose Analyzer II, Beckman, Fullerton, 
CA).  
Participants were asked to complete semiquantitative symptom questionnaires 
every 10 minutes. Symptoms could be scored from 0 (absent) to 6 (severe), and 
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included blurred vision, difficulty in speaking, feeling faint, difficulty thinking, 
confusion, dizziness, tingling, sweating, feeling hungry, palpitations, anxiety, 
trembling, dry mouth, weakness, nausea, and headache (11). In addition, sweat 
evaporation rate was measured by a dew-point sweat detection electrode 
(Evaporimeter EP1, Servomed AB, Stockholm, Sweden) connected to the inner 
portion of the forearm (12). Arterial blood samples for all analytes other than glucose 
were drawn at 30 minute intervals and immediately stored on ice. 
 
Analytical methods Plasma adrenaline and noradrenaline were analyzed by 
high performance liquid chromatography (HPLC) using a modification of an earlier 
described laboratory procedure (13). Plasma glucagon (6), insulin (6), C-peptide (6), 
and GH (14) were measured by radioimmunoassays. Plasma cortisol was assayed 
using the TDx batch analyzer of Abbott laboratories (Abbott Diagnostics, Hoofddorp, 
The Netherlands) (interassay CVs, 9.1% and 6.6% at plasma levels of  0.22 and 1.06 
µmol/L, respectively). HbA1C was measured using HPLC (Bio-Rad Laboratories, 
Veenendaal, The Netherlands) with reference values of 4.8–6.2%. Plasma 
theophylline and caffeine were determined by fluorescence polarization immuno 
assay (FPIA) and HPLC (limit of detection, 0.2 mg/L), respectively.  
 
Calculations and statistical analyses  Glycemic threshold for detection of 
sweat production was defined for each individual as the plasma glucose level at 
which dew-point electrode readings showed at least doubling of baseline values (6). 
Areas under the curve were calculated for the total symptom score (AUCsymptoms), 
using the trapezoidal method. Serial data were compared between groups by 
Table 1. – Baseline laboratory values on experimental days 
 
Variable After placebo After theophylline 
Fasting plasma glucose (mmol/L)   13.2 ± 0.7   12.6 ± 0.7 
Fasting plasma insulin (pmol/L)      89 ± 15      88 ± 10 
Glucagon (pmol/L)   14.1 ± 1.1   13.9 ± 1.6 
Adrenaline (nmol/L)   0.22 ± 0.03   0.25 ± 0.03 
Noradrenaline (nmol/L)   0.89 ± 0.11   1.13 ± 0.14* 
Cortisol (µmol/L)   0.53 ± 0.08   0.56 ± 0.09 
Growth Hormone (mU/L)   12.8 ± 5.0     7.5 ± 2.7 
Data are means ± SEM. To convert glucose to mg/dL multiply by 18.0, insulin to µU/mL divide by 6.0, 
glucagon to pg/mL divide by 0.287, adrenaline to pg/mL divide by 0.005485, noradrenaline to pg/mL divide by 
0.005911, cortisol to µg/mL divide by 27.59, and growth hormone to ng/mL divide by 2.59. *P < 0.05 versus 
placebo. 
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repeated measures analysis of variance (ANOVA) and differences in means were 
tested using paired Student’s t-test. For calculations and statistical analyses, the 
SPSS personal computer software package was used (SPSS, Chicago, IL). A 
P < 0.05 was considered statistically significant. Results in tables and figures are 
expressed as means ± SEM, unless otherwise indicated. 
 
RESULTS 
 
Tablet counts performed at the end of each 15-day period indicated a compliance of 
>95% on both occasions. Plasma theophylline levels were 5.9 ± 0.7 mg/L at baseline 
and remained stablely elevated at ~6.6 mg/L with theophylline, and they were below 
Figure 1. – Glucose levels (top) and glucose infusion rates (GIR, bottom) during clamps in placebo and 
theophylline studies. *P = 0.018 for average value during final 30 minutes. 
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detection limits with placebo. Caffeine levels remained below detection limits with either 
treatment. With theophylline, plasma noradrenaline levels were slightly higher, but 
otherwise baseline measurements did not differ between placebo and theophylline 
(Tables 1 and 2). Average plasma glucose levels during the final 30 minutes of each 
glycemic step were 4.9, 3.3, and 2.4 mmol/L during both treatments, with corresponding 
coefficients of variation all below 5% (Figure 1).  
 
Measurements during normoglycemia After insulin administration, plasma 
insulin levels increased to 524 ± 56 and 571 ± 43 pmol/L in the placebo and 
theophylline study-arm, respectively (P = NS). Glucose infusion rates required to 
maintain glucose at normoglycemia were similar between placebo and theophylline 
(Figure 1). Under normoglycemic conditions, there were no differences in 
counterregulatory hormone levels, symptom scores or cardiovascular parameters 
between theophylline and placebo.  
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Figure 2. – Mean (± SEM) concentrations of counterregulatory hormones in response to hypoglycemia in the 
presence of placebo or theophylline. P-values shown refer to the difference between placebo and theophylline 
(ANOVA). 
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Responses to hypoglycemia Exogenous glucose requirements as reflected by 
the glucose infusion rate were comparable in both treatments during the initial 
hypoglycemic step (plasma glucose, 3.3 mmol/L). However, exogenous glucose 
requirements during the second hypoglycemic step (plasma glucose, 2.4 mmol/L) 
were significantly lower with theophylline than with placebo (13.2 ± 2.3 versus 
16.8 ± 1.6 µmol·kg-1·min-1, P = 0.018). On both occasions, hypoglycemia stimulated 
the release of all counterregulatory hormones (all P < 0.001), except for glucagon 
(data not shown) (Figure 2). Growth hormone levels increased significantly more with 
theophylline than with placebo (P = 0.043). Individual responses of adrenaline, 
noradrenaline, and cortisol were not enhanced by theophylline.  
There was a trend towards a greater symptom response to hypoglycemia with 
theophylline than with placebo (Figure 3), but the difference was only statistically 
significant for the overall symptom response (calculated as area under the symptom 
curve) (P = 0.049). Sweating responses were higher (61 ± 15 versus 38 ± 11 g/m2, 
P = 0.035) and were elicited at higher glucose levels (2.6 ± 0.1 versus 2.3 ± 0.1 
mmol/L, P = 0.039) with theophylline compared to placebo (Figure 4). Increments of 
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Figure 3. – Symptom score of total hypoglycemic symptoms as assessed by questionnaire during the clamp. 
The insert depicts the area under the symptom curve (AUC). *P < 0.05. 
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heart rate (+9 ± 4 versus +3 ± 2 bpm, P < 0.001) and pulse pressure (+3 ± 2 versus 
0 ± 2 mmHg, P = 0.001) in response to hypoglycemia were also higher with 
theophylline than with placebo. The hypoglycemia-induced fall in systolic blood 
pressure was reduced after theophylline (–4 ± 2 versus –8 ± 2 mmHg, P = 0.033), 
whereas the fall in diastolic blood pressure was similar in both studies (Table 2). 
 
DISCUSSION 
 
In a previous study, we showed that a single dose of theophylline augments 
hormonal responses to and symptomatic awareness of experimental hypoglycemia in 
diabetic patients with hypoglycemia unawareness (6). However, there is 
disagreement as to whether counterregulatory responses remain stimulated when 
theophylline use is prolonged, as chronic theophylline use is normally associated with 
development of tolerance (7). In the present study, we measured counterregulatory 
and cardiovascular responses under standardized normoglycemic and hypoglycemic 
conditions after two weeks use of theophylline or placebo. Under normoglycemic 
conditions, the effects of theophylline were equivalent to those of placebo, which is 
consistent with the emergence of tolerance. However, two weeks of oral theophylline 
maintained to stimulate cardiovascular and thermoregulatory responses to 
Figure 4. – Individual and mean glycemic 
thresholds indicating first appearence of 
sweating responses by dew point electrode 
detection during hypoglycemia. 
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hypoglycemia, as reflected by increased responses of heart rate, pulse pressure, and 
sweating. Theophylline mildly stimulated symptom responses, whereas the effect on 
metabolic responses was mixed: the reduced exogenous glucose requirements at 
hypoglycemic nadir suggest that theophylline enhanced metabolic counterregulation 
under hypoglycemic conditions, but the stimulation of individual hormone responses 
was only significant for growth hormone and not for adrenaline, noradrenaline and 
cortisol. Alltoghether, these data suggest that prolonged use of theophylline does 
retain stimulating effects under hypoglycemic conditions that include a beneficial 
effect on hypoglycemia unawareness. 
At hypoglycemic nadir, exogenous glucose requirements are inversely related to 
the endogenous generation of plasma glucose and – therefore – to the glucose 
stimulating-capacity of metabolic counterregulation as a whole to raise plasma glucose. 
Thus, our observation of lower exogenous glucose requirements at hypoglycemic nadir 
with theophylline is compatible with enhancement of metabolic counterregulation as a 
whole. This effect of chronic theophylline is consistent with a study reporting an 
attenuated insulin-induced glucose fall after two weeks of theophylline (8). However, 
despite enhanced metabolic counterregulation and in contrast to the effect of a single 
dose (6), chronic theophylline did not significantly enhance individual hormonal 
responses to hypoglycemia (except growth hormone), although there was a tendency 
for higher responses of all counterregulatory hormones. The lack of statistical 
significance for individual hormone responses may reflect a type 2 statistical error, i.e. 
inclusion of additional participants to the trial might have provided more support for an 
Table 2. – Cardiovascular responses to hypoglycemia 
 
Variable Baseline Glucose targets during clamp (mmol/L) P-value 
  5.0 3.5 2.5  
Heart rate (bpm) 
Placebo 
Theophylline 
 
  70 ± 2 
  70 ± 2 
 
   68 ± 2 
   69 ± 2 
 
71 ± 2 
75 ± 3† 
 
  73 ± 2* 
  82 ± 4*† 
 
<0.0005 
Systolic BP (mmHg) 
Placebo 
Theophylline 
 
112 ± 4 
108 ± 3 
 
 111 ± 3 
 108 ± 4 
 
109 ± 3 
107 ± 4 
 
105 ± 3*  
103 ± 3* 
 
0.033 
Diastolic BP (mmHg) 
Placebo 
Theophylline 
 
  62 ± 2 
  60 ± 2 
 
   64 ± 1 
   62 ± 2 
 
61 ± 1 
59 ± 2 
 
  56 ± 2* 
  54 ± 2* 
 
0.939 
Pulse pressure (mmHg) 
Placebo 
Theophylline 
   
  49 ± 2 
  48 ± 2 
   48 ± 2 
   46 ± 2 
48 ± 2 
48 ± 3 
  49 ± 1 
  50 ± 2* 0.001 
Data are means ± SEM. *P < 0.05 for change from baseline (ANOVA). †P < 0.05 versus placebo at comparable 
glycemic level (t-test).  
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effect of theophylline. Alternatively, increased β-adrenergic sensitivity, which has been 
reported to occur in hypoglycemia unaware diabetic patients after avoidance of 
hypoglycemia (15), may explain enhanced responses to catecholamines despite 
unchanged plasma levels. There are some animal data that suggest that adenosine 
receptor antagonists interfere with adenosine-mediated adrenergic desensitization (16), 
but a direct effect of these agents on adrenergic sensitivity has not been investigated.  
It seems very unikely that the effect on insulin responsiveness was caused by 
enhanced growth hormone responses alone. Although growth hormone stimulates both 
glucose disposal and hepatic glucose production (17), these insulin-antagonistic effects 
normally do not become evident before 2 hours after hormone secretion (18). 
Moreover, short-term elevation of growth hormone is not associated with alterations of 
heart rate or other hemodynamics and has no role in the appearence of sweating 
responses.  
After appropriate abstinence, the acute effects of methylxanthine derivatives include 
vasopressor responses (19), stimulation of catecholamine release (20), and 
suppression of the cerebral circulation (21). Under hypoglycemic conditions, the 
stimulation of glucose counterregulation is thought to be due to cerebral 
hypoperfusion (3), especially beyond a critical glycemic threshold when an increase 
in cerebral blood flow should normally compensate for the decrease in glucose 
delivery (6). Near complete tolerance for humoral and cardiovascular effects of 
methylxanthines has been well-described to occur within four days of chronic use (7), 
although the exact nature of this phenomenon is incompletely understood. In contrast, 
it has been reported that methylxanthine-induced suppression of the cerebral 
circulation is much less sensitive to emergence of tolerance than the pressor and 
humoral effects (22). Our observation that theophylline did not affect cardiovascular 
parameters or hormonal levels under normoglycemic conditions is compatible with 
complete emergence of tolerance. Nevertheless, when glucose levels fell into the 
hypoglycemic range, many responses remained more pronounced with theophylline, 
argueing against complete emergence of tolerance. Considering the resistance of the 
cerebral circulation to become tolerant, it seems plausible that the enhanced 
counterregulatory and cardiovascular responses to hypoglycemia were due to 
sustained suppression of brain blood flow by theophylline, despite chronic use.  
Our study has a number of limitations. First, metabolic control and hypoglycemic 
incidence were not monitored during the study. This study was not designed as a 
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‘treatment’ study per se, but as a pharmacological proof of concept to assess 
theophylline’s potential in the management of hypoglycemia unawareness. Second, 
whether the effects of theophylline are sufficient to ameliorate hypoglycemia 
unawareness clinically cannot be simply derived from our data. Although an improved 
counterregulatory response to hypoglycemia is probably beneficial, a clinical benefit of 
reduced hypoglycemia unawareness would require longer observation periods, larger 
patient groups, and scrupulous monitoring of hypoglycemic events. Proper scoring of 
hypoglycemias in clinical situations is, however, notoriously difficult. Third, we cannot 
rule out that (slight) reductions in metabolic control (23) or in number of hypoglycemic 
events (24) might have played a role in the theophylline-induced promotion of 
counterregulatory responses to hypoglycemia. The slightly lower fasting plasma 
glucose levels at baseline with theophylline and a study reporting no effect of three 
months of caffeine on HbA1C or on number of hypoglycemias (9), however, do not 
support such a role. Yet, even when that would be the case, it would still establish the 
point of a sustained effect of prolonged theophylline. It could be argued that 
investigating nondiabetic subjects would have overcome these limitations. However, we 
specifically enrolled diabetic patients with clinically relevant hypoglycemia 
unawareness, as they constitute the target population for any counterregulation 
supporting intervention, and because they are probably more sensitive to the 
stimulating effect of theophylline than matched nondiabetic controls (6).  
In conclusion, two weeks of theophylline treatment increased cardiovascular, 
thermoregulatory, symptom and the composite of metabolic responses – but not 
individual hormone responses – to hypoglycemia in type 1 diabetic patients with 
hypoglycemia unawareness. We demonstrated that emergence of tolerance was 
incomplete for the effects of theophylline under hypoglycemic conditions. These results 
suggest that theophylline retains efficacy in supporting glucose counterregulatory 
responses to hypoglycemia, despite chronic use. Whether chronic theophylline, either 
alone or – because of the clear stimulation of heart rate and sweat responses – in 
combination with awareness training (25) focussed on these responses, translates into 
clinical improvement of hypoglycemia unawareness requires further study.  
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ypoglycemia is a fact of life for almost all patients with type 1 diabetes and for 
a substantial proportion of patients with advanced type 2 diabetes 
(approaching the insulin deficient end of the spectrum). The frequency of 
hypoglycemic events depends mainly on disease duration and magnitude of glycemic 
control, and may be as high as several events per week, some of which may pass 
unnoticed, and one or two complicated events per year. Because hypoglycemia itself 
exerts suppressive effects on hormone responses to and symptomatic perception of 
subsequent hypoglycemia, a vicious cycle of repeated exposure to hypoglycemia and 
reduced counterregulatory responses may ultimately lead to hypoglycemia 
unawareness. To emphasize the pivotal role of hypoglycemia, the combination of 
defective hormone responses and hypoglycemia unawareness is sometimes referred 
to as hypoglycemia-associated autonomic (or counterregulatory) failure. The exact 
prevalence of hypoglycemia unawareness is unknown, but it has been estimated that 
up to 25% of type 1 diabetic patients have trouble identifying hypoglycemia, whereas 
defective hormone responses are even more prevalent. By facilitating unopposed 
hypoglycemia, defective hormone responses and hypoglycemia unawareness not 
only maintain a high risk for frequent and severe hypoglycemic events, but – 
conversely – also act as limiting factor to optimize glycemic control. Gaining insight 
into the pathophysiology of these disorders and developing strategies to correct them 
may therefore both alleviate the burden of hypoglycemia and lead to improvements in 
glycemic control. The aim of the present thesis was to increase our understanding of 
counterregulatory failure and hypoglycemia unawareness and to explore the validity 
of a pharmacological approach to improve glucose counterregulation. 
 
PATHOPHYSIOLOGY OF HYPOGLYCEMIA UNAWARENESS 
 
In patients with type 1 diabetes, the capacity to increase glucagon levels in response 
to hypoglycemia is lost within a few years. Because adrenaline is equally capable of 
correcting hypoglycemia, this loss of the primary counterregulatory response has a 
very limited effect on hypoglycemic incidence. However, when adrenaline responses 
become attenuated in combination with an already absent glucagon response, the 
risk for iatrogenic hypoglycemia increases by at least 25-fold. Moreover, because 
adrenaline is involved in the appearance of (especially autonomic) symptoms, 
impairments in the adrenaline response may adversely affect hypoglycemic 
H 
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awareness. The impaired adrenaline response is thus a key component of both 
defective hormonal counterregulation and of hypoglycemia unawareness. In the first 
part of this thesis (chapters 2-5), we investigated whether the impaired adrenaline 
response reflects a functional defect or a defect in adrenaline releasing capacity, and 
whether adrenaline is implicated in the pathophysiology of hypoglycemia 
unawareness. In addition, we investigated the effect of hypoglycemia on 
inflammatory responses, and we reviewed studies on glucose counterregulation 
performed in type 2 diabetes.  
The current view on the nature of the impaired adrenaline response holds that 
the defect is caused by resetting of the threshold for adrenaline release to lower 
levels of glycemia (e.g. due to inappropriate sensing of hypoglycemia by the brain), 
rather than by reduced adrenomedullary function per se. In chapter 2, we tested this 
assumption by investigating the capacity of the adrenal medulla to synthesize 
adrenaline. We measured plasma metanephrine levels in diabetic patients with 
clinical hypoglycemia unawareness who were selected for established 
adrenomedullary failure under hypoglycemic conditions (by clamping). Because 
adrenaline leaking from adrenal storage vesicles is immediately converted to 
metanephrine and because this metanephrine is continuously secreted into the 
circulation, circulating metanephrine reflects adrenal stores of adrenaline and hence 
can be used as marker of adrenomedullary capacity. This relatively new approach 
has not yet been applied to diabetes before. We found that plasma metanephrine 
levels were approximately 30% reduced in type 1 diabetic patients with established 
adrenomedullary failure during hypoglycemia, when compared to matched 
nondiabetic controls, compatible with a reduced adrenomedullary capacity to secrete 
adrenaline. In response to hypoglycemia, the absolute increase in plasma 
metanephrine as percentage of the increase in plasma adrenaline was 6.7% in both 
patients and controls, indicating that the conversion of adrenaline directly released 
into the circulation was identical between the groups. Nonetheless, because the 70% 
suppression of the adrenaline response to hypoglycemia was more than twice the 
suppression of the metanephrine response, another factor such as resetting of the 
glycemic threshold, must be involved as well.  
We then investigated whether adrenaline, being a key component of the 
physiological response to hypoglycemia, was a mediator of hypoglycemia-induced 
counterregulatory impairments and hypoglycemia unawareness. Recent evidence 
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suggested the cortisol response to prior hypoglycemia as the mediator of some – but 
not all – components of hypoglycemia-induced counterregulatory failure. Because of 
its central role in the development of counterregulatory failure and of hypoglycemia 
unawareness, we hypothesized that adrenaline released during antecedent 
hypoglycemia would suppress adrenomedullary responses to subsequent 
hypoglycemia. To test this hypothesis, we mimicked the adrenaline response to 
hypoglycemia by exogenous adrenaline infusion and then measured 
adrenomedullary responses to subsequent hypoglycemia in 16 healthy nondiabetic 
volunteers (chapter 3). We found that prior elevation of plasma adrenaline did not 
affect hormonal responses to or symptomatic awareness of subsequent 
hypoglycemia, yet that it was associated with increased glucose requirements and 
attenuated blood pressure responses during subsequent hypoglycemia. The 
increased glucose requirements and attenuated hemodynamics after prior adrenaline 
are compatible with reduced responsiveness to counterregulatory hormone action, 
and probably reflect reduced β-adrenergic sensitivity. Thus, elevated adrenaline may 
attenuate the responsiveness to, but does not affect the release of counterregulatory 
hormones during or the symptomatic awareness of subsequent hypoglycemia, and 
as such the role of adrenaline in the development of hypoglycemia unawareness 
appears limited.  
In chapter 4, we investigated the effects of hypoglycemia on the proinflammatory 
cytokine network, to show that effects of hypoglycemia are not limited to the brain or 
to glucose counterregulation alone. We chose to examine the proinflammatory 
cytokine network, because in vitro studies suggest that the ambient glucose level is 
important for the production capacity of TNFα and because the system of 
proinflammatory cytokines is downregulated in response to stress. We found that in 
nondiabetic healthy subjects, hypoglycemia selectively downregulated the key 
proinflammatory cytokine TNFα in a concentration-dependent manner, whereas the 
proinflammatory cytokines IL-1β and IL-6 and the anti-inflammatory cytokine IL-10 
were not affected. In separate experiments, we excluded the roles of the 
experimental procedure per se, of hyperinsulinemia, and of elevated adrenaline in 
the effect on TNFα. We subsequently investigated the effect of hypoglycemia on 
cytokine kinetics in a group of type 1 diabetic patients with a history of repeated 
hypoglycemia. Remarkably, these diabetic patients already had a suppressed TNFα 
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production capacity under non-hypoglycemic conditions, whereas the effect of 
hypoglycemia was significantly attenuated.  
In contrast to the large number of studies available in type 1 diabetes, relatively 
little research has been done on the integrity of glucose counterregulation in type 2 
diabetes, whereas the studies that have been performed have produced conflicting 
results. In chapter 5, an overview is provided of studies on glucose counterregulation 
in type 2 diabetes. Despite differences in methodology and heterogeneity of the study 
populations, the studies clearly indicate that patients who use glucose-lowering 
agents – oral antidiabetic drugs or insulin – are indeed at risk for development of 
counterregulatory impairments, albeit to a considerable lesser extent than (insulin-
treated) type 1 diabetic patients. Functional β-cell reserve and insulin resistance are 
the two most important factors that help to prevent hypoglycemic events and hence 
to preserve counterregulatory function in type 2 diabetic patients. Conversely, 
patients who progress to the insulin-deficient state may be at similar risk to develop 
counterregulatory impairments as type 1 diabetic patients, especially when overt 
insulin resistance is absent. 
 
PHARMACOLOGICAL MANAGEMENT OF HYPOGLYCEMIA UNAWARENESS 
WITH ADENOSINE RECEPTOR ANTAGONISTS 
 
As outlined in chapter 1, the options to reverse or ameliorate counterregulatory 
failure and hypoglycemia unawareness are rather limited. Although it is possible to 
correct hypoglycemia unawareness by practicing hypoglycemia risk reduction, the 
techniques currently available all have limitations that make them difficult to apply to 
large groups of patients. We therefore decided to explore the validity of a 
pharmacological approach to improve counterregulatory function. The studies 
addressing this issue are described in the second part of this thesis (chapters 6-8). 
From a pharmacological point of view, the (central) effects of adenosine receptor 
antagonism may be beneficial in the management of hypoglycemia unawareness. 
Blocking of adenosine receptors within the brain reduces cerebral blood flow and 
simultaneously increases glucose requirements. This uncoupling of cerebral glucose 
supply and energy metabolism activates the brain and stimulates the adrenal medulla 
to synthesize catecholamines. Theophylline blocks central adenosine receptors and 
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has been shown to promote alertness and to enhance release of catecholamines. 
We hypothesized that these factors might be of help under hypoglycemic conditions, 
to enable prompter recognition of impending hypoglycemia and to slow its 
progression.  
In chapter 6, we investigated the effect of a single dose of intravenous 
theophylline on responses to a standardized hypoglycemic event. Experiments were 
carried out in 15 type 1 diabetic patients with clinically relevant hypoglycemia 
unawareness and 15 matched nondiabetic controls. We found that even a low dose 
of theophylline was sufficient to stimulate metabolic and cardiovascular responses to 
hypoglycemia in both groups of subjects. In the presence of theophylline, responses 
of sweating and heart rate increments – two key hypoglycemic symptoms that were 
quantified objectively – were stimulated and occurred at higher glucose levels. During 
theophylline stimulation in diabetic patients, hypoglycemia-induced responses of 
noradrenaline, cortisol, sweating, and hypoglycemic symptoms as assessed by 
questionnaire normalized, whereas the adrenaline response improved but did not 
normalize. Using transcranial doppler measurements, we found that theophylline 
decreased cerebral blood flow in both patients and controls and prevented the 
hypoglycemia-induced increase in cerebral blood flow. This observation suggests 
that the effect of hypoglycemia on cerebral perfusion is mediated by adenosine. 
Furthermore, we recorded a more profound fall in cerebral perfusion in patients than 
in controls, which is compatible with higher adenosine availability in the patients and 
explains why the effect of theophylline was generally more pronounced in the 
diabetic patients.  
Two factors of concern remained to be addressed. Firstly, as a consequence of 
stimulation of counterregulatory hormones, we found that theophylline reduced 
glucose requirements under normoglycemic conditions, which is compatible with 
decreased insulin sensitivity (i.e. insulin resistance). This is clinically relevant 
because reductions in insulin sensitivity are associated with increased risk for 
cardiovascular disease, especially when superimposed on conditions already known 
to harbor a high risk for cardiovascular disease, such as diabetes. Secondly, chronic 
theophylline use is associated with emergence of tolerance, so that the data 
described in chapter 6 cannot be merely extrapolated to prolonged use of 
theophylline. 
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In chapter 7, we investigated the effect of adenosine receptor antagonism on 
insulin sensitivity. Because of previous reports of glucose intolerance after caffeine 
use and the possible consequence of such reports on public health, we used the 
theophylline related methylxanthine derivative caffeine and performed this study in 
healthy volunteers. To discriminate between peripheral and central effects of 
adenosine receptor antagonism, we also investigated the effect of dipyridamole, an 
adenosine uptake inhibitor that increases interstitial adenosine concentrations and as 
such acts opposite to caffeine except that it cannot cross the blood-brain barrier. 
Using a placebo-controlled study design, we found that caffeine reduced insulin 
sensitivity by approximately 15% compared to placebo. In addition, caffeine 
increased plasma adrenaline levels fivefold and suppressed the insulin-induced fall in 
plasma free fatty acids. Both of these findings provide a mechanism of action by 
which the fall in insulin sensitivity could be explained. In contrast, dipyridamole had 
no effect on insulin sensitivity and did not alter plasma adrenaline or free fatty acids. 
These data indicate that the caffeine-induced fall in insulin sensitivity was probably 
mediated by plasma adrenaline and free fatty acids (due to central adenosine 
receptor antagonism), but that it is unlikely that peripheral adenosine receptor 
antagonism played a relevant role.  
The issue of emergence of tolerance was addressed in chapter 8. Chronic use 
of theophylline is associated with emergence of tolerance, a pharmacological 
phenomenon that already appears after 4 days of use. To determine whether 
treatment with adenosine receptor antagonists is a truely valid pharmacological 
approach to improve hypoglycemia unawareness, we conducted a placebo-controlled 
randomized cross-over study to investigate the effect of prolonged use of 
theophylline on glucose counterregulation in diabetic patients with hypoglycemia 
unawareness. Responses to standardized hypoglycemia were investigated in twelve 
patients, after two weeks use of oral theophylline (250 mg twice daily in slow-release 
preparations) or matching placebo. After two weeks, basal counterregulatory 
hormone concentrations and cardiovascular parameters were similar between 
theophylline and placebo treatments, which is compatible with complete emergence 
of tolerance. However, symptom, thermoregulatory and hemodynamic responses all 
remained stimulated by theophylline under hypoglycemic conditions. In addition, 
although the stimulation of individual hormone responses by theophylline did not 
reach statistical significance, exogenous glucose requirements at hypoglycemic nadir 
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were lower with theophylline indicating enhancement of the composite of metabolic 
responses. We concluded that despite the emergence of tolerance under 
normoglycemic conditions, prolonged use of theophylline retained the capacity to 
stimulate counterregulatory responses under hypoglycemic conditions. Moreover, 
because of emergence of tolerance, the effect of methylxanthine derivatives on 
insulin sensitivity might be expected to disappear during prolonged use of 
theophylline.  
 
CONCLUSIONS AND PERSPECTIVE 
 
Hypoglycemia is a clinical problem that almost exclusively affects diabetic patients, 
and is the limiting factor in pursuing optimal glycemic control. The unraveling of the 
full impact of hypoglycemia on the human body, of the mechanisms by which the 
body protects itself from hypoglycemia, and of the way these factors are altered in 
patients with diabetes may greatly benefit diabetes management. In the first part of 
this thesis, we aimed to increase our understanding of the pathophysiology of 
counterregulatory impairments and hypoglycemia unawareness. We tried to clarify 
some of the controversy concerning the pathophysiology of the impaired adrenaline 
response to hypoglycemia. Our studies provide evidence that reduced 
adrenomedullary capacity to synthesize adrenaline significantly contributes to the 
impaired adrenaline response in diabetic patients with clinical hypoglycemia 
unawareness, although it cannot be the only factor. To what extent this reduced 
secretory capacity is a pre-existent phenomenon, a complication of longstanding 
diabetes, or the result of gradual (hypoglycemia-induced) exhaustion of adrenal 
stores requires further study. Also, it should be investigated whether the defect is 
permanent or (partly) reversible. The fact that hypoglycemia risk reducing strategies 
seldomly lead to full recovery of the impaired adrenaline response to hypoglycemia 
suggests involvement of an irreversible component, for which reduced 
adrenomedullary capacity seems a plausible candidate. 
Concerning the mechanism by which antecedent hypoglycemia affects 
(adrenomedullary) responses to subsequent hypoglycemia, we suggested a 
mediating role for elevated plasma adrenaline levels. Our studies on this issue, 
however, seem to exclude a major role for elevated adrenaline in the development of 
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hypoglycemia unawareness. Nonetheless, the reduced responsiveness to 
counterregulatory hormones as we found after prior adrenaline is consistent with 
reduced β-adrenergic sensitivity. Reduced β-adrenergic sensitivity has recently been 
suggested to be a component of the hypoglycemia unawareness syndrome. Because 
hypoglycemia has been shown to reduce β-adrenergic sensitivity, this part of the 
hypoglycemia unawareness syndrome may indeed be mediated by the adrenaline 
response to antecedent hypoglycemia. 
Finally, we demonstrated that hypoglycemia in vivo selectively suppressed TNFα 
production capacity in healthy subjects, whereas in diabetic patients with a history of 
repeated hypoglycemia, TNFα production capacity was also suppressed in the 
absence of hypoglycemia. The selectivity for TNFα and the exclusion of involvement 
of adrenaline as primary stress hormone indicate that the effect of hypoglycemia on 
TNFα was mediated by the glucopenic nature of hypoglycemia rather than by the 
stress response it evoked. It further seems plausible that the suppressed TNFα 
production capacity in diabetic patients was a consequence of recurrent 
hypoglycemia-induced downregulation of TNFα, although it could also be a 
complication of diabetes per se. Theoretically, a downregulated TNFα production 
capacity might be unfavourable in terms of increased vulnerability to infections. To 
further explore the role of hypoglycemia (unawareness) in the cytokine network, 
follow-up studies are clearly required to answer these questions. 
In the second part of this thesis, we tested the validity of a pharmacological 
approach for the treatment of hypoglycemia unawareness. Our studies provide a 
rationale for the use of adenosine receptor antagonists, such as theophylline, to 
improve counterregulatory impairments in type 1 diabetic patients with hypoglycemia 
unawareness. Not only because theophylline promotes counterregulatory hormone 
responses to hypoglycemia and perception of hypoglycemic symptoms at an earlier 
stage of developing hypoglycemia, but also because it reduces cerebral blood flow 
and prevents hypoglycemia-induced increases in cerebral blood flow. These effects 
on cerebral blood flow are relevant, because elevations in cerebral perfusion may 
dampen the effects of hypoglycemia on the brain and – as such – have been 
implicated in the pathogenesis of hypoglycemia unawareness. The effect of 
theophylline on cerebral blood flow suggest a role for adenosine in the cerebral blood 
flow response to hypoglycemia and in the elevated cerebral blood flow found in 
patients with hypoglycemia unawareness. Therefore, blocking of adenosine could be 
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a specific target to correct glucose counterregulation in these patients. Furthermore, 
our studies on prolonged use of theophylline indicate that the stimulation of glucose 
counterregulation is maintained under hypoglycemic conditions, whereas it is lost in 
the absence of hypoglycemia. As a corollary, the decrease in insulin sensitivity, 
which we found after a single dose of caffeine and which might be seen as an 
important limiting factor, is likely to disappear when use of methylxanthines is 
continued. In other words, theophylline exerts its effects when stimulation of 
counterregulation is required (during hypoglycemia), whereas it is ineffective when 
these effects are unwanted or even counterproductive (during normoglycemia). The 
use of theophylline is therefore pharmacologically valid in the management of 
hypoglycemia unawareness. However, whether these findings translate into a 
relevant clinical benefit cannot be determined from our studies. Despite the promising 
results, a clinical trial of sufficient size is needed to establish the role for adenosine 
receptor antagonists as treatment for hypoglycemia unawareness clinically. 
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en hypoglycemie – een te lage bloedsuikerspiegel – komt bij gezonde mensen 
niet of nauwelijks voor. Bij patiënten met type 1 diabetes mellitus is het echter 
een allesbehalve zeldzaam fenomeen: gemiddeld 2 tot 3 maal per week. Ongeveer 
één keer per jaar (doch soms vaker) is er bovendien sprake van een dusdanig sterke 
daling van de bloedsuikerspiegel dat deze wordt gecompliceerd door een tijdelijke 
comateuze toestand of een epileptische aanval. We spreken dan van een ernstige of 
gecompliceerde hypoglycemie. Patiënten met type 1 diabetes missen het vermogen 
insuline te produceren en zijn afhankelijk van het meermaal daags onderhuids 
toedienen van het bloedsuikerverlagende hormoon insuline. Het feit dat 
hypoglycemieën bij deze patiënten optreden wordt verklaard uit het gegeven dat de 
insulinespiegel niet meer aan interne controle onderhevig is, maar het resultaat is 
van passieve opname vanuit het subcutane weefsel. Een (inmiddels) 
genormaliseerde bloedsuikerspiegel kan dan samengaan met een (nog) verhoogde 
insulinespiegel leidend tot (te ver) doordalen van de bloedsuiker. De hoge frequentie 
van hypoglycemieën bij type 1 diabetespatiënten wordt echter vooral bepaald door 
het falen van de glucosecontraregulatie, het systeem van hormoonreakties (glucagon 
en adrenaline) en lichamelijke verschijnselen dat normaliter bescherming biedt tegen 
het dalen van de bloedsuiker. Het falen van de glucosecontraregulatie treedt op 
naarmate hypoglycemieën vaker voorkomen en kan worden gezien als een soort 
gewenningsproces aan hypoglycemieën. Omdat een falende contraregulatie het 
optreden van hypoglycemieën vergemakkelijkt, ontstaat er een situatie waarbij de 
frequentie van hypoglycemieën toeneemt en het functioneren van de contraregulatie 
afneemt. Uiteindelijk leidt deze neerwaartse spiraal ertoe dat patiënten 
hypoglycemieën niet meer (tijdig) opmerken. Dit onvermogen om hypoglycemieën te 
herkennen wordt hypoglycemia unawareness genoemd, en komt bij ongeveer 25% 
van de type 1 diabetespatiënten voor. Behalve dat hypoglycemia unawareness de 
kans op (ernstige) hypoglycemieën verhoogt, is het ook de belangrijkste 
belemmerende factor voor verbetering van de metabole instelling. Opheldering van 
de pathofysiologie van unawareness en het ontwikkelen van strategieën om 
unawareness te behandelen kunnen dan ook zowel (direkt) ten goede komen aan de 
problematiek rond hypoglycemieën als (indirekt) aan de metabole instelling in het 
algemeen. In het eerste deel van dit proefschrift staan daarom studies beschreven 
die betrekking hebben op de pathofysiologie van hypoglycemia unawareness, terwijl 
in het tweede deel een farmacologische benadering om de hormonale respons op en 
E 
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de symptomatische gewaarwording van hypoglycemieën te bevorderen nader wordt 
bestudeerd. Bij een aantal onderzoeken wordt gebruik gemaakt van de 
hypoglycemische clamptechniek; dit behelst een methode om de bloedsuikerspiegel 
op een gecontroleerde wijze omlaag te brengen en op een vastgesteld niveau vast te 
houden (clampen). 
 
PATHOFYSIOLOGIE VAN HYPOGLYCEMIA UNAWARENESS 
 
Bijna alle patiënten met type 1 diabetes verliezen in de loop van enkele jaren na het 
stellen van de diagnose de mogelijkheid een adequate glucagonrespons te 
genereren in reaktie op een hypoglycemie. Dit leidt echter nog niet tot een 
toenemend aantal hypoglycemieën, omdat het glucosecorrigerend vermogen niet 
vermindert zolang de adrenalinerespons intact blijft. Wanneer ook de 
adrenalinerespons op hypoglycemieën tekort schiet, wordt het risico op een 
hypoglycemie 25 maal hoger. Bovendien kan vanwege de betrokkenheid van 
adrenaline bij het ontstaan van hypoglycemische waarschuwingssymptomen een 
defecte adrenalinerespons de gewaarwording van hypoglycemieën nadelig 
beïnvloeden. De defecte adrenalinerespons speelt dus een sleutelrol bij het ontstaan 
van zowel de falende hormonale contraregulatie als bij het ontstaan van 
hypoglycemia unawareness. Daarbij is er altijd vanuitgegaan dat de verminderde 
adrenalinerespons wordt verklaard doordat de bloedglucosespiegel waarbij de bijnier 
tot adrenalinesecretie wordt aangezet (de zg. glucosedrempelwaarde) naar lagere 
waarden is verschoven. Het is echter niet duidelijk of daarmee de defecte 
adrenalinerespons volledig is te verklaren. In hoofdstuk 2 werd onderzocht in 
hoeverre de defecte adrenalinerespons het gevolg zou kunnen zijn van een absoluut 
tekort aan adrenalineproducerend vermogen van de bijnier. Hoewel het 
adrenalineproducerend vermogen niet rechtstreeks te meten is, kan met behulp van 
metanephrinespiegelbepalingen in het bloed een betrouwbare indruk worden 
verkregen. Deze relatief nieuwe methode is nooit eerder toegepast bij diabetes. 
Plasmaconcentraties van metanefrine werden daarom bepaald bij type 1 
diabetespatiënten met klinische verschijnselen van hypoglycemia unawareness en 
een aantoonbaar gestoorde adrenalinerespons, en bij een leeftijds- en 
geslachtsgematchde controlegroep. Daarbij vonden wij bij de diabetespatiënten 
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gemiddeld 30% lagere plasmaconcentraties van metanefrine dan bij de 
controlegroep. In reaktie op een gestandaardiseerde hypoglycemie bleek dat de 
absolute toename in plasmametanefrinespiegels als percentage van de absolute 
toename in plasmaadrenalinespiegels, als maat voor de omzetting van door de 
bijnier heropgenomen adrenaline, vergelijkbaar was tussen diabetespatiënten en 
controleproefpersonen. Dit geeft aan dat het gevonden verschil tussen patiënten en 
controleproefpersonen niet verklaard kan worden door een verschil in omzetting van 
adrenaline in metanefrine. De lagere metanefrinespiegels bij de diabetespatiënten 
geven aan dat minder adrenaline ligt opgeslagen in de bijnier en duiden dus op een 
verminderde capaciteit van de bijnier om adrenaline af te geven. De ±30% lager 
capaciteit van de bijnier kan de veel ernstiger gestoorde adrenalinerespons op 
hypoglycemie bij diabetespatiënten (hier ±70% lager dan bij controles) echter niet 
volledig verklaren. Daarvoor zijn additionele factoren, zoals een verschuiving van de 
glucosedrempelwaarde, nodig. 
Vervolgens werd de rol van adrenaline in de pathogenese van het 
hypoglycemiegewenningsproces onderzocht. Recentelijk is gepubliceerd dat het 
remmende effect dat een voorafgaande hypoglycemie uitoefent op de hormonale en 
symptomatische reakties uitgelokt door een daaropvolgende hypoglycemie voor een 
deel gemedieerd lijkt te zijn door de gestegen cortisolspiegel. Vanwege de veel 
belangrijkere rol van adrenaline voor de glucosecontraregulatie veronderstelde wij 
een soortgelijk effect van een gestegen adrenalinespiegel. Dit onderzoek staat 
beschreven in hoofdstuk 3. Bij 16 gezonde vrijwilligers werden gepaarde 
hypoglycemische clampstudies uitgevoerd, éénmaal nadat enkele uren tevoren 
adrenaline gedurende een uur per infuus was toegediend en éénmaal nadat een 
placebo-oplossing was toegediend. Voorafgaande toediening van adrenaline bleek 
geen effect te hebben op de afgifte van contraregulerende hormonen of op de 
ontwikkeling van hypoglycemische verschijnselen tijdens de daaropvolgende 
hypoglycemie. Na voorafgaande adrenalinetoediening bleek echter de 
glucosebehoefte tijdens hypoglycemie te zijn toegenomen terwijl de 
bloeddrukrespons bleek te zijn afgevlakt. Beiden wijzen op een verminderde 
responsiviteit op de contraregulerende hormonen. Omdat de β-adrenerge receptor is 
betrokken bij zowel de bloeddruk als bij glucose-opname in spier- en vetweefsel, en 
omdat herhaalde prikkeling tot ongevoeligheid van de β-adrenerge receptor kan 
leiden, lijkt het plausibel dat deze resultaten worden verklaard door verminderde β-
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adrenerge gevoeligheid. Recentelijk is gesuggereerd dat hypoglycemia unawareness 
zou kunnen samenhangen met verminderde β-adrenerge gevoeligheid en zodoende 
zou adrenaline een – zij het beperkte – modulerende rol kunnen spelen in het 
ontstaan van unawareness. 
In hoofdstuk 4 werd het effect van hypoglycemie op het systeem van 
proinflammatoire cytokines bestudeerd, ondermeer om aan te tonen dat de invloed 
van hypoglycemie zich niet beperkt tot de hersenen en de glucosecontraregulatie 
alleen. In-vitro studies hadden eerder laten zien dat de productiecapaciteit van het 
proinflammatoire cytokine TNFα afhankelijk is van de lokale beschikbaarheid aan 
glucose, terwijl de productie en productiecapaciteit van meerdere proinflammatoire 
cytokinen (waaronder TNFα) geremd worden onder invloed van stress. Met behulp 
van een hypoglycemische clampstudie vonden wij bij gezonde vrijwilligers een 
selectief, concentratie-afhankelijk remmend effect van hypoglycemie op de 
productiecapaciteit van TNFα, maar niet op die van andere cytokinen (IL-1β, IL-6 en 
IL-10). Dit effect was niet het gevolg van de experimentele procedure zelf, van 
insuline, of van adrenaline. Vervolgens herhaalde we de experimenten bij patiënten 
met type 1 diabetes mellitus. Opmerkelijk genoeg bleek bij de patiëntengroep dat de 
TNFα productiecapaciteit al geremd was voordat de clamp werd gestart, terwijl het 
effect van hypoglycemie op TNFα nauwelijks meer aanwezig was. 
Onderzoek naar het functioneren van de glucosecontraregulatie bij patiënten met 
type 2 diabetes mellitus is slechts spaarzaam verricht, dit in tegenstelling tot het 
grote aantal studies dat betrekking heeft op type 1 diabetes. In hoofdstuk 5 staan 
alle studies beschreven die de glucosecontraregulatie bij patiënten met type 2 
diabetes onderzochten. Ondanks verschillen in methodologie en het heterogene 
karakter van de studiepopulatie (patiënten met type 2 diabetes verschillen onderling 
veel meer dan patiënten met type 1 diabetes, wat betreft mate van 
insulineresistentie, insulinedeficiëntie, (co-)medicatiegebruik, hypoglycemieën, 
etcetera), bleek duidelijk dat patiënten die insuline of orale glucoseverlagende 
medicijnen gebruiken een risico lopen op stoornissen in het functioneren van de 
glucosecontraregulatie, zij het in veel mindere mate dan bij patiënten met type 1 
diabetes het geval is. De resterende eigen insulineproductie en de mate van 
insulineresistentie bleken de twee belangrijkste factoren die hypoglycemieën konden 
voorkómen en zodoende het functioneren van de glucosecontraregulatie konden 
behouden. Echter, patiënten met een dusdanig vergevorderde diabetes dat de eigen 
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insulineproductie is gestopt lopen een risico op hypoglycemieën en daarmee op 
glucose contraregulatiedefecten die vergelijkbaar zijn met die van type 1 
diabetespatiënten, met name als de insulinegevoeligheid normaal is. 
 
FARMACOLOGISCHE BEHANDELING VAN HYPOGLYCEMIA UNAWARENESS 
MET ADENOSINERECEPTORANTAGONISTEN 
 
De mogelijkheden om glucosecontraregulatiedefecten en hypoglycemia 
unawareness te verbeteren of te herstellen zijn beperkt. Hoewel hypoglycemia 
unawareness vaak reversibel blijkt als hypoglycemieën volledig worden vermeden, 
hebben de technieken die dat kunnen bewerkstelligen dusdanige nadelen en 
bijeffecten (zoals verslechtering van de metabole instelling) dat zij in de praktijk 
ongeschikt zijn voor grote groepen patiënten. Wij besloten daarom te onderzoeken of 
een farmacologiche benadering uitkomst zou kunnen bieden. Deze onderzoeken zijn 
beschreven in het tweede deel van dit proefschrift (hoofdstuk 6-8). 
Farmacologisch gezien zou het gebruik van adenosinereceptorantagonisten van 
waarde kunnen zijn in de behandeling van hypoglycemia unawareness. In de 
hersenen leidt blokkering van de adenosinereceptor door vermindering van de 
cerebrale bloeddoorstroming tot een afname van het glucoseaanbod, terwijl de 
behoefte aan glucose juist toeneemt. Deze ontkoppeling tussen vraag en aanbod 
van glucose in de hersenen heeft een centraalopwekkend effect en stimuleert de 
bijnieren om stresshormonen af te geven. Het methylxanthine derivaat theophylline is 
een adenosinereceptor blokkerend middel, waarvan stimulerende effecten op de 
hersenen en de bijnieren zijn aangetoond. Deze stimulerende effecten zouden met 
name van nut kunnen zijn onder hypoglycemische omstandigheden om de daling in 
bloedsuikerspiegel af te remmen en om snellere herkenning van een hypoglycemie 
mogelijk te maken. 
In hoofdstuk 6 staat het onderzoek beschreven naar het effect van een 
enkelvoudige intraveneuze dosis theophylline op de (contraregulerende) reakties 
uitgelokt door een experimentele hypoglycemie. Dit onderzoek werd uitgevoerd bij 15 
type 1 diabetespatiënten met hypoglycemia unawareness en 15 controlepersonen 
zonder diabetes. Het onderzoek liet zien dat zelfs een relatief lage dosering 
theophylline voldoende was om hormonale en cardiovasculaire reakties op een 
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hypoglycemie te stimuleren in beide groepen personen. In aanwezigheid van 
theophylline werden de transpiratierespons en de versnelling van het hartritme 
gestimuleerd en uitgelokt bij relatief hogere glucosespiegels. In de patiëntengroep 
normaliseerden de hypoglycemie-geïnduceerde effecten op noradrenaline, cortisol, 
transpireren (objectief gemeten) en hypoglycemiesymptomen (gescoord met behulp 
van vragenlijsten) onder invloed van theophylline, terwijl de adrenalinerespons wel 
verbeterde maar niet geheel normaliseerde. Met behulp van transcraniële 
echodopplermetingen konden we aantonen dat theophylline bij zowel patiënten als 
gezonde proefpersonen de bloeddoorstroming door de hersenen verminderde en de 
toename van de bloeddoorstroming door de hersenen voorkwam. Deze bevinding is 
een sterke aanwijzing dat het effect van hypoglycemie op de cerebrale 
bloeddoorstroming via adenosine verloopt. Bovendien bleek theophylline een 
sterkere daling in de cerebrale bloeddoorstroming te veroorzaken bij 
diabetespatiënten dan bij mensen zonder diabetes, hetgeen een grotere 
adenosinebeschikbaarheid bij patiënten suggereert. 
Het positieve resultaat van dit onderzoek riep een tweetal nieuwe vragen op. Ten 
eerste bleek dat theophylline door het stimuleren van de afgifte van 
contraregulerende hormonen de insulinegevoeligheid – gemeten aan de hand van de 
behoefte aan glucosetoediening onder invloed van insuline – te hebben verminderd. 
Dit is klinisch van groot belang omdat afname van insulinegevoeligheid (lees: 
toename van insulineresistentie) geassocieerd is met een toegenomen risico op hart- 
en vaatziekten, met name als dat risico al verhoogd is door diabetes. Ten tweede is 
bekend dat chronisch gebruik van theophylline vrij snel leidt tot tolerantie voor het 
effect, dat wil zeggen dat het effect uitdooft. Dat betekent dat de resultaten van 
eenmalig theophyllinegebruik uit hoofdstuk 6 niet zomaar kunnen worden 
geëxtrapoleerd naar langdurig gebruik. 
In hoofdstuk 7 onderzochten we het effect van antagonisme van de 
adenosinereceptor op insulinegevoeligheid. Daartoe werd bij twaalf gezonde 
vrijwilligers de insulinegestimuleerde glucoseopname gemeten tijdens een 
normoglycemisch clamponderzoek, in aanwezigheid van òf het aan theophylline 
verwante coffeïne òf placebo. Coffeïne werd gebruikt vanwege de mogelijke 
gezondheidsgevolgen in bredere zin en omdat eerder was gerapporteerd dat 
coffeïne de glucosetolerantie zou kunnen verminderen. Om onderscheid te kunnen 
maken tussen zogenaamde centrale (vanuit de hersenen) en perifere (niet vanuit de 
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hersenen) effecten van adenosinereceptorantagonisme werd het onderzoek 
bovendien herhaald met dipyridamol. Dipyridamol is een adenosine-opnameremmer 
die de interstitiële adenosineconcentratie verhoogt, en zodoende tegengesteld werkt 
aan coffeïne. Dipyridamol kan echter de bloedhersenbarrière niet passeren. Coffeïne 
bleek in vergelijking met placebo de insulinegevoeligheid met ongeveer 15% te 
verminderen. Coffeïne veroorzaakte een vijfvoudige verhoging van de 
adrenalineconcentratie en onderdrukte de insulinegeïnduceerde daling van de 
vrijevetzuurconcentratie in het bloed. Adrenaline en vrije vetzuren hebben beide een 
insuline-antagonerend effect. Dipyridamol had daarentegen geen effect op 
insulinegevoeligheid en evenmin op de plasmaconcentraties van adrenaline of vrije 
vetzuren. Het lijkt er dus op dat de daling in insulinegevoeligheid door coffeïne via 
afgifte van adrenaline en vrije vetzuren (als gevolg van antagonisme van de centrale 
adenosinereceptor) verloopt, terwijl het onwaarschijnlijk is dat antagonisme van 
perifere adenosinereceptoren hierbij betrokken is. 
De kwestie van tolerantieontwikkeling wordt behandeld in hoofdstuk 8. Van 
theophylline is bekend dat tolerantie optreedt na 4 dagen van continue gebruik. Om 
te bepalen of behandeling met adenosinereceptorantagonisten een farmacologisch 
zinvolle benadering is om hypoglycemia unawareness te verbeteren, werd het effect 
van twee weken theophyllinebehandeling op reakties uitgelokt door een 
experimentele hypoglycemie (middels een clamp-studie) onderzocht. Twaalf type 1 
diabetespatiënten met hypoglycemia unawareness werd gevraagd aan deze 
placebogecontroleerde, gerandomiseerde studie deel te nemen. Na twee weken 
behandeling bleek theophylline in verglijking met placebobehandeling geen effect 
meer te hebben op de basale cardiovasculaire parameters (zoals bloeddruk en pols) 
en metabole parameters (hormonen), die gemeten werden direct voorafgaand aan 
de clamp. Ook was er geen verschil in insulinegevoeligheid, gemeten aan de hand 
van de behoefte aan intraveneuze glucosetoediening. Tijdens hypoglycemie bleek 
echter dat theophylline nog steeds een stimulerend effect had op 
hypoglycemiesymptomen (waarbij de mate van transpireren objectief kon worden 
vastgelegd) en reacties van bloeddruk en pols, in vergelijking met de 
placebobehandeling. Hoewel de stimulering van de afgifte van 
contraregulatiehormonen (zoals adrenaline en cortisol) geen statistische significantie 
bereikte, bleek de behoefte aan glucosetoediening (per infuus) onder 
hypoglycemische omstandigheden te zijn verlaagd met theophylline. Deze bevinding 
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geeft aan dat de glucosecontraregulatie als geheel met theophylline beter in staat 
was de glucosespiegel te corrigeren. Hoewel chronisch gebruik van theophylline 
onder normoglycemische omstandigheden leidt tot tolerantie, blijft er dus een 
stimulerend effect bestaan onder hypoglycemische omstandigheden.  
 
CONCLUSIES EN TOEKOMSTPERSPECTIEF 
 
Hypoglycemie is een klinisch probleem dat vrijwel alleen bij patiënten met diabetes 
mellitus voorkomt, en bij deze patiënten de beperkende factor is voor het verbeteren 
van de metabole instelling. Het ontdekken hoe hypoglycemie inwerkt op het lichaam, 
hoe het lichaam zich beschermt tegen hypoglycemieën en hoe dit is verstoord bij 
patiënten met diabetes  kan een belangrijke bijdrage leveren aan de behandeling van 
diabetes. In het eerste deel van dit proefschrift werd gepoogd het inzicht in de 
pathofysiologie van de gestoorde contraregulatie en van hypoglycemia unawareness 
te vergroten. Ons onderzoek naar de gestoorde adrenalinerespons op hypoglycemie 
bij patiënten met hypoglycemia unawareness heeft aangetoond dat dit deels 
veroorzaakt wordt door een verminderde capaciteit van de bijnier om adrenaline af te 
geven. In hoeverre deze verminderde synthesecapaciteit een pre-existent fenomeen, 
een complicatie van (langdurige) diabetes of het gevolg is van geleidelijke uitputting 
van de adrenaline-opslag in de bijnier (door herhaaldelijke hypoglycemieën) zal 
vervolgonderzoek moeten uitwijzen. Verder dient duidelijk te worden of dit defect 
blijvend is of (gedeeltelijk) reversibel. Een blijvend defect zou kunnen verklaren 
waarom het volledig vermijden van hypoglycemieën slechts tot gedeeltelijke 
verbetering van de gestoorde adrenalinerespons leidt en niet tot volledig herstel. 
Met betrekking tot de pathofysiologie van hypoglycemia unawareness 
postuleerden wij dat de gereduceerde reakties op een hypoglycemie als gevolg van 
voorafgaande hypoglycemische episodes veroorzaakt zou kunnen zijn door de hoge 
adrenalinespiegels. Het onderzoek naar deze kwestie heeft onze hypothese echter 
niet kunnen bevestigen; een belangrijke rol voor adrenaline in de ontwikkeling van 
hypoglycemia unawareness lijkt daarmee uitgesloten. De verminderde responsiviteit 
op de contraregulatiehormonen die wij zagen na voorafgaand toedienen van 
adrenaline zou echter kunnen wijzen op verminderde β-adrenerge gevoeligheid. 
Recentelijk is aannemelijk gemaakt dat verminderde β-adrenerge gevoeligheid een 
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bijdrage levert aan de klinische verschijning van hypoglycemia unawareness. Omdat 
voorafgaande hypoglycemie aanleiding zou kunnen geven tot verminderde β-
adrenerge gevoeligheid, zou dit onderdeel van hypoglycemia unawareness toch 
teruggevoerd kunnen worden op een effect van adrenaline. 
Tenslotte vonden wij een nog niet eerder gerapporteerd effect van hypoglycemie 
op de immuunrespons. In gezonde vrijwilligers bleek hypoglycemie selectief de 
productiecapaciteit van TNFα te remmen, terwijl in type 1 diabetespatiënten met de 
TNFα productiecapaciteit al verlaagd bleek te zijn onder basale (niet-
hypoglycemische) omstandigheden. Omdat adrenaline geen effect bleek te hebben, 
lijkt het effect van hypoglycemie op TNFα met name te worden veroorzaakt door een 
tekort aan glucose en niet door de (metabole) stressrespons die erdoor wordt 
uitgelokt. Waarschijnlijk is de onderdrukte TNFα-productiecapaciteit bij de 
diabetespatiënten het gevolg van herhaalde hypoglycemieën, al kan niet worden 
uitgesloten dat het een complicatie is van de diabetes zelf. In theorie zou een 
onderdrukte TNFα-productiecapaciteit nadelig zijn uit het oogpunt van afweer tegen 
infecties en dergelijke. Vervolgstudies zijn nodig om hierop antwoord te geven. 
In het tweede deel van dit proefschrift onderzochten wij de validiteit van een 
farmacologische benadering om hypoglycemia unawareness te behandelen. De 
studies beschreven in dit deel verschaffen de rationale voor het gebruik van 
adenosinereceptorantagonisten, zoals theophylline, om glucosecontraregulatie-
stoornissen bij type 1 diabetespatiënten met hypoglycemia unawareness te 
verbeteren. Wij toonden aan dat theophylline niet alleen de glucosecontraregulatie 
stimuleerde en ervoor zorgde dat hypoglycemiesymptomen in een eerder stadium 
van dalende glucosespiegels konden worden opgemerkt, maar tevens dat dit 
samenhing met een daling in cerebrale doorbloeding die persisteerde ondanks 
hypoglycemie. De effecten op de cerebrale doorbloeding zijn klinisch van belang, 
omdat een stijging van cerebrale perfusie de effecten van hypoglycemie op de 
hersenen zou kunnen afzwakken, en zodoende unawareness zou kunnen induceren. 
Het effect van theophylline op de cerebrale doorbloeding impliceert een rol voor 
adenosine in de stijging van de cerebrale doorbloeding tijdens hypoglycemie en in de 
gestegen cerebrale doorbloeding zoals die is gevonden bij patiënten met 
hypoglycemia unawareness. Omgekeerd kan men hieruit concluderen dat het 
remmen van adenosine (door blokkering van de adenosinereceptor) een bij uitstek 
doelgerichte behandeling zou kunnen zijn om de contraregulatiedefecten bij 
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patiënten met hypoglycemia unawareness te verbeteren. Het onderzoek naar het 
effect van langdurigere behandeling met theophylline laat bovendien zien dat de 
stimulatie van de glucosecontraregulatie met name tot uiting komt onder 
hypoglycemische omstandigheden en niet (meer) onder normoglycemische 
omstandigheden. Met andere woorden, theophylline is effectief op het moment dat 
het móet (namelijk tijdens hypoglycemie), maar niet effectief wanneer het niet nodig 
is of zelfs ongewenst (tijdens normoglycemie). Het is dus vanuit farmacologisch 
oogpunt valide om theophylline te gebruiken bij de behandeling van hypoglycemia 
unawareness en daarmee geassocieerde stoornissen. Men mag echter nog niet 
concluderen dat behandeling met theophylline zich vertaalt in een voor patiënten 
herkenbaar klinisch voordeel. Daarvoor zijn aanvullende klinische studies van 
voldoende omvang nodig. 
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uitvoeren van de transcraniële dopplermetingen bij het onderzoek naar het acute 
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het AMC) dank ik voor het enorme enthousiasme waarmee hij me heeft 
warmgemaakt voor het hypoglycemie-onderzoek.  
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vertrouwen in mij als zoon, dokter en – nu ook – als wetenschapper. Mijn zus Karin 
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